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ABSTRACT 
 
 
Hypoxia is a hallmark of most solid tumors. In response to hypoxic stress tumor 
cells adapt by regulating survival, metabolism and angiogenesis. The heterodimeric 
Hypoxia-Inducible Factor (HIF) transcription factors are the master regulators of this 
response. HIFs play key roles in many critical aspects of cancer biology including 
angiogenesis, stem cell maintenance, metabolic reprogramming, invasion, metastasis and 
resistance to radiation therapy and chemotherapy. Overexpression of HIF-1α and HIF-2α 
has been documented in multiple human cancers and HIF-1α protein is over-expressed in 
~30% of primary breast tumors and ~70% of metastases, which independently correlates 
with poor prognosis and decreased survival in patients. A precise role for HIF-2α in 
breast cancer is still being elucidated.  
 
Our lab has established primary mammary tumor epithelial cells (MTECs) from 
late stage carcinomas originating in PyMT+; Hif1a floxed mice. These MTECs were 
exposed to either Adenovirus-beta-gal or -Cre to create wild-type (WT) and knockout 
(KO) cells, respectively. Deletion of HIF-1 activity reduced primary tumor growth by 
~60% and the formation of lung macrometastases originating from mammary fat pad 
tumors by >90%. In addition, deletion of Hif1a reduced mammary tumorsphere 
formation efficiency (TSE) in vitro and tumor initiating cell (TIC) frequency in vivo. In 
contrast, in triple negative models of breast cancer, knockdown of HIF1A had the 
opposite phenotype, increasing TSE in vitro and increased primary mammary tumor 
growth in vivo. ITGA6 (CD49f) was identified as one HIF-1α-dependent cancer stem 
cell marker that enriches for both primary mammary tumor growth and metastasis to the 
lung. Microarray profiling conducted to identify genes differentially expressed between 
PyMT WT and KO cells and end-stage WT and KO tumors revealed several genes that 
were down-regulated in both data sets in response to deletion of Hif1a. One mRNA of 
particular interest, creatine kinase brain isoform (Ckb) was down-regulated in KO cells 
>100 fold and >2 fold in end-stage tumors. Transplantation of Ckb knockdown (KD) 
PyMT cells to the mammary fat pad delayed initiation of palpable tumors by >30 days. 
When cells were introduced into the circulation via tail vein injection, 20% of mice 
injected with Ckb KD cells developed lung metastases whereas 100% of mice injected 
with WT cells developed metastases. Likewise, when mice injected with WT PyMT cells 
were treated daily with a CKB chemical inhibitor, cyclocreatine (cCr), lungs of vehicle 
treated (saline) mice were almost completely covered with surface metastases, while 
lungs of cCr treated mice contained very few metastases.  
 
Overall, our data show that HIF-1α strongly promotes mammary tumor initiation, 
progression and metastasis, in part through regulation of TIC activity. Metastasis is the 
major cause of mortality in breast cancer patients. Further characterization of the distinct 
roles of HIF-1α versus HIF-2α in breast cancer and metastasis, and genes downstream of 
the HIFs, such as ITGA6 (CD49f) and CKB, that play a key role in driving tumor 
initiation and invasion, are likely to identify new pathways amenable to therapeutic 
intervention for patients with metastatic breast cancer. 
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CHAPTER 1.    INTRODUCTION 
 
 
Oxygen and Hypoxia 
 
Nearly all organisms have a constant requirement for oxygen (O2). Normoxia is 
defined as the level of oxygen required for normal physiologic processes to occur, 
whereas low or insufficient levels of O2 is known as hypoxia. Oxygen deprivation will 
cause death faster than any other organic substance. Mammals in particular have evolved 
to have a complex respiratory and circulatory system to ensure sufficient delivery of O2 
to the body in order to maintain homeostasis. In diseases that deprive cells of O2, such as 
heart attack and stroke, these systems are compromised resulting in dysfunctional enzyme 
activities, mitochondrial function, cytoskeletal structure, membrane transport and 
antioxidant defenses, ultimately leading to senescence, autophagy or cell death [2]. In 
cancer, tumor cells adapt to hypoxia, which can stimulate tumor growth, invasion, and 
metastasis [3]. General hypoxia occurs when the body as a whole is effected, whereas 
regional hypoxia may be confined to one specific area of the body. Hypoxia can also be 
heterogeneous within tissues, as occurs in cancer [4]. Additionally, hypoxic exposure 
may be acute, lasting a short time, or chronic, lasting longer periods of time and can be 
recurring [5]. In solid tumors, cells are often exposed to an O2 gradient that decreases 
gradually from efficient oxygenation to near anoxia. Moreover, tumor cells can undergo 
repeating cycles of O2 deprivation and reoxygenation [4].  
 
Due to their rapid growth and progression, tumors exceed available O2 and 
nutrients, and are therefore exposed to low pH, low glucose, and decreased oxygen. In 
order to adapt to this microenvironment and to continue expanding, tumors must bypass 
the normal controls regulating angiogenesis, cellular metabolism and the balance between 
survival or cell death [6]. The transcriptional response to hypoxia, known as the hypoxic 
response, is primarily regulated by the Hypoxia Inducible Factor (HIF) transcription 
factors [7].  
 
 
Oxygen and Hypoxia: Effects on Cancer Therapy 
 
It has been known for decades that hypoxic cells are resistant to killing by 
ionizing radiation [8]. Radiation damage produces a radical on DNA (DNA?) molecules. 
This radical then enters into competition for oxidation by O2 to become permanent. In the 
absence of oxygen, this radical becomes reduced and the DNA returns to its original form 
[8]. Therefore, DNA damage is attenuated in the absence of oxygen. As most solid 
tumors have heterogeneous levels of hypoxia, with some regions having nearly no O2, 
they are often treated unsuccessfully with radiotherapy [3, 9]. In addition to resistance to 
radiation, there have been many studies that demonstrate that hypoxic tumor cells are also 
resistant to chemotherapeutic agents. For example, hypoxic regions of tumors are often 
distant from blood vessels that carry anticancer agents through the mass. Therefore, 
hypoxic regions of the tumor may not be exposed to anticancer drugs [10, 11]. 
Additionally, hypoxia selects for cells that have lost sensitivity to p53-mediated apoptosis 
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resulting in decreased sensitivity to apoptosis inducing chemotherapies [12]. Also of 
interest, hypoxia upregulates genes involved in drug resistance such as members of 
membrane protein families responsible for pumping drugs out of the cell, including p-
glycoprotein and breast carrier resistance protein-1 (BCRP1) [13, 14]. Hence, hypoxia 
exerts a negative influence on survival from cancer. Therefore, developing strategies that 
can overcome or bypass hypoxia-mediated therapeutic resistance is an important research 
field in solid tumorigenesis. 
 
In particular, HIF-1 has been an attractive target for cancer therapies because it is 
a master transcriptional regulator of the hypoxic response and plays a key role in 
promoting angiogenesis, glucose utilization and tumor-cell survival in addition to its 
direct association with poor prognosis. Many pharmacological inhibitors of the HIFs and 
HIF-associated pathways have been developed and tested for the ability to prevent tumor 
growth in animal models, as reviewed in [15]. Yet, more research is needed to understand 
the functional relevance of HIF biology, and the role of HIF target genes and HIF-
dependent pathways during cancer progression and metastasis. Further elucidation of 
pathways and target genes downstream of the hypoxic response will provide valuable 
insight into the extensive role the HIF transcription factors play in tumor development, 
and may also reveal novel HIF-dependent genes that can be targeted for more effective 
cancer therapies. 
 
 
Regulation of Hypoxia Inducible Factors (HIFs)  
 
The HIFs bind DNA as a heterodimer composed of two basic helix-loop-helix 
(bHLH) proteins, the constitutively expressed aryl hydrocarbon nuclear translocator 
(ARNT/HIF-β), and its oxygen-responsive partner, the HIF-alpha subunits, HIF-1α or 
HIF-2α (Figure 1-1). Stability of the oxygen-responsive alpha subunits is tightly 
regulated at the post-translational level via interactions with the tumor suppressor protein 
von Hippel-Lindau (VHL) [16, 17]. VHL provides substrate specificity to a large elongin 
B/C, ring-box 1 (RBX1), cullin2 (CUL2) complex that functions as an E3 ubiquitin ligase 
to target proteins for poly-ubiquitinylation and degradation by the 26S proteasome [18]. 
Under normoxic conditions, HIF-1α is hydroxylated on 2 evolutionary conserved proline 
residues (Pro-402 and Pro-564 in humans) by a family of prolyl 4-hydroxylases (PHDs) 
that belong to the 2-oxoglutarate-dependent oxygenase superfamily [19, 20]. PHDs 
depend not only on O2 but also on iron and 2-oxoglutarate. These two hydroxyl groups 
are necessary for VHL binding to the HIF-alpha subunits, which then mediates their rapid 
destruction [18].  In contrast, in response to decreasing oxygen, PHD activity decreases; 
therefore, HIF-1α and HIF-2α are stabilized, facilitating their dimerization with the 
constitutively expressed ARNT/HIF-β to form the HIF-1 or HIF-2 transcription factor 
complexes. Increased protein stability results in the accumulation of nuclear HIF-1 or 
HIF-2 and coincides with a large and sustained increase in the transcription of genes that 
contain HIF binding elements (hypoxia response elements, HREs) in their regulatory 
regions. Microarray profiling has demonstrated that the HIFs directly stimulate or repress 
transcription of over one hundred genes in breast, renal, endothelial or embryonic 
fibroblast cells as part of the hypoxic response [21] [22, 23]. These target genes are  
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Figure 1-1. HIF protein structure and regulation. 
(A) The protein general structure of HIF-1α and HIF-2α is highly conserved. Both 
HIFα subunits contain a basic helix-loop-helix domain (bHLH), a Per-Arnt-Sim (PAS) 
domain, an oxygen-dependent degradation domain (ODD), and a C-terminal 
transactivation domain (TAD). The HIFα binding protein, ARNT (HIF-1β), does not 
contain the ODD. (B) Under normoxia, HIFα subunits are targeted for degradation via 
the hydroxylation of two key proline residues (red lines) in the ODD domain by the PHD 
enzymes, facilitating interaction with the VHL protein. At hypoxia, HIFα subunits are 
stabilized and bind to their shared partner ARNT to form the HIF-1 or HIF-2 
transcriptional complexes, which mediate transcription of downstream target genes by 
binding to the hypoxic response element (HRE) within their promoters. 
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implicated in control of a variety of cellular processes, including glucose transport, 
glycolysis, angiogenesis, cell cycle, chemotherapy and radiation resistance, invasion and 
metastasis, stem cell maintenance, stress response and apoptosis [24, 25]. While many of 
these genes can be regulated by either HIF-1 or HIF-2, some genes rely more heavily on 
one HIFα subunit or the other. For example the genes carbonic anhydrase 9 (CA9) and 
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) are more dependent 
upon HIF-1 activity, whereas epidermal growth factor (EGFR) and WNT1-inducible 
signaling pathway protein-2 (WISP2) depend more on HIF-2 regulated transcription [26]. 
In addition to canonical HIF target mRNAs, the HIFs are also known to be involved in 
microRNA (miRNA) regulation [27]. For example, the microRNA, miR-210, which has 
been shown to be both hypoxia-inducible and a direct HIF-1 transcriptional target [28] is 
inversely correlated with disease-free and overall survival in breast cancer patients [29].  
 
 
HIFs Role in Normal Development  
 
HIF1A and HIF2A mRNAs are expressed in all mammalian tissues [30, 31]. 
However, in contrast to HIF1A, HIF2A mRNA is more highly expressed in developing 
vascular endothelium, fetal lung, and catecholamine-producing cells [32-37]. Several 
studies conducted in genetically modified mouse models have clearly demonstrated that 
deletion of either HIF gene is deleterious to development. One of the first indications that 
hypoxia-induced gene expression is a critical regulator of mammalian development was 
observed following the genetic deletion of the HIFα binding partner, ARNT (HIF-1β)[38, 
39]. Arnt-/- mice died midway through gestation due to impaired blood vessel formation. 
In normal embryos, Hif1a expression increases between E8.5 and E9.5, and Hif1a–/– 
global knockout (KO) embryos die by E11 [40, 41]. In HIF-1α null mice, from E8.5 there 
was lack of blood vessel formation in the brain, along with a dramatic reduction in the 
number of somites and defective formation of the neural fold. In addition, these embryos 
exhibited multiple defects in cardiovascular development. Use of the nitroimidazole 
marker, EF5, which detects DNA and protein adducts in hypoxic cells, demonstrated 
global hypoxia in Hif1a–/– embryos [41] as compared to wild-type (WT) littermates. 
Therefore, HIF-1α is necessary for embryonic development. 
 
Unlike Hif1a, Hif2a seems to be more sensitive to the presence of modifier alleles 
in the various distinct mouse backgrounds used to generate the knockouts. As a result, 
independent groups have reported different phenotypes.  One study observed embryonic 
lethality at mid-gestation as a result of a defect in catecholamine synthesis upon Hif2a 
deletion [36]. Another group targeting Hif2a null mice observed embryonic lethality 
between E9.5 and 13.5. They found that post-vasculogenesis changes required for the 
formation of the adult vasculature did not take place in these mice [42]. A third group 
reported that Hif2a–/–embryos do not survive beyond E16.5, and while they had normal 
systemic vasculature, they experienced impaired fetal lung maturation [43]. 
 
Due to the lethality of global HIFα knockouts, conditional deletion of either Hif1a 
or Hif2a, using Cre/lox technology, has become a widespread useful tool in studying 
HIFα knockout phenotypes in adult mice in specific tissues of interest [44, 45]. 
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Investigators approach conditional knockouts by creating a “floxed” exon or promoter 
within a target gene by inserting loxP recombination sites in flanking introns or 
noncoding regions. Mice with “floxed” genes are normal and display no phenotype 
compared to WT controls. Floxed mice can then be bred with transgenic mice that 
express the Cre recombinase enzyme, which may be driven by a tissue-specific promoter. 
When the tissue-specific promoter is active, the Cre enzyme will excise the target 
sequence between the loxP sites thus creating a tissue-specific, conditional knockout of a 
gene. This approach has been used to study the HIFα family members and related HIF-
dependent proteins in many tissue types of the post-natal mouse.  
 
 As one example, Cramer et al observed that conditional deletion of Hif1a in 
myeloid cells led to an unexpected suppression of macrophage and neutrophil function 
[46]. Another group found that conditional deletion of Hif1a in skeletal muscle resulted 
in mice that had increased exercise endurance, but at the cost of increased muscle damage 
after repeated exercise bouts [47]. Conditional deletion of Hif2a 1 week after birth using 
a tamoxifen-inducible Cre system resulted in anemic mice [48]. Most closely related to 
our studies, the Johnson laboratory has deleted Hif1a in mammary epithelial cells 
(MECs), and has shown that deletion of Hif1a results in a failure of the mammary gland 
to functionally differentiate and to secrete milk proteins and lipids leading to impaired 
lactation [49, 50]. These data, along with other defects observed in heart, colon, skin and 
brain [51-54] indicate that the HIFs are essential for normal development. Therefore, the 
expression levels of the individual HIFα subunits must be tightly regulated since either 
their deletion or over-expression is detrimental to normal development and tissue 
physiology. 
 
 
HIFs Role in Tumorigenesis 
 
The biological function of the HIF pathway is highly relevant to tumorigenesis. 
HIFs play key roles in many critical aspects of cancer biology including angiogenesis 
[55-57], stem cell maintenance [58-60], metabolic reprogramming [61, 62]; autocrine 
growth factor signaling [63]; epithelial-mesenchymal transition [64-67], invasion [68, 
69], metastasis [70-72], and resistance to radiation therapy [73] and chemotherapy [74]. 
Overexpression of HIF-1α and HIF-2α has been documented in multiple human cancers, 
including breast cancer [75, 76]. In particular over-expression of HIF-1α protein has been 
observed in many tumor metastases, including breast cancer [77]. Immunohistochemical 
analyses demonstrated that there are detectable levels of HIF-1α protein in benign breast 
lesions, elevated levels in primary poorly differentiated tumors, and a marked further 
increase in tumor metastases, in contrast to virtual absence of HIF-1α staining in normal 
tissues [76, 78].  In a model of Ras-transformed, immortalized mouse embryonic 
fibroblasts (MEFs), injection of HIF-1α (or HIF-1β) wild-type or knockout cells to 
immunocompromised mice revealed that HIF-1α is a positive factor during 
tumorigenesis [49, 79]. In addition to the response to a hypoxic microenvironment, HIFα 
expression can be further enhanced by cancer-causing mutations. For example, loss of 
wild-type tumor suppressor p53, loss of VHL, loss of PTEN and HER2 amplification all 
result in either increased HIF protein expression or HIF-dependent transcription [80-82]. 
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Moreover, HIF levels can be activated by growth factor stimulation in an oxygen-
independent manner through the phosphatidylinositol 3-kinase (PIK3) or mitogen-
activated protein kinase (MAPK) pathways [24].  
 
 
HIFs Role in Breast Cancer 
 
Breast cancer is the second most commonly diagnosed cancer, with 1 in 8 women 
developing breast cancer over their lifetime. Relapse due to metastatic lesions is the 
primary cause of breast cancer related deaths. Oxygen tensions in advanced breast 
cancers can be as low as 0.1-1% O2 [83], a range commonly used to model tissue hypoxia 
in vitro. A majority of ductal carcinoma in situ (DCIS) and almost all poorly 
differentiated, invasive breast carcinomas over-express HIF-1α [84]. HIF-1α protein is 
over-expressed in ~29% of primary breast tumors and ~69% of metastases [76]. Either 
the over-expression of HIF-1α protein or the enrichment of a hypoxic gene signature in 
the primary tumor correlates with poor prognosis and decreased survival in breast cancer 
patients [21, 85]. 
 
Breast tumors are diverse in their genetic make-up and individual responses to 
therapy. In 2000 Perou et al characterized gene expression patterns in a set of primary 
human breast tumors using DNA microarrays [86]. The expression patterns identified by 
the array provided a distinctive molecular portrait for each tumor. Based on these data, 
tumors could be classified into five intrinsic subtypes of breast cancer distinguished by 
differences in their gene expression patterns. The five subtypes identified are commonly 
known as Luminal A (ER+, typically low grade), Luminal B (ER+, PR+, typically high 
grade), HER2- enriched (amplified for HER2 protein), Normal-like and Basal-Like (ER, 
PR, and HER2 negative) [86, 87]. 
 
Based on hierarchical clustering, the basal-like subtype is characterized by high 
expression of various markers of the basal or myoepithelial cell linages, such as the 
keratins 5 and 17, laminin and fatty acid binding protein. In addition, the basal-like 
tumors predominantly include tumors negative for the steroid receptors ER, PR, and 
HER2, hence they are commonly referred to as triple negative breast cancers (TNBC, 
Figure 1-2) [86, 87]. TNBCs tend to have the worst prognosis, as they rapidly develop 
resistance to conventional chemotherapies, including the frontline therapy doxorubicin 
(DOX), and patients are at a high risk for recurrence and decreased survival [88, 89]. The 
HER2-enriched tumors are characterized by high expression of several genes in the 
ERBB2 amplicon, including ERBB2 and GRB7. Recent studies from our lab have shown 
that HIF-1α protein is highly expressed in HER2/Neu positive murine mammary tumors 
and that HIF-1α is required to promote anoikis survival, a feature required for cells to 
acquire full metastatic potential [90]. Tumor samples in the normal-like group show the 
highest expression of many genes known to be expressed by adipose tissue and other 
nonepithelial cell types. In contrast, the luminal subtypes are characterized by high 
expression markers of the epithelial cell lineage, such as keratins 8 and 18, as well as 
high expression of estrogen receptor alpha (ESR1/ERα). These tumors, therefore, can be 
targeted with anti-estrogenic therapies, and patients tend to have better prognosis and  
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Figure 1-2. Overview of differences between triple negative and luminal breast 
cancer. 
Basal breast cancers, including triple negative breast cancers (TNBC), are generally 
ER/PR/HER2 negative and express high levels of HIFα proteins. Additionally, these 
tumors exhibit aggressive growth with metastases in the liver, lung, and brain and no 
FDA-approved targeted therapies are currently available. In contrast, luminal tumors are 
generally ER/PR positive and express lower levels of the HIFα proteins [1]. Luminal 
tumors are typically less aggressive and metastasize mainly to bone. There are many 
FDA approved therapies for luminal tumors. 
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longer survival times [91]. Whole genome expression profiling of the breast cancer 
subtypes has revealed that TNBCs and HER2-enriched tumors have an enriched hypoxic 
core gene signature as compared to luminal breast cancers [92]. Independently, the HIF 
gene signature was also identified as a major pathway enriched in TNBCs versus luminal 
cancers in The Cancer Genome Atlas Network (TCGA) study, which profiled over 800 
primary samples of human breast cancer [93].  
 
Although HIF-1α was previously hypothesized to be the predominant regulator of 
the hypoxic response in breast cancer cells [1, 22, 26], emerging evidence also indicates 
that HIF-2α may also play a role in breast cancer growth, as will be further discussed in 
Chapter 4. Recent studies have proposed that while HIF-1 controls the acute or 
immediate response to hypoxia during tumor development, HIF-2 may be responsible for 
the prolonged hypoxic response [26]. Furthermore, there is evidence indicating the role 
that HIF-1 or HIF-2 plays within tumors depends on their opposing regulation of MYC 
transcriptional activity  [94]. In addition to the differing roles each HIFα isoform plays in 
tumor progression, there have been conflicting reports on the prognostic value of HIF-2α. 
One study found HIF-2α associated with distant recurrence and poor outcome in invasive 
breast cancer [95], while another reported significantly longer patient survival in breast 
cancer with high levels of HIF-2α [26]. It is likely that both HIF-1 and HIF-2 each play 
important, and perhaps opposing roles, in the development of breast cancer and the 
contribution of each HIFα subunit in the various subtypes of breast cancer must be better 
understood for the development of successful targeted therapies against the HIF pathway. 
 
 
Significance of the Hypoxic Response in Metastasis  
 
The ultimate mortality of patients with solid tumors results from the occurrence of 
distance metastases.  Metastasis is the outcome of processes that involve interactions 
between cancer cells and their microenvironment to allow tumor cells to populate and 
colonize in new tissue habitats and, ultimately, cause organ dysfunction and death. The 
basic steps of metastasis include 1) local invasion of tumor cells into surrounding stroma, 
2) intravasation, cells entering into the blood stream, 3) circulation, 4) extravasion, exit of 
tumor cells from circulation into a new organ and 5) colony formation of cells at distant 
organ sites. All of these steps require the coordination of numerous genes, many of which 
are regulated by the HIF transcription factors [96]. The first step in local invasion 
requires basement membrane disruption, and this process is promoted by the HIF-1α 
dependent upregulation of cathepsin D (CTSD), urokinase-type plasminogen-activator 
receptor (uPAR), and matrix metalloproteinase-2 (MMP2) [97].  Hypoxia also 
upregulates expression of lysyl oxidase (LOX) to increase focal adhesion, cell migration 
and motility [70]. The HIF-1α target proteins matrix metalloproteinase 1 (MMP1) and 
MMP2 are synergistic mediators of vascular permeability and the intravasation step [98] 
and the hypoxia responsive factor TRKB, a suppressor of anoikis, may be responsible for 
keeping cells alive during circulation [99, 100]. Extravasion is promoted in a similar way 
to intravasation, by the HIF-1α target genes VEGF, MMP1 and MMP2. Furthermore, 
angiopoetin like 4 (ANGPTL4), another direct HIF-1α target gene, is responsible for 
extravasion of breast tumor cells to the lung [72]. Homing of tumor cells to distant organs 
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is responsible in part by chemokine receptor CRCX4, a direct HIF target gene. Once cells 
have extravasated in the organ, tumor cell outgrowth is also a hypoxia-mediated event 
involving genes such as connective tissue growth factor (CTGF), interleukin 6 (IL6), 
interleukin 8 (IL8), vascular endothelial growth factor (VEGF), osteopontin (OPN) and 
many others [101].  
 
Although significant progress has been made in early diagnosis of breast cancer 
and the treatment of hormone-receptor positive (“luminal”) and HER2+ breast cancers, 
the overall survival rate of patients with metastatic breast cancer (MBC) remains dismal. 
Since breast cancer deaths are due to metastatic disease, basic research need to focus 
more on identifying pathways that promote metastasis, and not just regulate primary 
tumor growth. The hypoxic response is clinically relevant to MBC since hypoxic tumor 
cells are refractory to chemotherapy and radiation and since hypoxia stimulates cell 
migration and metastasis [25, 102]. 
 
 
Identification of Novel or Understudied HIF-Regulated Genes to Identify New 
Therapeutic Targets in Breast Cancer 
 
As I will discuss further in Chapter 3, when Hif1a is conditionally deleted in the 
mouse MMTV- PyMT transgenic model of breast cancer, there is a delay in tumor 
latency and a dramatic reduction in lung metastases. These studies confirm that HIF-1α 
has a direct role in both breast cancer progression and metastasis. Therefore, strategies 
that down-regulate HIF-1α, or its downstream target genes, may be effective in 
enhancing clinical outcome. To better understand how hypoxia drives not only breast 
cancer progression, but also breast cancer metastasis, our lab performed whole-genome 
mRNA microarray profiling. We identified 94 mRNAs that are commonly differentially-
expressed in each of two settings: 1) WT and KO cells cultured at hypoxia (6h, 0.5% O2) 
and 2) in end-stage mammary tumors derived from transplantation of parental WT and 
KO cells, with 68 mRNAs being up-regulated and 26 mRNAs being down-regulated. 
Several of these genes were identified that regulate cell proliferation and/or the metastatic 
switch, in additional to multiple genes involved in stem cell maintenance. In Chapter 5, 
which reviews data generated from the whole genome screen, I will discuss some of these 
genes in further detail. In addition, in Chapter 6, I will further focus on one gene we 
found to be particularly relevant to breast cancer biology, creatine kinase brain isoform 
(Ckb). 
 
There are currently a number of different HIF inhibitors being used in small 
animal studies and clinical trials, as reviewed in [24, 103]. While some have shown initial 
success in delaying tumor growth and prolonging survival, such as digoxin [104], YC-1 
[105, 106] and PX-478 [107], the most effective therapies have been those that target 
HIF-related pathway genes. For example, Traztuzumab (Herceptin) is a frontline therapy 
in the treatment of patients with HER2-enriched breast cancers [80], and as previously 
described HIF-1α is highly expressed in HER2 positive tumors. Additionally, mTOR, 
which regulates HIF-1α translation initiation, can be inhibited by Rapamycin [108], 
another commonly used chemotherapy drug in the treatment of cancers, including breast 
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cancer. Doxorubicin and daunorubin, two anthracyclines which have been reported in one 
study to inhibit HIF transcriptional activity [24] are also frontline therapies in the 
treatment of several solid tumors. 
 
All of these drugs, although initially effective, do come with drawbacks and 
debilitating side effects. Moreover, most of these compounds treat only the recurrence of 
the primary tumor and do not focus on the prevention or treatment of MBC. Therefore, 
identifying novel or understudied HIF-dependent genes, such as those identified on our 
microarray, may lead to improved targeted therapies for the treatment of not only primary 
tumors, but also for the inhibition of metastasis, perhaps with decreased negative side 
effects, leading to increased patient survival. 
 
 
Hypoxia and Cancer Stem Cells 
 
 
Cancer Stem Cell Theory and Regulation of Breast Cancer Stem Cell Activity by 
HIF 
 
Breast cancer cells exhibit properties of cancer stem-like cells (CSCs), also 
referred to as tumor initiating cells (TICs). The CSC hypothesis postulates that tumors 
arise from a small population of cancer cells with stem cell-like properties [109], with a 
corollary that CSC-like cells play a primary role in relapse promoting refractory disease 
and death due to metastases [110]. Hypoxic exposure promotes self-renewal of several 
cell types, including neurospheres, hemapoietic stem cell cells (HSCs) and embryonic 
stem (ES) cells [111]. HIF-1 is also necessary in vivo for HSCs since its deletion causes 
stem cell exhaustion [112]. In addition, hypoxic regions of secondary breast tumors that 
arise after treatment of the primary tumor with anti-angiogenic therapies are enriched 
with CSC-like cells [113]. Another common feature of hypoxic cells and CSCs is that 
both hypoxic regions of tumors and CSC-like cells are known to be highly refractory to 
radiation and chemotherapy [102, 114]. 
 
Accumulating evidence supports the hypothesis that stem cells and TICs exist in a 
hypoxic niche microenvironment [111]. The direct relationship of the hypoxic response 
to TIC activity has been demonstrated in adult glioma, human acute myeloid leukemia 
(AML) and murine lymphoma [60, 115]. In gliomas, expression of HIF2A was enriched 
in CSCs, and knockdown of HIF2A, but not HIF1A, reduced TIC activity in cells derived 
from patient xenografts [115]. In contrast, HIF-1 was found to be essential for maintaining 
TIC activity in a syngeneic rodent transplant model of lymphoma and in AML patient 
xenografts via regulation of the Notch pathway [60].  Interestingly, in gliomas, the TIC 
population was enriched via cell sorting based on the expression of a single cell surface 
marker, CD133 (PROM1). PROM1, a transmembrane protein without a known ligand, is a 
known hypoxia-responsive protein regulated by HIF-1 [116, 117]. Several studies have 
shown that the population of breast tumor cells with the ability to self-renew is enriched 
with the ability to initiate tumorigenesis in vivo [118-121]. Furthermore, TICs may drive 
metastasis [122, 123].  
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HIF Regulation of Cancer Stem Cells in the MMTV-PyMT Mouse Model  
 
The specific contribution of HIF-1α or HIF-2α in regulating TIC activity in breast 
cancer is still being defined, particularly in the context of syngeneic rodent models that 
recapitulate the breast cancer microenvironment. The MMTV-PyMT model is one of the 
most commonly utilized pre-clinical mouse models in breast cancer research since tumor 
latency is short and there is a high frequency of metastasis to the lung [124]. Whole-
genome array profiling indicates that PyMT tumors most closely resemble the luminal B 
subtype of human breast cancer [125], although end-stage PyMT tumors are estrogen and 
progesterone receptor (ER/PR)-negative [124]. Dr. Seagroves has previously shown that 
conditional deletion of Hif1a in PyMT+ tumors by crosses to mice expressing MMTV-
Cre recombinase delayed the onset of palpable tumors, delayed the progression of 
hyperplasias to carcinomas and reduced lung metastases [126]. Our lab created in an 
improved model system in which Hif1a is efficiently deleted in the mammary tumor 
epithelium via ex vivo viral transduction with Cre recombinase prior to the injection of 
mammary tumor cells to the cleared fat pads of recipient mice [127]. Validating the use 
of a transplantation paradigm in lieu of intact transgenic mice, PyMT tumor cells 
transplanted serially into recipients exhibit similar morphology and gene expression 
profiles as the original tumors [128].  
 
 As I will review in further detail in Chapter 3, using these novel HIF-1α wild type 
(WT) and null (KO) mammary tumor epithelial cells (MTECs), we demonstrated that 
HIF-1α prominently augments primary tumor growth and lung metastasis and accelerates 
relapse due to metastasis through regulation of breast CSC activity.  Furthermore, we 
demonstrated for the first time that HIF-1α promotes mammary tumorsphere formation 
and enhances TIC frequency in vivo, in part through regulation of the expression of 
markers associated with the basal lineage, the Notch pathway and CD133. Together, 
these data indicated that suppressing the hypoxic response may be beneficial not only to 
reduce primary tumor mass but also to suppress the breast TIC sub-population that may 
be ultimately responsible for patient relapse. Through our studies investigating the 
expression of several cell surface markers in WT and KO PyMT cells and tumors, we 
observed that several cell surface proteins routinely used to enrich cells for CSC activity 
were up-regulated by HIF-1. One set of results from these studies, focusing on HIF-
dependent regulation of CD49f, will be further discussed in Chapter 4. 
 
 
Moving into Translational Research: Investigating the Role of HIF-1 and HIF-2 in 
Human Models of Luminal and Triple Negative Breast Cancers 
 
 Traditionally, cancer research has focused on in vitro characterization of 
conventional human cell lines derived from patient samples. In the 1990’s several 
genetically modified syngeneic mouse models were created that represented an 
improvement in modeling breast cancer [129]. While these models have provided 
valuable insight into cancer biology, they still face some limitations. One of the main 
drawbacks in using genetically modified mouse models is that, as a result of originating 
from a murine background, tumors do not always replicate the histology, physiological 
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effects, biochemical pathways or metastatic pattern observed in the corresponding human 
tumor type [129, 130]. Additionally, the use of conventional human breast cancer cell 
lines cultured in monolayer in the presence of serum only partially replicates the genetic 
features and metastatic potential of tumors observed clinically in patients [131]. These 
limitations make it difficult to accurately predict patient responses to therapy. Recently 
advances have been made in patient derived mouse xenograft models that more faithfully 
replicate clinical phenotypes. For example, Dr. Alana Welm at The Huntsman Cancer 
Institute (HCI) has developed a new model of serially transplantable, orthotopic breast 
tumor grafts [132] that represents the next major advance in modeling metastatic breast 
cancers in mice. In addition, Zhang and colleagues [133] and Kabos and colleagues [134] 
have had success in establishing patient derived xenografts (PDXs), as reviewed in 
Landis et al [135].  
 
 To create the HCI breast tumor tissue bank, the Welm laboratory transplanted 
fresh primary tumor material, metastatic breast cancer samples or freshly collected tumor 
cells present in pleural fluid into female NOD/SCID mice immediately following harvest 
[132]. As of 2011, thirteen tumor lines from 10 patients were successfully maintained 
through multiple rounds of serial transplantation. Being serially passaged only through 
mice, these tumors were never exposed to in vitro cell culture conditions and 
manipulations, and, therefore maintained their gene expression and SNP profiles over 
sequential generations, and recapitulated the same sites of metastasis in the mouse from 
the primary tumor as was clinically observed in the patients. The tumors engrafted 
represent a variety of breast cancer subtypes including 6 luminal tumors, 1 HER2-
enriched tumor, and 5 basal-like tumors [132]. All tumor grafts were evaluated by 
pathologists following 4-8 rounds of serial transplantation, and all retained the key 
characteristics of the original tumors. The most striking feature of these tumor grafts was 
their ability to spontaneously metastasize from the orthotopic site with the same patterns 
of metastasis as seen in the original patient. Further evaluation using molecular gene 
signatures demonstrated that tumor grafts clustered with their original human tumor and 
within a node containing other primary tumors of their subtype. The features of this 
model provide a unique way in which to study breast cancer and offer multiple 
advantages over breast cancer cell lines including (1) the ability of grafts to maintain 
critical features of the original tumors including histopathology, clinical markers, and 
gene expression profiles; (2) the representation of all major clinical types of breast 
cancer; and (3) the spontaneous metastasis of grafts to many of the same organs that were 
affected in patients. 
 
 Use of the HCI tissue bank will be useful in our lab to explore the differing roles 
that the HIFs may play in different subtypes of breast cancer. For example TNBCs and 
HER2-enriched tumors have relatively high levels of both HIF-1α and HIF-2α compared 
to luminal tumors [1, 92], and this could confer to them more rapid and aggressive 
growth. As I will discuss in greater detail in Chapter 6, by knocking down individual 
HIFα subunits in specific tumor subtypes, we will be poised to evaluate how deletion of 
each HIFα gene impacts primary tumor growth and metastases. Moreover, labeling the 
tumor cells with a reporter, such as firefly luciferase (Luc2), will facilitate live 
bioimaging over time. Using these tools and techniques, we will have the ability to assess 
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how rapidly tumors and their metastases form in the presence or absence of HIF1A, 
HIF2A or both genes, even before we are able to manually measure any tumor mass with 
calipers. Finally, we plan to use this resource to study novel HIF-dependent genes, 
originally identified in the MMTV-PyMT transgenic mouse in a more clinically relevant 
human model to propose of testing novel, targeted HIF therapies that may be beneficial in 
the clinic to prevent MBC or to prolong overall survival (OS). 
 
 
Hypothesis and Specific Aims 
 
Our hypothesis is that there is a subset of novel or understudied HIF-1α-
dependent genes in mammary tumor epithelial cells (MTECs) that primarily contribute to 
tumor growth and/or metastasis. Additionally, there is a population of tumor-initiating 
cells with stem-like features that require the HIF-1 or HIF-2 transcription factors to 
promote tumor initiation, growth, metastasis and chemoresistance. Two aims were 
designed to investigate this hypothesis: 
 
• To investigate the contribution to tumor growth and metastasis of the most highly 
HIF-1-dependent genes with a prior implicated role in cancer. 
• To delineate the role of HIF regulation of tumor initiating cells (TICs) and how 
TICs may influence therapeutic resistance in human breast cancers. 
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CHAPTER 2.    VHL DELETION IMPAIRS MAMMARY ALVEOLOGENESIS 
BUT IS NOT SUFFICIENT FOR MAMMARY TUMORIGENESIS† 
 
 
Introduction 
 
Hypoxia-Inducible Factor-1 (HIF-1)α is over-expressed in most solid tumors and 
correlates with poor prognosis and high risk of metastasis in breast cancer patients.  
Because HIF-1α protein stability is tightly controlled by its interaction with the tumor 
suppressor protein von Hippel- Lindau (VHL), deletion of VHL results in inappropriate, 
constitutive HIF-1α expression.  In order to determine if VHL plays a role in normal 
breast development, and if HIF-1α over-expression is sufficient to initiate breast cancer, 
we conditionally deleted Vhlh (the murine VHL homologue) in the mammary epithelium 
using the Cre/lox system.  Upon first pregnancy and lactation, loss of Vhlh produced 
subtle changes in epithelial cell differentiation.  However, Vhlh-/- mammary glands from 
multiparous mice exhibited a progressive loss of alveoli with each pregnancy/lactation 
cycle and the few alveoli that formed were poorly differentiated.  Deletion of Vhlh in the 
epithelium also impacted the mammary stroma, as indicated by increased microvessel 
density, accompanied by areas of hemorrhage.  However, deletion of Vhlh, and therefore, 
constitutive Hif-1α expression, was not sufficient to induce mammary tumorigenesis, 
consistent with a lack of report of increased breast cancer risk in patients with VHL 
disease. Moreover, co-deletion of Hif1a/Vhlh was not sufficient to rescue the Vhlh-/- 
phenotype, suggesting that additional genes besides HIF-1α are mis-regulated in response 
to deletion of Vhlh in the breast epithelium. 
 
 
Methods 
 
 
Animals 
 
Vhlh conditional mice (flanked by loxP sites, or “floxed”) were obtained directly 
from Dr. Volker Haase and generated as described in [136]. Hif1a conditional mice were 
generated as in [41, 49]. Mice expressing the MMTV-Cre (line D) or the Wap-Cre 
transgene were obtained from Dr. Kay-Uwe Wagner (University of Nebraska, Eppley 
Cancer Center) [137, 138]. Female mice used in experiments were generated by mating 
floxed/floxed; MMTV- or Wap-Cre-positive male mice with floxed/floxed (“double 
floxed”, DF); Cre-negative females, producing littermate control (Cre-negative) and test 
(Cre-positive) progeny. To co-delete Hif1a and Vhlh, Vhlh/Hif1a compound DF females 
were bred to Vhl/Hif1a floxed/floxed males positive for MMTV-Cre. Therefore, in all 
cases, expression of Cre would induce homozygous deletion of the floxed gene. Animals 
                                                
 
† Adapted with permission. Seagroves, T. N., Peacock, D.L, et al. (2010). "VHL deletion 
impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis." Am 
J Pathol 176(5): 2269-2282. 
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were housed in microisolator cages and provided food and water ad libitum in an 
Association for Assessment and Accreditation of Laboratory Animal Care (AALAC)-
approved facility under protocols approved by the University of California San Diego or 
the University of Tennessee Health Science Center (UTHSC) Laboratory Animal Use 
and Care Committee. 
 
 
Protein Extraction and Western Blotting 
 
Whole inguinal mammary glands were harvested from C57BL/6 female mice 
(JAX, Bar Harbor, ME) at the following developmental stages:  mature virgin (12 wks of 
age), day 6 (6-P), 10 (10-P), 15 (15-P) and 18 (18-P) of pregnancy, based on the date of 
plug observed as day 0, day 10 of lactation and at involution (following 4 days of forced 
weaning from day 10 of lactation); n=3 mice/time point. Using procedures previously 
described [139], tissue extracts were prepared from whole mammary glands for each time 
point from frozen, pooled tissue that was ground to a fine powder under liquid nitrogen 
and immediately homogenized in a modified RIPA buffer to produce a whole cell extract 
(WCE) comprised of cytoplasmic and nuclear proteins. WCE were resolved on 10% Bis-
Tris NuPAGE gels (Invitrogen, Carlsbad, CA) and blotted to PVDF membrane 
(Millipore, Bellirica, MA). The membrane was blocked in 5% non-fat dry milk prior to 
addition of anti-VHL antibody (clone Ig32, BD Biosciences, San Jose, CA) at 1:200 for 
3h at RT, followed by incubation in a 1;10,000 dilution of anti-mouse IgG-HRP (GE Life 
Sciences, Piscataway, NJ) for 30 minutes, and development in ECLPlus substrate (GE 
Life Sciences). Membranes were stripped and re-probed with an anti-guinea pig 
cytokeratin 8/18 primary antibody (Progen GmbH; Heidelberg, Germany) at 1:5,000 for 
1h at RT, followed by incubation in a 1:5,000 dilution of donkey anti-guinea pig IgG-
HRP (Jackson Immunologicals, West Grove, PA), prior to exposure to ECLPlus 
substrate. 
 
 
Continuous Breeding and Lactation Studies 
 
To examine the effects of Vhlh deletion in multiparous females, homozygous 
floxed, Cre-negative or Cre-positive females were housed singly and continuously bred to 
FVB males. During constitutive breeding, all pups were weaned at 21 days of age. For 
glands harvested during the lactation period, litter size was normalized on the date of 
birth to 8 pups per dam, using either the endogenous litters (born to the dam) or by cross-
fostering pups that were born to lactating FVB dams. To permit accumulation of milk in 
the lactating gland, all litters were weaned from nursing dams for 2-3h prior to gland 
harvest, and all pups then returned to the mother once she recovered from anesthesia. 
 
 
Tissue-Harvest, Histology and Whole-Slide Scanning 
 
Individual inguinal (#4) or thoracic (#3) mammary glands were biopsied from 
anesthetized mice at specified time points during the first pregnancy or lactation and/or 
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during sequential survival surgeries performed on the same animal over the course of 
multiple gestations. Each gland was fixed in neutral phosphate-buffered formalin (NBF) 
for 6h at room temperature (RT) and/or flash frozen in liquid nitrogen for preparation of 
RNA or protein. Fixed tissue was embedded in paraffin and 5μm sections prepared. 
Sections were stained with hematoxylin and eosin (H&E) or used for 
immunohistochemistry.  
 
 
Immunohistochemistry 
 
Antigen retrieval, GLUT-1 and CD34 immunostaining and the calculation of 
microvessel density using Chalkley analysis were performed as previously described [50, 
126]. To detect HIF-1α, sections were incubated with a 1:100 dilution of a rabbit 
polyclonal anti-human HIF-1α antibody (generated to amino acids 600-800) generously 
provided by Dr. Robert Abraham, Burnham Institute, La Jolla, CA. Leukocytes were 
detected with the pan-leukocyte marker CD45 (BD Biosciences) at a 1:100 dilution. 
VEGF was detected with a 1:40 dilution of a goat polyclonal antibody to murine VEGF 
(R&D Biosystems, Minneapolis, MN). The Vector ABC Elite staining kit (Vector 
Laboratories, Burlingame, CA) was utilized in conjunction with DAB (3,3'-
diaminobenzidine) or DAB Impact peroxidase reagent (Vector Laboratories) to visualize 
all immunoreactive complexes. All slides were counterstained with Harris hematoxylin. 
To determine the percentage of proliferating mammary epithelial cells (MEC) during 
pregnancy, 15-P females were injected 2h prior to tissue harvest with 0.1mL/10g body 
weight of cell proliferation reagent (Bromodeoxyuridine, BrdU, GE LifeSciences). BrdU 
incorporation was detected by anti-BrdU-FITC antibody (BD Biosciences, San Jose, CA) 
and the average percentage of BrdU+ cells/MEC (n=5 animals/genotype) was determined 
as previously described [140]. Similar procedures were utilized to calculate the 
percentage of CD45+ cells/total MEC in glands harvested from multiparous dams, except 
that 5 random fields at 40x magnification were observed (n=4 animals/genotype). To 
visualize the gross vasculature of the mammary gland, thrice parous lactating dams were 
anesthetized, the thoracic mammary gland was bathed in PBS and the glands were 
digitally imaged under a Leica dissecting stereozoom microscope.  Dams were then 
returned to their respective weaned litters following recovery from surgery. 
 
 
Automated Analysis of Epithelial Cell Content 
 
The Aperio Pixel Density algorithm was utilized to quantitate the number of MEC 
contained within inguinal, H&E-stained glands harvested from mice at 15-P (n=4 
mice/genotype) or 18-P (n=3 mice/genotype). Default settings for this algorithm were 
adjusted until pixels from the stroma and the vasculature were not detected. The 
following settings were utilized: Image Zoom, 1; Mark-up Compression, 0; Compression 
Quality, 30; Classifier Neighborhood, 30; Classifier, 30; Hue Value, 0.75; Hue Width, 
0.35; Color Saturation Threshold, 0.25; Iwp (high), 200; Iwp (low), 175; Ip (low), 100, 
Isp (low); Inp (high), -1. The total number of positive pixels was calculated by adding the 
weak, median and strongly positive pixel values (Nweak, Np and Npositive, respectively) 
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and dividing this total by the area analyzed (in mm2). The average number of positive 
pixels/mm2 was then compared between genotypes.  In all cases, the area occupied by the 
inguinal gland lymph node was excluded. 
 
 
Gene Expression Analysis by RT-PCR 
 
Total RNA was prepared from flash frozen whole, inguinal mammary glands 
harvested at 18-P or on the date of birth during the first lactation. Tissue was ground to a 
fine powder under liquid nitrogen and homogenized immediately in RNABee reagent 
(Isotex Diagnostics, Friendswood, TX). Total RNA was prepared according to 
manufacturer instructions and RNA quality was analyzed by the Agilent 2100 
Bioanalyzer (Santa Clara, CA). Only samples with RNA Integrity Number (RIN) values 
higher than 9.0 were chosen for preparation of cDNA using the High-Capacity cDNA 
Reverse Transcription kit (ABI, Foster City, CA). Real-time PCR was performed using 
optimized primer and FAM-labeled probe sets designed by the Roche Universal Probe 
Library Assay Design Center software available on the Roche website. Real-time PCR 
was performed using the Roche LightCycler 480 machine for 40 cycles. The crossing 
point (Cp) for each sample was determined using the Roche absolute quantitation 
algorithm. The average sample Cp value was then calculated for all independent 
replicates/genotype/time point. To control for cDNA input, the average sample Cp values 
were first normalized based on expression of the Ints3 gene. To compensate for changes 
in MEC content among genotypes, Ints3-normalized, average Cp values were then 
normalized for expression of cytokeratin 18 (Krt18). The average fold-change (FC) in 
gene expression was determined by comparing the dual-normalized Cp values between 
control (floxed/floxed) and gene-deleted samples using the ΔΔCp method. 
 
 
Statistics 
 
Statistical significance was determined using an unpaired Student’s t test (Prism 
4.0, GraphPad). All p-values less than 0.05 were considered to reflect statistically 
significant changes between genotypes.  
 
 
Results 
 
 
VHL Expression Increases during Pregnancy and Decreases during Involution 
 
To determine the expression levels of VHL over the course of development of 
normal mammary gland, whole cell protein extracts (WCE) were prepared from whole 
mammary glands harvested from C57BL/6 nulliparous, pregnant, lactating or involuting 
females and VHL detected by western blotting. As a positive control, extract from a 
whole E15 embryo was included. A single isoform of VHL was detectable at 24 kDa at 
all stages of development. Expression of VHL increased dramatically from early (6-P) to 
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mid-pregnancy (10-P), a period of rapid alveolar expansion, and levels remained high 
until involution, a time of extensive epithelial cell death and tissue remodeling  
(Figure 2-1A).  Based on the increased expression of cytokeratins 8/18 over the course of 
mammary gland development, known markers of the luminal mammary epithelium, VHL 
expression appears to increase as the number of epithelial cells increases. These data 
suggest that murine VHL is preferentially expressed by mammary epithelial cells (MEC) 
relative to the mammary stroma, in agreement with prior reports for the human breast 
[141].  
 
In order to specifically delete Vhlh in the mammary epithelium, a Cre/lox strategy 
was employed.  Previously characterized Vhlh homozygous floxed mice were bred to 
either MMTV-Cre or WAP-Cre transgenic mice. Whereas in line D of MMTV-Cre mice 
the Cre transgene is activated upon puberty and induces recombination throughout 
mammary gland development [137], the Wap-Cre transgene is only induced at high 
levels beginning at mid-pregnancy [142]. Furthermore, there is promiscuous expression 
of Cre when its expression is driven by the MMTV promoter since recombination activity 
was observed in other tissues, including the skin, B and T cells and the pancreas. In 
contrast, expression of the Wap-Cre transgene is highly restricted to the mammary 
epithelium of pregnant and lactating mice [137]. 
 
 To confirm that we successfully generated Vhlh conditional knockout mammary 
epithelium (VhlhMEC-/-), WCE were prepared from whole mammary glands of age-
matched, littermate lactating dams that were either negative or positive for the Wap-Cre 
transgene and subjected to western blotting for VHL. VHL was barely detectable in 
extracts prepared from Wap-Cre-positive mice, confirming efficient deletion of Vhlh. The 
blots were stripped and re-probed with antibodies to cytokeratin 8/18 (CK8/18)  
(Figure 2-1B).  The extent of deletion of VHL observed at lactation was similar between 
Wap-Cre and MMTV-Cre transgenic mice (data not shown). 
 
 
Conditional Deletion of Vhlh Impairs MEC Proliferation and Differentiation during 
Pregnancy 
 
We next assessed the contribution of Vhlh to mammary gland development by 
comparing the histology of wild type and Vhlh-/-MEC mammary glands in which deletion 
was achieved via expression of the MMTV-Cre (line D) transgene. In this particular line 
of MMTV-Cre transgenic mice, Cre is activated in epithelial cells at approximately 3 
weeks of age, when ductal morphogenesis is in progress [137]. However, no gross 
differences in ductal branching or extent of outgrowth into the mammary fat pad were 
observed in mature nulliparous mice that had completed ductal morphogenesis Likewise, 
no gross changes were observed in alveolar number or appearance at day 6 of pregnancy 
(early pregnancy) or at day 10 of pregnancy (mid-pregnancy) [143].   
 
 The transition from differentiation during pregnancy to successful milk secretion 
at lactation has been divided into two stages, termed secretory differentiation and 
secretory activation [144]. The first phase, secretory differentiation, begins at mid- 
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Figure 2-1. Expression of murine VHL increases over the course of normal 
mammary gland development as epithelial cell content increases. 
(A) Western blotting for VHL was performed using tissue whole cell extracts (WCE, 100 
μg/lane) prepared from mid-gestation embryos (15-E) or whole mammary glands 
harvested from mice over the course of gestation and lactation. Extracts were prepared 
from mature nulliparous (vir) mice, at day 6, 10 or 15 of pregnancy (6-P, 10-P, 15-P), at 
mid-lactation (10-L) or 10-L followed by 4 days of forced involution (4-Inv). The same 
blot was stripped and reprobed with antibodies to cytokeratins 8/18 (CK8/18) to indicate 
the relative abundance of mammary epithelial cell (MEC) content at each stage of 
development. Note the increased expression of VHL from day 6 of pregnancy to day 10 
of pregnancy that persists throughout lactation, and then dramatically decreases at 4-Inv, 
a peak period of MEC cell death. The virgin sample was overloaded as indicated by the 
increased expression of CK8/18 in this lane relative to sample prepared from 6-P mice. 
(B) To confirm efficient deletion of Vhlh in response to Wap-Cre-mediated 
recombination (conditional knockout, CKO), tissue WCE were prepared from whole 
glands isolated from two independent control (WT) or CKO lactating dams during the 
third round of lactation. VHL expression is reduced by > 90% when normalized for MEC 
content based on CK8/18 expression. 
 
Data generated by T.N. Seagroves. 
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gestation with the production of significant quantities of milk protein and lipid. The 
second phase, secretory activation, depends on the completion of secretory 
differentiation, and is coordinated with the birth of pups to begin lactation. Therefore, we 
next analyzed tissue histology at day 15 of pregnancy (15-P), a period well within the 
secretory differentiation phase. At this stage, differentiation may be visualized by H&E 
staining by the presence of large cytoplasmic lipid droplets (CLD) within MEC as well as 
the presence of proteinaceous material in the alveolar lumen, which is likely comprised of 
milk proteins that accumulate in preparation for lactation [145].  
 
 At day 15 of pregnancy, alveoli formed in Vhlh-/-MEC glands were not 
differentiated since the alveolar lumens remained closed (Figure 2-2B). This was in 
contrast to the control glands (Figure 2-2A), which contained alveoli with defined 
lumens and the presence of CLD. Moreover, there appeared to be fewer alveoli per field 
in Vhlh-/-MEC glands compared to controls. To determine if there were differences in MEC 
proliferation at this stage, the percentage of MEC incorporating bromodeoxyuridine 
(BrdU) was measured. The average percentage of cells positive for BrdU incorporation 
decreased by 30% in Vhlh-/-MEC glands compared to control glands (5.2% vs. 7.5%) 
(Figure 2-2E). To confirm these results, we also compared the MEC content of glands at 
day 15 of pregnancy by automated quantitation of images of whole-slide digitized H&E-
stained sections using a pixel density algorithm as described in the methods. The number 
of pixels corresponding to the mammary epithelium/mm2 of tissue was decreased by 22% 
(n=4 mice/genotype, Figure 2-2F). By day 18 of pregnancy (18-P), just prior to 
parturition, H&E-stained slides showed that the glands containing Vhlh-/-MEC appeared to 
maintain a reduced number of alveoli per field (Figure 2-2D). Moreover, there were also 
lobuloalveolar units within the gland that did not appear to be well-differentiated. 
Automated pixel density analysis revealed that epithelial content was reduced by ~50% at 
18-P (n=3 mice/genotype, Figure 2-2F). 
 
To assay for molecular changes in differentiation, real-time PCR was also 
performed using cDNA prepared from 18-P glands (Figure 2-2G). Three markers of 
secretory differentiation were analyzed, adipose differentiation-related protein (ADRP; 
also known as adipophilin), ß-casein (CSN2) and whey acidic protein (WAP). Whereas 
ß-casein is one of the earliest markers of differentiation induced by pregnancy hormones, 
Wap and Adrp are expressed during later stages of differentiation [146, 147]. Antibodies 
to ADRP have also been used to immunostain the surface of CLD produced by 
differentiated MEC [145]. In addition, we assayed for changes in expression of two direct 
HIF-1 target genes, Glut-1 and Vegf.  Compared to control glands, expression of Adrp, 
Csn2 and Wap mRNA decreased by 2.6-fold, 6.2-fold and 46.4-fold, respectively, in 
Vhlh-/-MEC glands. As would be expected when Vhlh is deleted, expression of Glut1 
mRNA increased by 40% and the expression of Vegf mRNA increased by 10.5-fold. 
Together, these results demonstrate that loss of VHL activity delays both MEC 
proliferation and secretory differentiation during pregnancy and impacts gene expression. 
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Figure 2-2. Reduced alveolar proliferation and differentiation in response to Vhlh 
deletion via MMTV-Cre. 
Mammary glands were harvested from floxed control (A, C, H, J) or Vhlh -/-MEC (B, D, I, 
K) glands at day 15 (A-B; 15-P, 200x magnification) or day 18 of pregnancy (C-D; 18-P, 
200x magnification), day 10 of the first lactation (H-I; 10Lac#1) or day 10 of the second 
lactation (J-K; 10Lac#2), sectioned and stained with H&E. All scale bars represent 10 
μm. (A-B) Note the decreased number of alveoli per field and the lack of differentiation 
in Vhlh -/-MEC glands at 15-P. (C-D) Fewer alveoli were also observed in Vhlh -/-MEC 
glands at 18-P. (E) The percentage of BrdU+ cells per total number of MEC was 
determined at day 15-P in individual mice (n=5/genotype), and the means compared 
between genotypes. (F) The number of hematoxylin-positive pixels associated with 
MEC/mm2 gland scan area was compared using whole-slide scanned, digitized slides by 
the automated Aperio Pixel Density algorithm as described in the methods. The mean 
number of pixels plus the SEM is presented. (G) Real-time PCR was performed to 
compare expression of Adrp, ß-casein (Csn2), Wap, Glut1 and Vegf mRNAs in control 
and Vhlh -/-MEC glands harvested at day 18 of pregnancy. The normalized fold-change 
(FC) in gene expression is expressed relative to expression levels observed in cDNA 
samples from control glands. Blue or orange bars indicate those genes for which relative 
expression decreased or increased, respectively. The average fold-change plus the SEM is 
presented. (H-K) H&E-stained sections were prepared from mammary glands harvested 
from mid-lactation dams during the first (10Lac#1; H-I, 400x magnification) or second 
(10Lac#2; J-K, 200x magnification) cycles of lactation from the same cohort of test and 
control mice. As expected, the morphology of the wild type gland remains relatively 
unchanged from the first to the second lactation (H vs. J).  
 
Data generated by D.L. Peacock, T.N. Seagroves and L.P. Schwab. 
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Deletion of Vhlh Results in Subtle Changes in Secretory Activity during First 
Lactation 
 
In contrast to the strong lactation phenotype we observed previously upon 
deletion of Hif1a in MEC during the first period of lactation [50], lactating mammary 
glands comprised of Vhlh-/-MEC were able to successfully produce milk, as no striking 
changes in pup size were apparent at weaning of the first litter. However, upon close 
histological examination of biopsied glands, subtle defects in MEC secretory function 
were observed in lactating glands at day 10 of lactation, a period of peak milk production 
(Figure 2-2H-I). After a weaning period of 2-3h to permit milk accumulation in the 
gland, much less evidence of milk production was present in the Vhlh-/-MEC alveoli 
compared to controls. Moreover, the majority of MEC within lobuloalveolar units of 
Vhlh-/-MEC glands were not completely flattened with a basal nuclear location, as was 
observed in control glands. In addition, the Vhlh-/-MEC alveoli exhibited reduced lumen 
size and areas of adipose tissue were still visible in each field. 
 
 Multiple lobuloalveolar units present within the Vhlh-/-MEC glands also exhibited 
an abundance of cytoplasm that stained heavily basophilic. This feature is indicative of 
hypersecretory, apocrine metabolism, and is reminiscent of the Arias-Stella reaction. The 
Arias-Stella phenomenon refers to a pathology of the endometrium that is found in a 
subset of pregnant women characterized by nuclear hyperchromatism, cytoplasmic 
swelling and vacuolization of apocrine epithelium due to a premature response to 
pregnancy hormones [148]. Therefore, at first lactation, deletion of Vhlh produces a mild 
secretory phenotype.   
 
In contrast, during the second round of lactation, more severe defects were noted. 
Histological examination of biopsied glands revealed a more dramatic inhibition of 
alveolar differentiation and secretion at day 10 of lactation (Figure 2-2J-K).  As 
expected, the histology of the glands of wild type mice between the first and second 
lactation periods was indistinguishable. Because the phenotypes observed in MMTV-Cre-
positive transgenic females did not manifest until pregnancy and lactation, we then 
proceeded to confirm these observations using the Wap-Cre transgenic line. Furthermore, 
by using Wap-Cre to delete Vhlh, we avoided any potential indirect effects on mammary 
gland development due to the promiscuous expression of MMTV-Cre in other cell types 
besides the mammary epithelium [137]. 
 
 
Deletion of Vhlh Contributes to Progressive Lactation Failure 
 
The primary goal of utilizing Wap-Cre transgenic mice to delete Vhlh in 
continuously bred, multiparous females was to determine if its deletion, and therefore, 
HIF-1α constitutive expression, was sufficient to result in mammary tumorigenesis. We 
also sought to determine if use of Wap-Cre transgenic mice would phenocopy the Vhlh 
deletion lactation phenotype observed in the MMTV-Cre transgenic mice. To perform 
continuous breeding, littermate Vhlh control (wild type; WT) or Vhlh -/-MEC females were 
constitutively housed with FVB males since prior studies have shown that continuous 
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breeding dramatically accelerates mammary tumorigenesis [149, 150]. Therefore, we 
reasoned that if loss of the tumor suppressor Vhlh is sufficient for mammary tumor 
initiation, then mammary tumors would be observed in aged, multiparous females due to 
selection for stochastic mutations in Vhlh-/-MEC. Furthermore, continual breeding would 
maintain constitutively high Cre transgene levels due to pregnancy hormone stimulation 
of the Wap promoter [147].  
 
In order to observe changes in histology during successive rounds of lactation, 
individual thoracic or inguinal mammary glands were harvested from the same cohort of 
lactating dams during survival surgery at the first, third and fifth period of lactation 
(Lac#1, Lac#3 or Lac#5) and sections prepared for H&E analysis. As observed following 
deletion of Vhlh by the MMTV-Cre transgene, at day 10 of the first round of lactation, 
although there were mild defects in secretory activation in Vhlh-/-MEC glands  
(Figure 2-3A vs. Figure 2-3B), pups were able to thrive and appeared to be normal size 
at weaning of the first litters.  In contrast, by the second round of lactation, there was a 
27% decrease in the mean pup weight at day 10 of lactation (Figure 2-3E), although 
these litters survived and could be successfully weaned to independent cages at 21 days 
of age.  
 
In contrast, by the third round of lactation, 100% of litters born to Wap-Cre 
positive dams were visibly severely runted throughout lactation and pup weight was 
decreased by 62% at day 10 of lactation (Figure 2-3E). As evident in H&E-stained 
sections of glands harvested during the third lactation period, there were dramatic 
reductions in the both the number of Vhlh-/-MEC alveoli and the ability of the alveoli 
formed Vhlh-/-MEC to produce milk. Moreover, the majority of alveoli present were poorly 
organized, and in several areas, no distinct alveolar lumen could be observed. Whereas 
the entire lactating mammary gland of wild type multiparous mice is compromised of 
fully differentiated alveoli, in the Vhlh-/-MEC glands, the paucity of alveoli present was 
striking. In fact, the Vhlh-/-MEC glands were only 20-30% filled with alveoli by the third 
round of lactation (Figure 2-3C). Alveoli exhibiting hypersecretory, basophilic 
cytoplasmic secretions were also frequently observed. By H&E staining, there also 
appeared to be increased leukocyte infiltration and microvessel density around the 
remaining islands of alveoli, which became even more pronounced in the Vhlh-/-MEC 
glands after subsequent rounds of lactation (for example, Figure 2-3G, fifth lactation). 
However, patches of well-differentiated lobuloalveolar units could also be detected in the 
thrice parous gland. The non-uniform appearance of the lobuloalveolar units in the Vhlh-/-
MEC glands likely results from the mosaic expression pattern of the Wap-Cre transgene 
during pregnancy and lactation (Figure 2-4).  
 
To test whether these impaired alveologenesis and differentiation phenotypes 
were incremental in nature and progressively escalated upon additional rounds of 
breeding, we then harvested glands from the same cohort of mice between days 2-10 
lactation during the fifth lactation. No defects were noted in multiparous control glands 
(data not shown), however the phenotype of the multiparous Vhlh -/-MEC gland was even 
more pronounced. Only 10-15% of the Vhlh -/-MEC glands were filled with alveoli  
(Figure 2-3F-G) and the alveoli exhibited little evidence of differentiation or milk 
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Figure 2-3. Deletion of Vhlh via Wap-Cre phenocopies results obtained with 
MMTV-Cre. 
Mammary glands were harvested from the same cohort of control or Wap-Cre+ 
multiparous dams during successive rounds of lactation and stained with H&E (A-D, F-
G). All scale bars represent 10 μm. (A-B) During the first cycle of lactation (10Lac#1), 
the Vhlh -/-MEC mammary gland accumulated less milk and there were subtle changes in 
MEC architecture, including the more frequent presence of basophilic cytoplasm in 
lobuloalveolar units (B) as compared to control glands (A), 400x magnification. 
Progressive changes in MEC content were determined by H&E staining of glands 
biopsied from dams at day 2 of the third (C-D) or fifth (F-G) of lactation. As observed at 
low power magnification (50x), there are relatively few alveoli present in the Vhlh- /-MEC 
mammary gland during the third (C, 2Lac#3) or the fifth (F, 2Lac#5) rounds of lactation. 
As indicated from higher power images obtained from the same Vhlh-/-MEC mammary 
glands (D, G, 200x magnification), in response to Vhlh deletion there is a complete 
collapse of the alveolar lumen and there are multiple, large CLD still trapped in the MEC 
at the third lactation that should not be present during lactation (D, black arrows). By the 
fifth lactation, the lobuloalveolar structure is more disorganized, there are no distinct 
alveolar lumens and there appears to be increased microvessel density (D vs. G) and 
immune cell infiltration (G, black circles). The mean pup weight per litter +/- SEM was 
calculated between control and Vhlh -/-MEC dams (n>5 dams/genotype) on day 10 during 
the second (Lac. #2) and third (Lac. #3) cycles of lactation. 
 
Data generated by T.N. Seagroves. 
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Figure 2-4. Mosaic nature of Cre expression under control of the Wap promoter. 
Cre (brown staining) was detected by immunostaining formalin-fixed tissue sections as 
described in [50]. The 15-P example demonstrates that Cre-positive lobules may be 
adjacently located to Cre-negative lobules. Cre expression continues to be mosaic in the 
lactating mammary gland. 
 
Data generated by T.N. Seagroves. 
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production. By the fifth round of lactation, no endogenous litters born to Vhlh -/-MEC dams 
survived past the date of birth, therefore, pups obtained from lactating FVB females were 
cross fostered to Cre-positive dams daily to ensure a continuous suckling stimulus.  These 
glands were harvested at day 2 of lactation since lactation failure was evident due to lack 
of milk in the stomachs of nursing pups. None of the Vhlh -/-MEC glands harvested from 
dams bred five times contained areas that appeared by H&E-staining to be differentiated 
enough to produce milk. In summary, extreme changes in gland structure were observed 
beginning at the third round of lactation, including loss of alveoli, decreased evidence of 
secretory differentiation, increased immune cell infiltration and increased microvessel 
density, which all became more prominent during subsequent rounds of breeding. 
Because the proportion of affected MEC increased with each period of gestation and 
lactation, it is possible that VHL is necessary for maintaining the regenerative potential of 
the secretory mammary epithelium. 
 
 
Deletion of Vhlh Does Not Promote Mammary Carcinoma in Aged Females 
 
Although we had expected to observe that deletion of a tumor suppressor that 
causes HIF-1α over-expression would result in mammary tumorigenesis, we did not 
observe any hyperplastic alveolar nodules or carcinomas in any mammary glands 
biopsied from multiparous Wap-Cre-positive mice.  No palpable masses or tumors were 
observed in any of the Vhlh conditional knockout females subjected up to eight 
pregnancies and maintained up to 24 months of age (n=9 mice/genotype).  Instead, as 
described, we observed a progressive loss of the secretory epithelium with each round of 
pregnancy. Therefore, it is clear that deletion of Vhlh in the MEC is not sufficient to 
promote mammary tumorigenesis. These data are consistent with the lack of report of 
mutations in VHL in sporadic breast cancer. 
 
Although no overt tumors were detected, we did observe in H&E-stained sections 
from multiparous, lactating females (3rd-5th lactation period) features suggestive of mild 
dysplasia (n=5 mice). These areas were estimated to occur in less than 3% of the 
epithelial cells. The dysplastic lesions were noted only during the lactation period in Cre-
positive dams that had been bred at least three times. For example, there were ducts 
oracini that contained multiple, fingerlike projections characterized by large MEC with 
dark, snout-like, amphophilic cytoplasms that projected into the ductal/alveolar lumens. 
The nuclei of these regions also were occasionally hyperchromatic. Within these regions, 
there were also pockets of cells that appeared to be syncitia with 2 or more nuclei 
observed per cell (Figure 2-5).  However, these changes were not permanent since the no 
dysplastic regions were observed the same dams when contralateral glands were prepared 
for histology 14 days after removal of the litter. Therefore, we did not observe any direct 
evidence that loss of Vhlh transforms the mammary epithelium. 
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Figure 2-5. In multiparous dams, Vhlh-/-MEC glands exhibit evidence of mild 
dysplasia. 
Example of rarely observed fingerlike projections into the ducts, 200x magnification. (B) 
Example of the more commonly observed fingerlike projections into the alveolar lumen, 
200x magnification. (C) Example of a region containing syncitia of bi-nucleated cells 
(yellow circles) as well as basophilic staining cells, 400x magnification. All scale bars 
represent 10 μm. 
 
Data generated by T.N. Seagroves. 
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Constitutive Expression of HIF-1α , GLUT1 and VEGF, Increased Microvessel 
Density and Enhanced Recruitment of Leukocytes in Response to Vhlh Deletion 
 
To further characterize markers downstream of VHL in the Vhlh -/-MEC glands, 
including HIF-1α and its direct transcriptional targets, Vegf and Glut1, we performed 
immunostaining on glands harvested from multiparous Wap-Cre transgenic females 
during the third lactation period.  Of note, we had previously demonstrated that GLUT1 
immunoreacitivity is strongly down-regulated in the normal mammary gland when Hif1a 
is deleted in MECs [50]. Because high levels of VEGF can induce leukocyte infiltration 
and blockage of VEGF signaling can reduce immune cell infiltration into breast tumors 
[151], we also stained sections with a pan-leukocyte marker, CD45. 
 
In wild type glands, HIF-1α was detected primarily in the nucleus, as expected, 
and was expressed by approximately 60% of the acinar MEC (Figure 2-6A). In contrast, 
deletion of Vhlh caused up-regulation of HIF-1α expression (Figure 2-6B). It should be 
noted that in response to Vhlh deletion, HIF-1α immunoreactivity was observed in both 
the nucleus and the cytoplasm of MEC, but that no expression was detected in the more 
basally-located myoepithelial cells or in the cells immediately adjacent to the alveoli, 
which by H&E-staining appeared to be infiltrating immune cells (Figure 2-6G, circled 
regions). The expression of GLUT1 (basolateral localization) and cytoplasmic VEGF was 
also strongly up-regulated in the Vhlh -/-MEC glands compared to wild type glands 
(Figure 2-6C and 2-6D and Figure 2-6E and F), confirming that the HIF-1α protein 
detected by immunostaining was transcriptionally functional. 
 
 
Epithelial-Specific Deletion of Vhlh Induces a Stromal Response 
 
Although deletion of Vhlh produces multiple MEC phenotypes, there were also 
severe defects in the mammary-associated stromal vasculature resulting from MEC-
specific deletion of Vhl. This was first noticed during gross dissection of lactating glands. 
As shown in (Figure 2-6G and 2-6J), Vhlh -/-MEC glands harvested from thrice lactating 
multiparous dams were hypervascular, and the blood vessels leading to the mammary 
gland were dilated as compared to vessels in control glands. The Vhlh -/-MEC glands in 
multiparous mice also bled profusely during surgical resection, requiring heavy 
cauterization. Closer observation under a stereozoom microscope revealed the presence 
of large areas of hemorrhage within the glands (Figure 2-6J). In addition, there was very 
little accumulated milk within the Vhlh -/-MEC glands; the only milk present was restricted 
to few patches of presumably non-recombined alveoli.  Finally, during milk collection, 
blood could occasionally be extracted along with milk from dams harboring Vhlh -/-MEC, 
but not from wild type dams (data not shown). These data demonstrate VHL expression 
in the mammary epithelium is necessary for maintenance of the vasculature of the normal 
mammary gland and that VHL-regulated signals originating from the mammary 
epithelium control the proper branching and integrity of the mammary gland vasculature. 
To quantitate the changes in microvessel density between genotypes, Chalkley analysis 
was performed following immunostaining with anti-CD34 antibodies. As shown in  
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Figure 2-6. Changes in HIF-1α , GLUT1 and VEGF expression, microvessel 
density and immune cell infiltration in multiparous mice. 
(A-F) Deletion of Vhlh in the mammary epithelium results in uniform over-expression of 
HIF-1α (B), GLUT1 (D) and VEGF (F) by MEC in thrice multiparous mice. Paraffin 
sections from formalin-fixed control (WT) or Vhlh-/-MEC mammary glands generated from 
Wap-Cre transgenic stocks were prepared from glands isolated from lactating dams 
during the third round of lactation.  All scale bars represent 10 μm. Following antigen 
retrieval in citrate buffer, sections were stained with antibodies to HIF-1α, glucose 
transporter-1 (GLUT1), vascular endothelial cell growth factor (VEGF) or the pan-
leukocyte marker CD45. (A-B) HIF-1α signal (brown nuclear stain) was detected in 
approximately 60% of MEC in WT lactating tissue (A), whereas intense nuclear staining 
as well as cytoplasmic staining of HIF-1α was observed in all MEC in which Vhlh was 
deleted (B). Note the lack of HIF-1α staining in the stromal cells immediately adjacent to 
and surrounding the alveoli (B); the majority of these stromal cells have the morphology 
of myoepithelial cells (white arrowheads) or leukocytes (black arrowheads), 400x 
magnification. (C) As expected, GLUT1 is expressed by all WT MEC at lactation, but 
there was an extreme up-regulation of GLUT1 expression in the Vhlh -/-MEC glands (D), 
200x magnification. (E-F) Similarly, low levels of VEGF were expressed by WT glands 
(E), whereas expression of VEGF was strongly up-regulated in the Vhlh-/-MEC glands (F), 
400x magnification. (G-H) Deletion of Vhlh results in hyper-vascularity and hemorrhage 
of the mammary gland. The gross appearance of thrice multiparous wild type (G-H) or 
Vhlh -/-MEC (I-J) thoracic mammary glands was compared by imaging live, anesthetized 
mice under a stereozoom dissecting microscope. The edge of the thoracic gland is shown 
in each low power field (G, I, 12.5x magnification). The dashed blue box indicates the 
area highlighted in panels G and I. In these panels individual alveoli and their supporting 
blood vessels can be visualized (H, J, 25x magnification). In control dams, all alveoli are 
fully distended with milk (G, white opaque material), and the uniform basketlike network 
of vasculature that surrounds each alveolus can be identified (H). In contrast, in Vhlh -/-
MEC glands, the majority of vessels supporting the alveoli are hyper-dilated, overall vessel 
density appears to be increased and there are areas of hemorrhage (J, orange asterisk). 
The large intramammary vessels are also dilated (J, white arrows). Moreover, the paucity 
of milk-containing alveoli in the Vhlh null gland is striking, as there are only a few 
lobules capable of producing milk (yellow dashed oval). (K-L) Sections were stained 
with anti-CD45 antibodies. Very few CD45+ cells were detected in the stroma of wild 
type lactating glands (K, arrowheads), whereas there was an increase in the number of 
CD45+ cells present in the Vhlh -/-MEC glands (L).  To quantitate changes in microvessel 
density and leukocyte infiltration, Chalkley analysis was performed following 
immunostaining for CD34 (M) and the mean percentage of CD45+ cells/total number of 
MEC was determined (N). The mean Chalkley score and the percentage of CD45+/MEC 
± SEM is presented. 
 
Data generated by D.L. Peacock, T.N. Seagroves and R.L. Krueger. 
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Figure 2-6M, there was a 30% increase in the mean Chalkley score in multiparous Vhlh -
/-MEC glands. 
 
Finally, whereas CD45+ cells were occasionally detected in the stroma 
surrounding lobuloalveolar units in the wild type lactating gland (Figure 2-6K), we 
observed a dramatic increase in the number of CD45+ cells present in the stroma of the 
Vhlh-/-MEC glands immediately surrounding abnormal acini (Figure 2-6L), possibly due to 
increased production of VEGF. The mean percentage of CD45+ cells/total MEC 
increased >2.0-fold in multiparous Vhlh -/-MEC glands (Figure 2-6N). 
 
 
Conditional Co-Deletion of Hif1a Does Not Rescue the VHL-Dependent Phenotypes 
 
Because HIF-1α is a key substrate of VHL that at least partially confers the 
phenotypes observed in VHL disease, we then tested whether conditional co-deletion of 
Hif1a could rescue the Vhlh-dependent phenotypes. To achieve deletion as early as 
possible during mammary gland development, the MMTV-Cre line D transgene was 
utilized. As shown in Figure 2-7, deletion of Hif1a was not sufficient to rescue the 
phenotypes resulting from Vhlh deletion. In fact, during the first lactation period, there 
were fewer alveoli present in the double knockout gland (Figure 2-7C) than were 
observed in glands in which either Vhlh (Figure 2-3D) or Hif1a (Figure 2-7B) had been 
singly deleted. Moreover, the few alveoli present in the co-deleted gland were more 
collapsed and poorly differentiated compared to alveoli present in either the control 
glands (Figure 2-7A) or the glands in which Hif1a alone was deleted (Figure 2-7B). No 
pups survived that suckled the co-deleted gland, even during the first lactation period, 
therefore, exogenous pups were continuously cross-fostered to maintain the suckling 
stimulus.  
 
To measure changes in gene expression, cDNA was prepared from glands 
biopsied from co-deleted or Vhlh-deleted glands on the date of birth, when secretory 
activation begins (n=3 mice/genotype).  Relative to control glands, expression of Vegf 
mRNA was up-regulated 3.4-fold in Vhlh-deleted mice compared to 2.0-fold in co- 
deleted glands. In addition, expression of ß-casein (Csn2) mRNA was down-regulated 
67% in Vhlh-deleted glands and 5.5-fold in co-deleted glands and the expression of Wap 
mRNA was decreased 50% in Vhlh-deleted glands and 10.6-fold in co-deleted glands. 
Therefore, the decreased expression of differentiation markers in the co-deleted gland 
corresponded with changes observed by histology. 
 
 
Discussion 
 
We have generated the first conditional knockout mouse model to target deletion 
of Vhl and co-deletion of Vhlh and Hif1a within the epithelium of the mammary gland. 
We have shown that in the normal murine mammary gland, VHL expression increases 
over the course of pregnancy as MEC content increases and then decreases sharply at 
involution when MEC regress. These data are supported by previous observations that 
  33 
 
 
 
Figure 2-7. Co-deletion of Vhlh and Hif1a via does not rescue the Vhl lactation 
phenotype. 
Mammary glands were harvested from mice of each genotype at day 2 of lactation of the 
first gestation, sectioned and stained with H&E. All scale bars represent 10μm. In each 
case, deletion was achieved using the MMTV-Cre line D transgene. (A) Lactation is 
normal in Cre-negative Vhlh/Hif1a floxed control dams. (B) Single deletion of Hif1a via 
MMTV-Cre line D produces mammary glands with poorly differentiated alveoli and 
trapped CLD, as previously reported [50], although dams were capable of nursing litters. 
(C) Co-deleted Vhlh/Hif1a -/-MEC glands contain relatively few alveoli, which are poorly 
differentiated and characterized by small lumens. (D) Expression of Vegf, ß-casein 
(Csn2) and Wap mRNA was compared between Vhlh -/-MEC and Vhlh/Hif1a -/-MEC glands 
on the date of birth, when secretory activation begins. The normalized fold-change (FC) 
in gene expression is expressed relative to expression levels observed in cDNA samples 
from control glands.  The average fold-change (FC) +/- SEM is presented per genotype 
per gene (dark grey bars, single Vhlh deletion, hatched bars, Vhlh/Hif1a co-deletion). 
 
Data generated by D.L. Peacock, L.P. Schwab and T.N. Seagroves. 
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expression of VHL is primarily localized to the epithelium rather than the stroma [141, 
152, 153]. Conditional deletion of Vhlh in response to either MMTV-Cre or Wap-Cre 
transgene expression reduced alveolar proliferation and secretory differentiation during 
the first round of pregnancy.  
 
Although there were subtle defects in MEC architecture during the first period of 
lactation, dams were able to complete lactation without impacting pup growth. In 
contrast, beginning during the second period of lactation, average pup weight was 
decreased. In addition, with each subsequent gestation, deletion of VHL resulted in the 
continued loss of alveoli capable of producing milk, leading to complete lactation failure.  
The potential of Vhlh -/-MEC to re-populate the parous mammary gland with functional 
alveoli was strikingly reduced by the third lactation, which resulted in a decrease in 
average pup weight of ~60%. The progressive nature of this phenotype was revealed by 
the observations that both the number of alveoli Vhlh -/-MEC and the differentiation 
potential of the MEC continued to decrease with each subsequent pregnancy until 
lactation completely failed by the fifth period of lactation. Changes in mammary 
epithelial cell (MEC) architecture and secretory function were also accompanied by 
changes in the mammary stroma, including increased microvessel density, hemorrhage 
and increased leukocyte infiltration. 
 
Moreover, Vhlh deletion in the mammary epithelium and the downstream up-
regulation of HIF-1α was not sufficient to induce mammary hyperplasias or carcinomas. 
These results are consistent with observations that no VHL mutations have been detected 
in sporadic breast cancer and the lack of reports of increased lifetime incidence of breast 
cancer in VHL patients [152]. Although mutations in VHL may not play a role in breast 
cancer, recent studies have shown that VHL mRNA levels are altered in breast cancer 
patients.  For example, real-time PCR analysis of 124 breast cancer tissue samples 
indicated that levels of VHL mRNA are decreased in node-positive breast cancers, in 
patients with poor prognosis and in patients with metastases or high grade tumors [153]. 
These results imply that decreases in VHL expression may occur as breast cancer cells 
become less-differentiated and more aggressive, which would parallel with the observed 
timing of over-expression of HIF-1α during tumor progression in breast cancer patients 
[84]. 
 
 
A Role for VHL in Mammary Progenitor Cells 
 
The striking reduction in the number of alveoli observed in Vhlh -/-MEC glands with 
each sequential lactation, combined with the previously described ability of the Wap-Cre 
transgene to target a population of self-renewing, progenitor cells known as parity-
induced MECs (PI-MECs) [142, 154], suggests that loss of Vhlh may inhibit the renewal 
capacity of the MEC. The PI-MECs are hormone-responsive progenitor cells that have 
the capacity to proliferate and to renew over several generations [142, 155]. It has been 
observed using the flox-STOP-ROSA26 reporter line of mice that the MEC exposed to 
Wap-Cre during the first gestation period constitute an increased percentage of the total 
regenerated mammary epithelium during subsequent pregnancy cycles, forming both 
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ducts and alveoli comprised of luminal epithelial cells [142]. Therefore, the inability of 
Vhlh -/-MEC glands of multiparous mice to fully re-populate with alveoli and to achieve 
complete secretory activation upon multiple, successive pregnancies is particularly 
intriguing since the Wap-Cre transgene targets Cre expression to differentiated cells as 
well as the PI-MECs.   
 
The most dramatic decreases in alveolar number accompanied by the reduced 
ability to differentiate fully to produce milk were noted in Wap-Cre transgenic females 
bred at least 3 times. Because the MEC derived from the PI-MEC population expressing 
Wap-Cre will expand with successive rounds of pregnancy and lactation, it is possible 
that there would be a larger proportion of Vhlh-deleted MEC present in the Wap-Cre+ 
glands with each successive round of lactation. This phenomenon could explain why the 
Vhlh deletion phenotypes were enhanced with each gestation period and why dams were 
able to successfully nurse their litters at the first and second lactations, but could not 
maintain their litters during subsequent lactations. 
 
There is increasing evidence that the VHL/HIF axis is involved in stem cell 
renewal, as reviewed by Keith et al. [156]. For example, in murine embryonic stem (ES) 
cells, HIF-1α and HIF-2α are expressed, but HIF-2α is not transcriptionally active [157]. 
In human cancer cell lines, HIF-1α has been shown to physically interact with the Notch 
intracellular domain and with ß-catenin, which modulates transcriptional target gene 
activation [158, 159]; both the Notch and Wnt/ß-catenin pathways genes are key players 
in stem cell regulation. The relationship of this axis to cancer stem cell biology is 
particularly intriguing since hypoxic regions of solid tumors are known to be highly 
resistant to radiation and chemotherapy [160] and since cancer stem cells are thought to 
represent the therapeutic-resistant fraction of tumors [161]. Therefore, anti-HIF therapies 
may enhance the clinical response to chemotherapy or radiation [162, 163].  
 
In the normal murine mammary gland and in various mouse models of breast 
cancer, the pluripotent population of primitive stem cells defined by enriched self-
renewal in vitro and outgrowth potential in vivo has been defined as CD24+ (heat stable 
antigen) and CD29hi or CD49fhi (α6-integrin) [118, 121, 164-166]. A sub-population of 
the PI-MECs have been shown to co-express CD24/CD49f [167]. This population is 
thought to exhibit characteristics of a more committed progenitor MEC with limited 
pluripotent potential rather than a more primitive stem cell since most PI-MECs did not 
belong to the long-term label-retaining population [168]. Together, these observations are 
consistent with our data that that the predominant defect in Vhlh-/-MEC glands from 
multiparous females is a failure of the alveoli to regenerate and to differentiate during 
pregnancy. We propose that the luminal progenitor cell population that has the potential 
to form ductal and alveolar luminal MEC decreases in response to loss of Vhlh.   
 
Further investigation is warranted to determine if HIF-1α also plays a direct role 
in regulation of mammary progenitor cell expansion or lineage commitment. Our 
hypothesis is not without precedent as HIF-1α has been shown to act through the Notch3 
pathway to promote breast cancer stem cell renewal when cells are cultured under 
hypoxic conditions [169] and since the Rich laboratory has found that the HIFs directly 
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regulate cancer stem cell activity in glioblastomas [115]. In fact, in the glioma model, 
there was HIF-dependent, preferential expression VEGF and GLUT1 in the cancer stem 
cell population compared to the non-stem population [115]. 
 
 
A Key Role for Local VEGF in Regulating the Mammary-Associated Vasculature 
 
The increased microvessel density, presence of hemorrhage and increased 
immune cell infiltration observed in multiparous glands may be due to the up-regulation 
of Vegf mRNA levels, which was initially observed in Vhlh-/-MEC glands during the first 
round of pregnancy and lactation. By the third period of lactation, we also observed via 
immunostaining extremely high levels of VEGF protein localized to the mammary 
epithelium. These phenotypes contrast with our previous observations of the effects of 
conditional Hif1a deletion in the mammary gland, in which we observed profound 
defects in alveolar differentiation without any impact on alveolar cell 
number/proliferation, changes in microvessel density or changes in Vegf mRNA 
expression [50].  
 
However, it is unlikely that VEGF acts alone to cause the Vhlh-dependent 
phenotype. This conclusion is derived from our observations that co-deletion of Hif1a in 
the Vhlh null background only slightly reduced Vegf mRNA levels, but enhanced the 
block in lactation when compared to deletion of either Hif1a or Vhlh alone. It is known 
that VEGF and VEGF receptor (VEGFR) expression increases during pregnancy and 
lactation and that VEGF immunostaining switches from the stroma to the epithelium 
during late gestation and lactation [170, 171]. Therefore, local VEGF produced by MEC 
is critical for lactation as demonstrated by conditional deletion of Vegf in the mammary 
gland via expression of the cytokeratin-5 (K5)-Cre transgene. In these experiments, 
deletion of Vegf in MEC and myoepithelium resulted in decreased angiogenesis during 
pregnancy and blocked milk production at lactation [172]. Therefore, it would be of 
interest to determine if co-deletion of Vegf could reverse the multiple vascular 
phenotypes observed in the Vhlh -/-MEC mammary gland. In this scenario, Vegf would not 
be expected to rescue MEC secretory defects or the production of milk. 
 
 
Hif1a Deletion Cannot Rescue the Vhlh Phenotype, a Role for Other VHL-
Regulated Targets 
 
Based on the strong correlation between loss of VHL function and constitutive 
HIF activity in VHL patients [173], we predicted that co-deletion of Hif1a would at least 
partially rescue the Vhlh phenotype.  We focused on deletion of Hif1a in these studies 
rather than Hif2a since up to 80% of genes in breast epithelial cells are transcriptionally 
regulated by HIF-1α rather than HIF-2α [22, 174]. Moreover, in a panel of breast cancer 
cell lines, HIF-2α expression was low to undetectable, also pointing to HIF-1α as the 
primary regulator of the hypoxic response in the breast [175]. The dependence of breast 
cancer cells upon HIF-1α for mediating the hypoxic response was later confirmed using 
  37 
specific siRNAs to either HIF-1α or HIF-2α and then analyzing expression of key HIF 
target genes [22].  
 
 Instead of ameliorating the Vhlh-dependent phenotypes, co-deletion of Hif1a 
resulted in a further reduction in the number of alveoli at lactation. In addition, the few 
alveoli that formed exhibited even less evidence of secretory activity by histology than 
was observed for single deletion of either Hif1a or Vhlh. In addition, dams harboring co-
deleted mammary glands were incapable of producing enough milk to support their litters 
even at the first round of lactation. These results suggest that in the context of the Vhlh-
deleted gland, HIF-1α over-expression acts in part to maintain pathways required for 
proper secretory differentiation and milk production. However, the phenotypes arising 
from deletion of Vhlh cannot solely reflect enhanced HIF-1α activity as co-deletion of 
Hif1a could not rescue lactation and instead amplified the impaired lactation phenotype. 
Therefore, additional VHL-regulated substrates or interacting proteins besides the HIFs 
must contribute to the pathology observed in the Vhlh -/-MEC glands.  
 
There is increasing evidence that VHL regulates multiple proteins through HIF-
independent pathways [176, 177], including via protein-interaction activities that are 
independent of its ability to target proteins for proteasome-dependent degradation. For 
example, VHL has been implicated in regulation of the physical integrity of cells and the 
extracellular matrix network, through modulation of microtubule stability [178] and the 
processing of the fibronectin extracellular matrix [179, 180]. VHL also physically 
interacts with several other proteins [177]. For example, VHL interactions stabilize the 
putative tumor suppressor Jade-1 (gene for apoptosis and differentiation in epithelia), 
which then promotes ubiquitinylation of ß-catenin [181]. Finally, it is possible that 
deletion of Vhlh in the mammary epithelium may also lead to premature senescence 
independent of HIFα function via up-regulation of the cyclin-dependent kinase inhibitor 
p27, as recently described in mouse embryonic fibroblasts [182]. 
 
 
A Role for VHL in the Prolactin Response 
 
The mammary gland is resilient and often compensates for lack of gene function 
in subsequent pregnancies by ameliorating the phenotype observed at first lactation. Our 
data suggest that VHL function is critical to regulate either the ability of progenitor cells 
to develop into differentiated epithelium. An alternate explanation is that the Vhlh -/-MEC 
are unable to respond to pregnancy hormones. Interestingly, the incremental loss of 
alveolar differentiation phenotype observed upon deletion of Vhlh is similar to that 
observed previously upon Wap-Cre mediated deletion of Jak2 in the murine gland, the 
kinase that activates STAT5 in response to prolactin. Conditional deletion of Jak2 
completely blocks alveolar proliferation and differentiation, which is compounded by a 
failure to maintain differentiated cells during lactation [183].  Similarly, deletion of Stat5 
via Wap-Cre, in which Stat5 is deleted after alveolar differentiation has initiated, results 
in a loss of differentiated cells, suggesting that STAT5 is also needed for maintaining 
alveolar differentiation [184]. Previous studies have shown that hypoxia can activate 
STAT5 through JAK2 in normal murine HC11 MEC and in MCF7 breast cancer cells 
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[185], however, it is unclear whether STAT5 activation would also occur in response to 
deletion of Vhlh since HIF-1α is constitutively expressed. 
 
 
Summary 
 
In conclusion, although VHL does not function as a classic tumor suppressor in 
the breast, we have shown for the first time that it is required to regulate proper 
development and expansion of the mammary epithelium during repetitive cycles of 
pregnancy and lactation. Since the mammary gland is not essential for survival of the 
individual animal, the conditional deletion model system we have developed will be 
useful to continue to dissect the general role of VHL in regulation of proliferation, 
differentiation and/or self-renewal of secretory epithelium. 
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CHAPTER 3.    HYPOXIA-INDUCIBLE FACTOR 1α  PROMOTES PRIMARY 
TUMOR GROWTH AND TUMOR-INITIATING CELL ACTIVITY IN 
BREAST CANCER ‡ 
 
 
Introduction 
 
Over-expression of the oxygen-responsive transcription factor Hypoxia Inducible 
Factor (HIF)-1alpha correlates with poor prognosis in breast cancer patients. The 
MMTV-PyMT (polyoma virus middle T) mouse is a widely utilized pre-clinical mouse 
model that resembles luminal breast cancer and is highly metastatic. Prior studies in the 
PyMT model demonstrated that HIF-1 is essential to promote carcinoma onset and lung 
metastasis, although no differences in primary tumor endpoint size were observed. Using 
a refined model system, we investigated whether HIF-1 is directly implicated in 
regulation of tumor-initiating cells (TICs) in breast cancer. Mammary tumor epithelial 
cells (MTECs) were created from MMTV-PyMT mice harboring conditional alleles of 
Hif1a, followed by transduction ex vivo with either Adenovirus-beta-galactosidase or Cre 
to generate wild type (WT) and HIF-1 null (KO) cells, respectively. The impact of HIF-1 
deletion on tumor-initiating potential was investigated using tumorsphere assays, limiting 
dilution transplantation and gene expression analysis. Efficient deletion of HIF-1α 
reduced primary tumor growth and suppressed lung metastases, prolonging survival. Loss 
of HIF-1 led to reduced expression of markers of the basal lineage (K5/K14) in cells and 
tumors and of multiple genes involved in the epithelial to mesenchymal transition. HIF-
1α also enhanced tumorsphere formation at normoxia and hypoxia. Decreased expression 
of several genes in the Notch pathway, Vegf and Prominin-1 (CD133) were observed in 
response to HIF deletion. Immunohistochemistry confirmed that CD133 expression was 
reduced in KO cells and in tumorspheres. Tumorsphere formation was enhanced in 
CD133hi versus CD133neg cells sorted from PyMT tumors. Limiting dilution 
transplantation of WT and KO tumor cells into immunocompetent recipients revealed 
>30-fold enrichment of TICs in WT cells.  These results demonstrate that HIF-1alpha 
plays a key role in promoting primary mammary tumor growth and metastasis, in part 
through regulation of TICs. HIF-1 regulates expression of several members of the Notch 
pathway, CD133 and markers of the basal lineage in mammary tumors. Our results 
suggest that CD133, which has not been profiled extensively in breast cancer, may be a 
useful marker of TICs in the PyMT model. These data reveal for the first time that HIF-1 
directly regulates breast TIC activity in vivo. 
 
 
 
 
                                                
 
‡ Adapted with permission. Schwab, L. P., Peacock, D. P., et al. (2012). "Hypoxia-
inducible factor 1alpha promotes primary tumor growth and tumor-initiating cell activity 
in breast cancer." Breast Cancer Res 14(1): R6. 
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Methods 
 
 
Animals 
 
Mice harboring two alleles of exon 2 of Hif1a flanked by loxP sites (double-
floxed, DF) were provided by Dr Randall Johnson (University of California San Diego) 
on a mixed genetic background (129Sv-C57BL/6) and were described in full detail in 
[41]. Hif1a stock mice were first backcrossed to the FVB/Nj strain (The Jackson 
Laboratory, Bar Harbor, ME, USA) for 11 generations prior to being bred to MMTV-
PyMT transgenic mice obtained from Dr Kent Hunter (National Cancer Institute, 
Frederick, MD, USA), which had previously been backcrossed to the FVB/Nj strain. 
Lung metastasis induced by the PyMT transgene is highly penetrant in the FVB/Nj 
background [186]. All procedures were approved by Institutional Animal Care and Use 
Committee at the University of Tennessee Health Science Center. 
 
 
Establishing Hif1a Wild-Type and Knockout Mammary Tumor Epithelial Cells 
 
Several mammary tumors (> 500 mm3) were isolated from Hif1a DF, PyMT+ 
bigenic female mice. Tumors were chopped with scalpels and then with razor blades, and 
the paste was digested with 1 mg/ml collagenase type III (Worthington Biochemical 
Corp, Lakewood, NJ, USA) in RPMI media containing 5% fetal bovine serum (FBS) (5 
ml/g tissue) for 2 hours at 37°C. Organoids were pelleted at 1,100 rpm, washed four 
times with digestion buffer and then plated into standard tissue culture plates in plating 
medium as described previously [187]. After 48 to 72 hours, the plating medium was 
switched to complete mammary epithelial cell growth medium (GIBCO DMEM: Nutrient 
Mixture F-12 (DMEM/F-12; Invitrogen, Carlsbad, CA, USA), 5% FBS, 5 μg/ml insulin 
(Sigma-Aldrich, St Louis, MO, USA), 10 ng/ml recombinant murine epidermal growth 
factor (EGF, Invitrogen). At passage 6, MTECs were transduced with either adenovirus 
β-galactosidase (adeno-β-gal) or adeno-Cre at a multiplicity of infection (moi) of 80 
plaque-forming units (pfu)/cell to generate WT and KO MTECs, respectively. Adenoviral 
transduction was repeated, and the deletion efficiency between WT and KO MTECs was 
confirmed by both quantitative RT-PCR (qRT-PCR) and Western blot analysis. After 
adenoviral transduction, MTECs were weaned to medium containing only 2% FBS 
(DMEM/F-12 + 2% FBS). 
 
For subcultivation, cells were rinsed twice with Puck's A saline, then incubated 
for up to 60 minutes at 37°C in a 3:1 solution of dispase II/0.25% trypsin reconstituted in 
Puck's A. No ethylenediaminetetraacetic acid (EDTA) was utilized to subcultivate cells 
because treating cells with trypsin-EDTA changed tumor cell morphology from an 
epithelial (cuboidal) to a mesenchymal-like (spindle) appearance. All cells were passaged 
less than 30 times before use in tumorsphere or in vivo assays. Spent media were 
routinely tested for mycoplasma using the MycoAlert Kit (Lonza, Basel, Switzerland). 
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All cells were grown either at normoxia in an air-jacketed CO2 incubator (5% 
CO2; SANYO, Wood Dale, IL, USA) or at hypoxia (0.5% O2, 5% CO2) in a multigas 
incubator (SANYO) in which N2 gas displaces O2. Cells were exposed acutely (≤6 hours) 
or chronically (> 6 hours to several days) to hypoxia and were removed from chronic 
hypoxic exposure only for brief periods to change the media. 
 
For immunostaining of cultured cells, WT or KO cells passaged with a dispase-
trypsin mixture were plated into tissue culture-treated chamber well slides (BD 
Biosciences, Franklin Lakes, NJ, USA or EMD Millipore Corporation, Billerica, MA, 
USA), grown to 60% to 80% confluence and then post fixed for 20 minutes at room 
temperature with 2-4% paraformaldehyde (PFA)-PBS, followed by permeabilization with 
0.5% Triton X-100 for 5 minutes. Cells stained with CD133 were not permeabilized. 
Primary antibodies to CD133, Troma-I (K8), cytokeratin 14 (K14) and cytokeratin 5 (K5) 
were incubated overnight at 4°C. All cells were stained with 4',6-diamidino-2-
phenylindole (DAPI) prior to being mounted with VECTASHIELD Mounting Medium 
(Vector Laboratories, Burlingame, CA, USA). 
 
 
Western Blot Analysis 
 
Insoluble material remaining after preparation of whole-cell extract (WCE) was 
reextracted in high-salt (HS) solution (400 mM NaCl) buffer as described in Chapter 2, 
except that the deubiquitinase inhibitor N-ethylmaleimide (NEM) was added to a final 
concentration of 0.5 μM. HS-WCE was resolved on 3% to 8% Tris-acetate gels (1 to 10 
μg/lane; Invitrogen) and transferred onto polyvinylidene fluoride membranes prior to 
blocking with 5% milk and enhanced chemiluminescence-based detection of antibody 
complexes.  
 
 
Gene Expression 
 
Total RNA was prepared using RNA-Bee RNA isolation reagent (amsbio, Lake 
Forest, CA, USA), and RNA quality was confirmed by the Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA) assay. RNA with an RNA integrity 
number > 9.0 was used to prepare cDNA using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA). qRT-PCR was performed 
using optimized primer and 6-carboxyfluorescein-labeled probe sets designed using 
Universal ProbeLibrary Assay Design Center software (Roche Applied Science, 
Indianapolis, IN, USA) as described previously in Chapter 2. To control for cDNA input 
(40 to 80 ng/reaction) when using cultured cells as the source of RNA, the crossing point 
(Cp) values were normalized based on the expression of the integrator complex subunit 3 
(Ints3) gene, which is expressed at moderate levels in the mammary gland. This gene 
changes < 20% between WT and KO cells cultured at normoxia or hypoxia and in WT 
and KO tumors by Illumina whole-genome expression arrays (Illumina Inc, San Diego, 
CA, USA) (TNS, personal observations). To compensate for any changes in epithelial 
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content in whole tumors between genotypes, because only the tumor epithelium is deleted 
for Hif1a, Ints3-normalized Cp values were also normalized to Krt18 (cytokeratin 18). 
 
 
Cell Growth and Invasion Assays 
 
MTECs were grown in normoxic culture (ambient air; 5% CO2) or hypoxic 
culture (0.5% O2, 5% CO2) in medium buffered with 25 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES). On the day before enumeration, either 350,000 
cells/well in 6-well format (complete growth medium) or 100,000 cells/well in 12-well 
format (2% FBS medium) were seeded into multiwell plates. In all cases, the medium 
was changed postplating, but was not replenished for the duration of the experiment. 
Cells were harvested after culture for 0, 24, 48, 72 or 96 hours of culture at normoxia and 
hypoxia. All cells were plated in triplicate or quadruplicate per genotype/oxygen 
tension/time point. Each replicate was counted by hemacytometer, and counts were 
verified using an Accuri personal flow cytometer after gating against cell debris (BD 
Biosciences). 
 
For invasion assays, WT and KO MTECs that had been gradually weaned to 
medium supplemented with 0.5% FBS were cultured overnight in serum-free DMEM/F-
12 medium. The next day 25,000 cells were plated onto control inserts or Matrigel-coated 
transwell inserts (BD Biosciences) and attracted to wells containing complete growth 
medium with 5% FBS. Cells were plated in triplicate per genotype/oxygen tension. The 
mean cell invasion index corrected for random migration was calculated after 48 hours 
according to the manufacturer's instructions. Changes in invasion are expressed as a fold 
changes relative to the invasion index observed for WT cells cultured at normoxia (fold 
change = 1.0). 
 
 
Mammary Tumor Epithelial Cell Transplant into FVB Recipients 
 
MTECs dissociated into single cells with 0.05% trypsin-EDTA were counted 
using a hemacytometer and diluted into HBSS. When transplanted into recipients at 
relatively low density (≤500 cells/gland), cells were diluted 1:1 (vol:vol) with growth-
factor reduced Matrigel-Hank's balanced salt solution (HBSS). At higher densities, cells 
were resuspended in HBSS alone. Cells were kept on ice until injection into the right 
inguinal mammary fat pads (10 μl) of 3-week old female FVB/Nj recipients (The Jackson 
Laboratory) using a 26-gauge PT2 needle mounted on a Hamilton syringe, followed by 
clearing of the endogenous epithelium. Recipients were palpated one or two times per 
week, and outgrowths were measured with digital calipers to calculate tumor volume as 
described previously [126]. 
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Tissue Histology and Immunostaining 
 
Tumors were harvested from anesthetized mice and flash-frozen in liquid nitrogen 
for preparation of RNA or protein, or they were fixed in 10% neutral buffered formalin 
(NBF) for 6 hours at room temperature for histological staining (H & E) and 
immunostaining. Paraffin-embedded sections (5 to 7 μm) were immunostained after 
antigen retrieval (1 × citrate buffer), followed by development with a VECTASTAIN 
Elite ABC Kit and ImPACT DAB (diaminobenzidine) substrate (Vector Laboratories). 
Alternatively, to prepare frozen sections suitable for CD133, Troma I, K14 and K5 
immunofluorescent staining, anesthetized mice were perfused intracardially with 10% 
NBF. Tumor tissue was postfixed for 10 minutes in NBF at room temperature prior to 
cryoprotection overnight at 4°C in 30% sucrose-PBS, embedding in OCT medium and 
preparation of 10 μm sections by cryostat. Sections used for visualizing the keratins were 
postfixed for an additional 10 minutes in 10% NBF prior to 0.5% Triton X-100 
permeabilization.  
 
 
Lung Metastasis and Survival Studies 
 
Lungs were either harvested from recipients at the same time as primary tumors 
(at a volume of approximately 1,000 mm3), 8 weeks after primary tumor resection (500 to 
750 mm3) or when recipients subjected to tumor resection were moribund as indicated by 
decreased body condition scores and panting. Lungs were inflated with 10% NBF and 
postfixed in NBF overnight. Paraffin-embedded sections (7 μm) representing every 100 
μm of lung tissue were obtained for each paraffin block, and all sections were stained 
with H & E. The individual H & E-stained section containing the highest number of 
metastases per recipient, as evaluated by counting each slide under a light microscope at 
× 50 original magnification, was used to determine the mean of metastases per genotype. 
 
 
Tumorsphere Culture and Immunostaining 
 
WT or KO MTECs were briefly trypsinized, washed and strained (40 μm filter) to 
obtain single cells. The presence and viability of single cells were verified by viewing 
trypan blue-stained cells using a hemacytometer, and only cells with > 90% viability 
were used in sphere assays. Single cells were resuspended in serum-free DMEM-F-12 
mammosphere media containing 20 ng/ml mouse recombinant EGF, 20 ng/ml basic 
fibroblast growth factor, 1 × B27 (all from Invitrogen) and 4 μg/ml heparin (Sigma-
Aldrich, St Louis, MO, USA) as described previously [188]. Primary tumorspheres were 
derived by plating 30,000 single cells/well into six-well ultra-low-adhesion dishes. 
Secondary and tertiary tumorspheres were plated at 5,000 to 10,000 cells/well and 2,000 
cells/well, respectively. Dishes were cultivated at normoxia or hypoxia (0.5% O2; 5% 
CO2) for 10 to 14 days prior to enumeration of spheres. Individual spheres ≥ 100 μm 
from each replicate well (n ≥ 12 wells/genotype/oxygen tension) were counted under a 
dissecting microscope. The percentage of cells capable of forming spheres, termed the 
"sphere formation efficiency" (SFE), was calculated as follows: [(number of spheres 
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formed/number of single cells plated) × 100]. End point tumorspheres were collected 
from ultra-low-adhesion dishes, washed with PBS, then flash-frozen for preparation of 
RNA or dried onto slides for 10 to 15 minutes at 37°C. Slides were postfixed with 4% 
PFA-PBS for 15 minutes and immunostained. All slides were stained with DAPI prior to 
being mounted in either ProLong Gold antifade reagent (Invitrogen) or VECTASHIELD 
Mounting Medium (Vector Laboratories). 
 
 
Tumor Digestion and Flow Sorting 
 
 All mammary gland tumors used for flow-sorting experiments were harvested 
from intact Hif1a DF, MMTV-PyMT+ (equivalent to HIF-1α WT) transgenic female 
mice at a size of > 300 mm3 but < 1,500 mm3. Necrotic areas were removed from solid 
tumor tissue, and solid tissue was cut into small fragments with scissors. Tumor tissue 
was then weighed and chopped for 5 minutes with scalpels, followed by 5 minutes of 
chopping to a fine paste with razor blades. The tissue paste was digested in digestion 
buffer (DMEM/F-12, 1 × gentamicin, 1 × antibiotic-antimycotic (Sigma-Aldrich), 300 
U/mL collagenase type III (Worthington Biochemical Corp) and 100 U/mL 
hyaluronidase (Sigma-Aldrich)) for 1 to 2 hours at 37°C at 125 rpm (10 mL/g tissue). 
Digested tissue was pelleted by centrifugation, and the red blood cells were lysed with a 
solution of 0.8% NH4Cl-HBSS. To obtain single cells, organoids were further digested 
with 0.25% trypsin-EDTA for up to 10 minutes at 37°C and washed with serum-
containing medium to inactivate trypsin, followed by a final digestion for 10 minutes at 
37°C in 5 mg/ml dispase II (Roche Applied Science)/Puck's A solution containing 1 
mg/mL DNase I (Roche Applied Science). The cell suspension was passed through a 40 
μm filter insert, and this flow-through was then passed through a flow cytometer tube 
with a 35 μm filter cap insert to further enrich for single cells. Viability post-digestion 
was routinely assessed by trypan blue staining. Only cells with viability > 85% were 
subjected to antibody staining. 
 
Isolated single cells were resuspended to a density of up to 5 million cells/ml in 
flow buffer (HBSS, 2% FBS, 10 mM HEPES) and incubated for 1 hour on ice with the 
biotin- or fluorophore-conjugated antibodies. These antibodies included a biotin-
conjugated anti-mouse hematopoietic lineage panel supplemented with anti-mouse 
CD31-biotin, anti-mouse CD133-phycoerythrin (CD-133-PE) and anti-mouse CD24-
fluorescein isothiocyanate (CD24-FITC), each at a 1:100 dilution. Secondary antibody 
incubation (streptavidin-allophycocyanin) in flow buffer was performed for 30 minutes 
on ice. After being stained, cells were strained through a clean flow cytometer tube with a 
35 μm filter cap. To determine cell viability, either SYTOX Blue (1 μM; Invitrogen) or 7-
AAD (1 μg/ml; BD Biosciences) was added to each flow tube sample 10 to 20 minutes 
before flow cytometry analysis. 
 
Cells were subjected to cytometric profiling using a 100 μm nozzle at a sheath 
pressure of 20 psi on a BD Biosciences FACSAria flow cytometer (maintained by the 
University of Tennessee Health Science Center Flow Cytometry and Sorting Core) 
equipped with violet (404 nm), blue (488 nm), green (532 nm) and red (635 nm) lasers 
and applying FACSDiva software. All sample and collection tubes were maintained on 
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ice. BD Biosciences CompBeads stained with either CD133-PE or CD24-FITC were used 
to set the compensation gates, and cells stained with isotype-matched secondary 
antibodies were used as controls for staining specificity. Cells heat-killed for 30 minutes 
at 65°C were used to gate against dead cells positive for SYTOX Blue or 7-AAD. 
Lineage-negative (Linneg) cells were identified by gating against cells positive for the 
mouse lineage panel (BD # 559971) plus CD31-biotin. Because almost 100% of cells 
isolated from late-stage carcinomas of the PyMT-transgenic mouse were positive for 
CD24-FITC as previously described [118], viable, Linneg mammary tumor cells were 
gated in a two-way sort for CD133hi versus CD133neg cells. 
 
Sorted cell samples were collected directly on ice into 15 mL conical tubes 
precoated with 20% FBS, and a subset of collected cells was subjected to postsorting 
analysis to verify the purity and viability of the sorted populations. Sorted cell 
populations were immediately pelleted, washed to remove FBS and counted using a 
hemacytometer prior to reconstitution in mammosphere medium and plated in six-well 
ultra-low-adhesion dishes (Corning Life Sciences, Corning, NY, USA) at the indicated 
densities. FACSDiva plots were imported into FlowJo version 7.0 software (Tree Star 
Inc, Ashland, OR, USA) for data analysis and creation of histogram plots. 
 
 
Limiting Dilution Transplantation 
 
WT or KO MTECs were briefly trypsinized, washed with HBSS and serially 
diluted into 1:1 HBSS/Matrigel. Six dilutions per genotype (500, 200, 100, 50, 25 or 10 
cells/10 μl) were introduced into the right inguinal cleared fat pads of FVB/Nj recipients. 
Tumor-initiating potential was defined as the ability to form a palpable tumor mass > 5 
mm diameter (approximately pea-sized). The estimated TIC frequency was calculated 
using Extreme Limiting Dilution Analysis (ELDA) software [189]. Fisher's exact (χ2) test 
was used as a complementary approach to compare TIC activity between WT and KO 
cells at each cell density evaluated (GraphPad Prism version 4.0 software; GraphPad 
Software, Inc, San Diego, CA, USA). All animals were palpated twice weekly until 
surgical resection of the primary tumor or euthanasia. 
 
 
Image Acquisition 
 
Western blots were scanned at 600 dpi and imported into Photoshop software 
(Adobe Systems, Inc, San Jose, CA, USA). Digital images of immunostained or H & E-
stained tissue sections and cells cultured on chamber well slides were captured using a 
Leica DM6000 upright fluorescence microscope (Leica Microsystems, Inc, Buffalo 
Grove, IL, USA) mounted with a SPOT Insight cooled charge-coupled device camera 
(SPOT Imaging Solutions, Inc, Sterling Heights, MI, USA) and imported into Photoshop 
using SimplePCI software (Hamamatsu Photonics, Sewickley, PA, USA). All images 
between genotypes and conditions per experiment were digitally captured for the same 
exposure time. Immunostaining images were not digitally altered to reduce background  
or to adjust brightness or gain. Confocal images of spheres were captured every 0.75 μm 
with a Zeiss LSM210 microscope system (Carl Zeiss, Thornwood, NY, USA). 
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Appropriate gain and black level settings were determined based on spheres incubated 
with secondary antibody alone. All images were captured using the same gain and 
exposure settings, and upper and lower thresholds were set using the range indicator 
function. No additional background correction algorithms were applied. Digital slices 
were merged into a single, composite image using Zeiss Zen software. 
 
 
Results 
 
 
A Mammary Tumor Model with Constitutively Deleted HIF-1α  
 
We observed that HIF-1α expression generally increased during tumor 
progression in MMTV-PyMT mice as previously observed in patients [84], thereby 
confirming that the MMTV-PyMT model is appropriate for these studies  
(Figure 3-1). To generate a parental pool of MTECs, mammary tumors were isolated 
from Hif1a floxed (DF), PyMT+ females (FVB/Nj background), and epithelial cells were 
transduced with ether adeno-β-gal or adeno-Cre to create HIF-1α WT and KO cell lines, 
respectively. Efficient Hif1a deletion was confirmed by qRT-PCR and Western blot 
analysis (Figure 3-1).  
 
During expansion, MTECs were weaned from complete growth medium to 
medium supplemented only with 2% FBS, as low-serum medium was previously utilized 
to evaluate cell growth [126]. The levels of HIF-1α detected by Western blot analysis 
following acute (0 to 6 hours) or prolonged (> 6 hours) hypoxia was determined using 
WT MTECs. On the initial day of hypoxia exposure, cells were 80% confluent prior to 
transfer to a hypoxic chamber for 24, 12, 8, 6 and 3 hours prior to harvest. Cells taken 
from normoxic culture (labeled as time t = 0) were harvested at the same time as cells 
that had been exposed to hypoxic conditions for 24 hours. Similar to the profile observed 
in Hep3B cells [190], HIF-1α peaked by 3 hours of exposure to 0.5% O2, and, by 24 
hours, expression had attenuated to basal levels (Figure 3-2A). This decrease in HIF-1α 
expression may be due HIF-1α's role in transcriptional regulation of the prolyl 
hydroxylase (PHD) enzymes, which mediate HIF-1α's turnover by the proteasome, 
thereby creating a negative feedback loop [191]. 
 
 In contrast, when WT cells were cultured in the presence of serum and EGF, HIF-
1α levels were not attenuated by prolonged hypoxia exposure (Figure 3-3), and, in fact, 
HIF-1α stabilization at hypoxia remained robust for at least 24 hours. Compared to the 
levels of HIF-1α expression observed in cells cultured in 2% FBS alone, EGF treatment 
increased HIF-1α levels approximately four-fold at normoxia (time t = 0), and this 
upregulation increased to > 10- or > 20-fold following 3 or 24 hours in hypoxic culture, 
respectively. The effect was not due to the differences in serum or insulin concentrations 
between culture media because WT cells cultured in 5% FBS + 5 μg/ml insulin without 
EGF expressed levels of HIF-1α similar to those of cells cultured in 2% FBS alone (data 
not shown). Overall, these results indicate that EGF is a potent regulator of HIF-1α 
expression in normoxic PyMT mammary tumor cells, as previously observed in SK-BR-3 
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Figure 3-1. HIF-1α  expression increases during tumor progression in the 
MMTV-PyMT model and confirmation of HIF-1α  deletion. 
HS-WCE protein extracts were prepared from two individual transgenic MMTV-PyMT 
female mice (FVB/Nj strain) between 6-9 weeks of age. By palpation, each mouse had at 
least one mammary gland with hyperplastic (HP; palpable as grainy), early carcinoma 
(EC, <250mm3) or late carcinoma (LC, >500mm3) lesions, which was expected, since 
tumor progression among glands is asynchronous in this model. Two independent glands 
(one from each mouse) per stage were utilized to prepare HS-WCE for western blotting. 
As shown, HIF-1α expression generally increases during progression, and is most 
abundant in late stage carcinomas.  Included as controls are HS-WCE prepared from WT 
and KO MTECs grown to 80% confluence followed by hypoxic exposure for 6h at 0.5% 
O2. A cross-reactive band (CRM) at ~76kDa was detectable when using lot E2 of the 
Novus Biologicals anti-mouse HIF-1α primary antibody (NB 100-479).  KO cells were 
transduced twice with Adenovirus-Cre in monolayer culture at 80-100 p.f.u./cell in order 
to achieve >99% deletion efficiency as determined by qRT-PCR and western blotting. 
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Figure 3-2. Effect of HIF-1α  deletion upon growth and invasion. 
A. WT MTECs grown to 80% confluence were subjected hypoxia culture for the 
indicated number of hours for up to 24h, or cells were continued to be cultured at 
normoxia, such that the t=0 sample was harvested on the same day as the t=24h hypoxic 
sample. HS-WCE were resolved on 3-8% Tris-Acetate gels and blotted to PVDF 
membrane, which was divided horizontally at approximately 60kDa. The top half of the 
blot was blotted for HIF-1α and the lower portion was blotted for lamin (loading control) 
to avoid the need to strip and reprobe the blot. B. Growth curve of WT and KO MTECs 
cultured at normoxia (Nor) or hypoxia (Hyp) in growth medium supplemented with 5% 
FBS + EGF (left panel) or with 2% FBS (right panel). For cells grown in 5% FBS + EGF, 
a representative graph is shown, in which the mean cell number ± S.E.M. per time point 
of quadruplicate wells per genotype/oxygen tension is plotted per time point.  For cells 
grown in 2% FBS, the grand mean of cell number ± S.E.M. is presented, calculated as an 
average of the mean cell number observed per replicates per time point, as observed in 
three replicate experiments.  All data was analyzed by two-way ANOVA (*p<0.05). C. 
The mean fold-change in invasion was normalized to the invasion index observed for WT 
cells cultured at normoxia (FC=1.0). Data represent the mean fold change in invasion 
observed in three independent experiments. All columns were compared to each other 
using one-way ANOVA analysis with a Bonferroni post-test, *p<0.05. 
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Figure 3-3. HIF-1α  protein expression increases in response to EGF treatment at 
normoxia, and EGF prolongs HIF-1α  stabilization at hypoxia. 
WT MTECs were either cultured in complete growth medium (containing 5% FBS + 5 
μg/mL insulin + 10 ng/mL EGF) or in medium supplemented with 2% FBS only for at 
least five passages prior to re-plating to test the effect of EGF treatment on HIF-1α 
expression. Cells grown to 80% confluence were incubated at hypoxia for the number of 
hours indicated (3, 6, 24).  All cells were put into hypoxic culture beginning 24h prior to 
harvest of the t=0h time point, such that cells at the t=0h time point (normoxic control) 
were harvested at the same time as the t=24h hypoxia time point.  Cells were exposed to 
hypoxia for the indicated number of hours prior to removal from culture and the 
immediate extraction of HS-WCE.  HIF-1α was detected using lot E2 of NB 100-479. 
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and MCF-7 cells [192], and that EGF prolongs HIF-1α stabilization under hypoxic 
conditions. 
 
 
HIF-1α  Promotes Cell Growth and Invasion 
 
To determine whether the HIF-1α KO PyMT+ MTECs derived from ex 
vivo adenoviral transduction behave similarly in vitro as previously described [126]; cell 
growth was compared in WT and KO cells cultured at normoxia and hypoxia. Cell 
growth was also compared for WT and KO cells cultured in complete or minimal (2% 
FBS only) growth medium. By 48 hours of culture, and then throughout the time course, 
there was a statistically significant difference between WT and KO cell number at 
normoxia and hypoxia for each medium formulation (Figure 3-2B); overall, fewer KO 
than WT cells were observed following exposure to either oxygen tension. Cells cultured 
in complete growth medium grew faster than those in reduced serum. In cells grown in 
5% FBS + EGF, more KO than WT cells were often observed by 96 hours of culture at 
normoxia (Figure 3-2B), owing to the acidic environment of the superconfluent WT cells 
as reported previously [193]. As expected, hypoxia exposure decreased the rate of growth 
for both WT and KO cells, although the difference between WT and KO cell density was 
the most striking following extended hypoxia exposure (≥ 72 hours). 
 
Cells cultured in 2% FBS medium were gradually weaned to reduced serum 
(0.5% FBS) prior to use in invasion assays since immediate serum withdrawal resulted in 
massive cell death even when cells had been routinely cultured in medium containing 2% 
FBS. Deletion of Hif1a reduced invasion at normoxia by 3.9-fold and by 3.5-fold at 
hypoxia (Figure 3-2C). In contrast, significant induction of invasion by WT cells during 
hypoxia was not observed as previously described [126]. Although there was a trend 
toward increased invasion, the differences were not significant on the basis of analysis of 
variance (ANOVA) analysis. Likewise, there was no significant difference in the 
invasion potential of KO cells between normoxic and hypoxic culture. 
 
 
Expression of Basal Markers Is Reduced in Cultured Knockout Cells 
 
The expression of markers of the luminal lineage (Troma-I, detecting cytokeratin 
8, K8) and the basal lineage (cytokeratins 5 and 14, K5 and K14) by WT and KO cells 
was evaluated by immunofluorescent staining of nearly confluent cells that were cultured 
overnight (12 to 14 hours) at normoxia or hypoxia (Figure 3-4). The majority of WT and 
KO MTECs cultured at normoxia (Figure 3-4A and 3-4E) and hypoxia (Figure 3-4I and 
3-4M) stained with antibodies to K8. This was expected because the PyMT model is a 
luminal-like model of breast cancer. However, fewer KO cells expressed K14 when 
cultured at either normoxia (Figure 3-4B vs 3-4F) or hypoxia (Figure 3-4J vs 3-4N). 
Hypoxic culture downregulated K14 expression in both WT and KO cells (Figure 3-4B 
vs 3-4J and Figure 3-4F vs 3-4N). Overall, fewer KO cells were dual-positive for K8 
and K14 (yellow cells), suggesting a reduction in a bipotent progenitor cell population in 
response to HIF-1α deletion. The most striking phenotype was that no K5+ cells could be  
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Figure 3-4. Loss of basal marker expression in cultured HIF-1 KO cells. 
WT or KO cells were plated onto tissue-cultured treated slides and grown to sub-
confluence, at which time a subset of cells were exposed overnight to hypoxic culture or 
remained under normoxic culture. Cells were co-stained with Troma-I (K8, green) and 
K14 (red) (panels a-c, e-g, i-k and m-o) or with K5 alone (panels d, h, l, p); all slides 
were counterstained with DAPI. Images were captured at 200x magnification (scale bar 
indicates 50 μm). 
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detected in KO cells cultured at either normoxia (Figure 3-3D vs 3-3H) or hypoxia 
(Figure 3-4L vs 3-4P). Hypoxic induction of K5 mRNA has previously been reported in 
MCF-7 cells, [194]; however, an increase in the number of K5+ cells was not apparent in 
PyMT WT cells exposed to hypoxia (Figure 3-4D vs 3-4L). 
 
 
Primary Mammary Tumor Growth Is HIF-1α-Dependent 
 
To evaluate the contribution of HIF-1α to primary tumor growth in a syngeneic 
transplant approach, WT or KO MTECs (n = 50,000) were injected into single, cleared 
inguinal mammary fat pads of FVB/Nj recipient females. Single-side injections were 
utilized to prevent one tumor from influencing the outgrowth of a contralateral tumor. 
There was an approximately 60% decrease in the wet weight and volume of KO tumors 
at week 8 post-transplant, when recipients bearing WT tumors required euthanasia in 
compliance with institutional maximum tumor size recommendations (Figure 3-5A). 
Moreover, the rate of KO tumor growth was slower over the entire course of tumor 
development (Figure 3-5B). When fewer WT or KO cells were utilized to generate 
mammary tumors (500 cells/gland), there was a more pronounced delay in the ability of 
KO cells to form a tumor with a volume > 500 mm3 (Figure 3-5C). The median time to 
form large tumors increased from 64 days for WT cells to 127 days for KO cells 
 (Figure 3-5C). 
 
To confirm that end point KO tumors did not express HIF-1α, Western blotting 
was performed using extracts isolated from three randomly selected whole WT or KO 
tumors. Very low levels of HIF-1α were detected in KO end-stage tumors (Figure 3-5D). 
Residual expression was likely observed because of the presence of stromal components 
derived from the host recipients, such as tumor-associated macrophages. As expected, the 
expression of three classic HIF-1 target genes, vascular endothelial growth factor (Vegf), 
phosphoglycerate kinase 1 (Pgk1) and glucose transporter 1 (Slc2A1 or Glut1), was 
reduced in KO tumors (Figure 3-5E). However, the gross histopathology of tumors was 
not affected by deletion of Hif1a; all tumors were poorly differentiated, solid 
adenocarcinomas as previously described in the PyMT-transgenic mouse [124] (Figure 
3-6). 
 
Because WT tumors were larger than KO tumors, they also exhibited more 
extensive necrosis than KO tumors. Because a larger percentage of KO tumor cells were 
viable, it is not surprising that more Ki67 and caspase 3-positive cells in KO tumors were 
detected by immunostaining (Figure 3-5F and Figure 3-7). Overall, these changes would 
be expected to have a zero net effect on KO tumor growth. In addition, as previously 
reported for late-stage PyMT carcinomas [124], tumors derived from transplanted WT or 
KO cells did not exhibit any cells positive for ERα by immunostaining (Figure 3-8). 
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Figure 3-5. Deletion of Hif1a decreases primary tumor growth. 
A. WT or KO cells (50,000) were transplanted into FVB/Nj recipients. All tumors were 
harvested at day 56 to evaluate tumor weight, volume and burden (% tumor weight/total 
body weight) (n=10 recipients/genotype, p <0.05, unpaired Student’s t-test).  B. The 
growth rate of WT and KO tumors at 50,000 cells input. Best-fit curves were established 
based on a polynomial fit algorithm in Prism 4.0. Data in A-B are representative of seven 
independent experiments (>60 recipients/genotype). C. When 500 WT and KO cells are 
input, the median time to 50% of recipients to develop tumors >500 mm3 is 64 days for 
WT and 127 days for KO (n=14 recipients/genotype, p <0.001, log-rank test). D. Western 
blotting for HIF-1α in three independent tumors (500-750 mm3) per genotype; WT and 
KO cells that were cultured 6h at hypoxia serve as positive and negative controls (CRM, 
cross-reactive material). E. Mean fold-change ± S.E.M in expression of HIF-1 targets in 
KO tumors as determined by qRT-PCR (n=5 tumors/genotype). F. An increase in Ki67+ 
cells in KO tumors is balanced by an increase in caspase-3+ cells (n=5 tumors/genotype, 
*p <0.05, Student’s t-test). 
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Figure 3-6. Histology of HIF-1α  WT and KO end-stage tumors. 
H&E-stained sections of end-stage (>750 mm3) tumors derived from WT or KO cells. 
The WT tumors typically contained more extensive areas of necrosis than KO tumors. 
One representative tumor per genotype was imaged using the 5x, 20x, and 63x objectives 
of a Leica DM6000 upright microscope with a SPOT camera, for a final magnification of 
50x, 200x or 630x, respectively.  Scale bar indicates 50 μm. 
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Figure 3-7. Ki67 and activated caspase-3 immunostaining in end-stage PyMT 
tumors. 
Paraffin-embedded, formalin fixed tissue sections from WT and KO tumors (>500-750 
mm3) were immunostained with either Ki67 or activated caspase-3 antibodies and 
immunoreactive complexes detected using the Vectastain ABC Elite kit and developed 
with DAB Impact, followed by counterstaining with Harris hematoxylin.  Scale bar 
indicates 100 μm. 
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Figure 3-8. Expression of p63 and ERα  in WT and KO end-stage PyMT tumors. 
Representative results of p63 and ERα immunostaining in WT and KO tumors 
(n=4/genotype), along with expression observed in normal, virgin mammary glands, 
which serve as the positive control (n=2 mice/~8-weeks of age, FVB strain); 200x 
magnification, scale bar is 50 μm.  Black arrows point to examples of positive cells. No 
obvious changes in p63 expression or localization were detected between WT and KO 
tumors, whereas p63 was located basally within the virgin mammary ductal tree, as 
expected. No immunoreactivity for ERα was detected in end-stage WT or KO tumors 
(which were derived from late stage carcinomas of the MMTV-PyMT transgenic mouse), 
whereas almost all ductal epithelial cells in the virgin mammary gland expressed ERα. 
  
  59 
HIF-1α Promotes an Epithelial-to-Mesenchymal Transition Phenotype and 
Regulates K5 Expression in vivo 
 
To determine whether the expression of K5 and K14 was reduced in KO tumors 
as in cultured cells, expression of K8, K14 and K5 was also evaluated by 
immunofluorescent staining of end-stage tumors harvested from FVB recipients bearing 
WT or KO tumors (four tumors/cohort). The immunostaining pattern was compared to 
that observed in tumors harvested from intact PyMT-transgenic mice. In contrast to 
results obtained in cultured cells, very few cells were dual-positive for K8 and K14 in 
WT tumors. Furthermore, no cells positive for K5 or K14 were detected in any KO 
tumors (Figure 3-9A) (four tumors/genotype). In contrast, there were no obvious changes 
in the expression or localization of p63 detected by colorimetric immunostaining of 
paraffin-embedded sections (Figure 3-8). 
 
qRT-PCR analysis of RNA prepared from the same tumors for which sections 
were prepared for immunostaining revealed that Krt14 (K14) and Krt5 (K5) mRNA 
levels were reduced in KO tumors by 3.8- and 2.0-fold, respectively. As expected based 
on the ability of hypoxia to promote an epithelial-to-mesenchymal transition (EMT) 
phenotype through the Notch pathway [195], multiple core genes in the EMT signature 
were downregulated in KO tumors compared to WT tumors, including Snail, Slug, 
Twist1 and Fn1 (fibronectin), whereas expression of Krt18 (K18) was not affected by 
HIF-1α deletion (Figure 3-9B). 
 
 
Constitutive Hif1a Deletion Represses Metastasis and Prolongs Survival 
 
Initially, metastasis was evaluated in WT or KO tumor recipients by harvesting 
lungs on the same day as the primary tumors. Because recipients bore a single tumor, in 
contrast to the transgenic model, in which all ten mammary glands become tumor-laden, 
very few metastases were present. The lungs from WT hosts exhibited a mean of two 
micrometastases, and the majority of lungs from KO hosts were devoid of metastases 
(Figure 3-10A). 
 
One caveat with regard to interpreting these data is that the tumors developed by 
the KO cells were 60% smaller than the WT (Figure 3-10B). Therefore, to compare the 
effect on lung metastasis when WT and KO tumor volumes were equivalent, the primary 
tumor was resected during a survival surgical procedure when tumors were at least 1.5 
cm in diameter with a corresponding volume range of 500 to 750 mm3. Animals 
subjected to survival surgery to resect the primary tumor were divided into two cohorts. 
In the first cohort, females were euthanized 8 weeks post surgery. WT tumor cells 
developed large macrometastases visible to the naked eye, as well as several 
micrometastases visible by microscopic analysis, with a mean of 19 metastases per lung 
(Figure 3-10B and 3-10A). In contrast, lungs from KO tumor recipients contained 50% 
fewer metastases (Figure 3-10B and 3-10C), which were also smaller overall than the 
WT metastases. Furthermore, 50% of host mice transplanted with WT cells were deemed 
moribund and required euthanasia prior to the 8-week postsurgical period, whereas all  
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Figure 3-9. Loss of cells expressing K14 or K5 in HIF-1 KO tumors is 
accompanied by a reduction in the expression of markers of EMT. 
A. Frozen sections were prepared from tumors harvested from PyMT+ transgenic mice, 
or from WT and KO tumors harvested from FVB recipients. All tumors were ≥500 mm3 
in volume. Sections were co-stained with antibodies to K14 (red) and K8 (green) or K5 
(red) alone, and counterstained with DAPI.  Images were captured at 200x magnification; 
the scale bar represents 50 μm.  B. The mean fold-change ± S.E.M. in gene expression 
observed in end-stage KO tumors of Krt14 and Krt5 mRNAs, as well multiple markers of 
EMT, as determined by real-time PCR performed using primers and probes in Table S2 
(n=5 tumors/genotype).  The mean ± S.E.M. of biological replicates is graphed. The 
expression of Snail, Slug, Twist1, Fn1, Krt14 and Krt5 mRNAs was reduced in KO 
tumors compared to WT tumors, however, the expression of Krt18 varied less than 20% 
between genotypes. 
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Figure 3-10. HIF-1α  expression in tumor epithelium is required for metastasis. 
A. Mean number of micrometastases ± S.E.M observed when lungs are harvested at the 
same time as the primary tumor (>1,000 mm3) (n=9 WT, 14 KO recipients, *p< 0.05, 
unpaired student’s t-test). B. Enhancement of lung metastases when WT and KO primary 
tumors are surgically resected at equivalent volumes (500-750 mm3), followed by 8 
weeks of survival (n=32 WT, 22 KO recipients, *p <0.05 Student’s t-test). C. 
Representative images of lungs harvested from WT or KO MTEC recipients 8 weeks 
after tumor resection (50x magnification). D. The impact of HIF-1α expression in tumor 
cells on the survival of recipients following tumor resection.  A subset of animals 
subjected to primary tumor resection was allowed to survive until moribund due to 
metastasis.  The morbidity hazard ratio is 3.78 times higher when hosts bear WT tumors 
(n=14 WT, 15 KO hosts, log-rank test, p=0.00039, 95% C.I. =1.53-9.31). 
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hosts harboring KO cells lived the full 8 weeks. Therefore, although KO MTECs retain 
the capacity to complete the full metastatic program, metastasis is significantly 
suppressed. 
 
In the second cohort subjected to the tumor resection paradigm, recipients were 
allowed to survive until moribund due to lung metastases (Figure 3-10D). Recipients 
bearing WT tumors succumbed to lung metastases sooner than KO recipients did  
(Figure 3-10D). The median survival increased from 66.5 days for WT recipients to 88 
days for KO recipients (14 WT and 21 KO; log rank score, p < 0.001). Furthermore, 
about 25% of mice implanted with KO tumors (5 of 21) lived longer than 1 year and did 
not develop any lung metastases as evaluated by H & E staining of sections from their 
lungs. 
 
 
Deletion of Hif1a Decreases Tumorsphere Formation 
 
To begin to determine whether HIF-1α may play a role in regulating breast cancer 
stem cell activity, single WT or KO cells were placed into tumorsphere culture. All data 
shown in Figure 3-11 are representative of experiments with several biological 
replicates. As shown in Figure 3-11A, the mean sphere forming efficiency (SFE) 
decreased 4.1-fold in the primary, 2.2-fold in the secondary and 2.5-fold in the tertiary 
generations of spheres derived from KO cells, respectively. The mean SFE among 
biological replicate experiments varied from 0.06% to 1.55% for WT cells and from 
0.015% to 0.85% for KO cells. Variability in the sphere assay among biological 
replicates by more than a log10 factor is not unusual [196]. More importantly, SFE within 
each experiment was always greater for WT cells than for KO cells. 
 
As shown in Figure 3-11, the mean fold enrichment in SFE in WT cells was 4.3-
fold for the primary generation (range 2.85- to 7.23-fold), 4.1-fold for the secondary 
generation (range 1.85- to 6.7-fold) and 2.61-fold for the tertiary generation (range 2.1- to 
2.79-fold). In each case, the mean fold change was determined on the basis of at least 
three biological replicates/genotype/generation. Because the WT and KO cells had 
previously been cultivated in monolayer in the presence of serum, the ability of HIF-1α to 
promote SFE was confirmed using tumor cells derived from freshly digested Hif1a DF, 
PyMT+ tumors originating in intact transgenic mice. 
 
Following isolation from freshly digested tumors, single cells were immediately 
exposed in suspension to adeno-β-gal or adeno-Cre (moi of 80, for 2 to 3 hours), washed 
to remove viral particles and then plated at equal density into sphere culture conditions. 
Spheres derived from the primary generation were digested with trypsin, reexposed to 
adeno-β-gal or adeno-Cre in suspension (80 moi for 2 to 3 hours) and plated for second-
generation spheres. Deletion efficiency was determined for each generation by qRT-PCR 
of genomic DNA isolated from a fraction of cells collected at 72 hours postplating, prior 
to the formation of large tumorspheres. 
 
In contrast to the established KO MTECs, not all floxed cells exposed 2-3h to  
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Figure 3-11. HIF-1α  promotes tumorsphere formation in cultured cells and in 
freshly isolated tumor cells independent of oxygen tension.  
A. Representative experiment in which the mean sphere formation efficiency (SFE) ± 
S.E.M. was determined when WT and KO cells were cultured in tumorsphere culture 
conditions. Tumorspheres ≥100 μm were scored positive, and the mean SFE (the 
percentage of cells capable of forming spheres per total number of single cells plated) per 
experiment (n≥12 wells/genotype; p<0.05, unpaired Student’s t-test) was determined at 
each of the primary, secondary and tertiary generations of spheres. B. A representative 
experiment in which the mean primary and secondary SFE ± S.E.M. was determined 
when single cells were isolated from mammary tumors of Hif1a DF; MMTV-PyMT+ 
mice followed by immediate adenoviral transduction (n≥12 wells/genotype; p<0.05, 
unpaired Student’s t-test). C. Comparison of SFE when WT or KO cultured cells were 
subjected to normoxia or chronic hypoxia. Immediately following plating of single cells, 
dishes were cultured at normoxia or hypoxia throughout the duration of the experiment, 
therefore, cells were exposed to chronic hypoxia. The graph presents mean SFE obtained 
from the secondary generation of spheres (n≥12 wells/genotype). Differences among 
columns were analyzed by ANOVA,  *p <0.05. D. The mean fold change in gene 
expression observed in KO tumorspheres evaluated by qRT-PCR. The grand mean fold 
change ± S.E.M. was determined from three independent experiments; cDNA was 
derived from three preparations of WT and KO secondary spheres grown in 6-well 
format and pooled at experiment endpoint to prepare total RNA (n=3 pools of 
spheres/genotype). The mean expression of Notch 4 (N4), Dll1, Hey1, Hey2 and Prom1 
(CD133) was reduced in KO tumorspheres by greater than 1.5-fold, whereas the mean 
expression of Notch1, Notch2, and Notch3 (N1-N3), or Vegf did not vary by more than 
50% between genotypes. The decreased expression in KO tumorspheres is indicated as a 
negative fold-change. 
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adeno-Cre were deleted for Hif1a. A mean deletion efficiency of 71% or 84% was 
observed following the first or second round of transduction with adeno-Cre,respectively. 
Despite incomplete Hif1a deletion primary and secondary SFE was reduced in Hif1a-
deleted cells by 2.53-fold and 2.30-fold at the primary and secondary generations, 
respectively (Figure 3-11B). The mean fold change in SFE between WT and Hif1a 
deleted (KO) cells among three biological replicates of this assay was 5.74-fold for the 
primary generation (range of 2.53-8.2- fold) and 4.38-fold for the secondary generation 
(range of 2.30-6.54-fold). These results confirm that the enrichment in SFE observed for 
WT cells previously cultured in monolayer with FBS was not an artifact due to culture 
conditions, and suggested that HIF-1α may promote breast TIC potential in vivo. 
 
Sphere formation was also assayed after culture of WT and KO cells at normoxia 
or chronic hypoxia. Figure 3-11C presents data from one experiment in which there was 
a 2.28-fold reduction in KO SFE at normoxia and a 2.1-fold reduction in KO SFE at 
hypoxia, as compared to WT cells. Among biological replicates the mean fold reduction 
in KO SFE at normoxia was 3.26-fold (range of 2.20-6.15-fold) and 6.85-fold at hypoxia 
(range of 2.1 to 9.17-fold). Although there was a trend towards hypoxia increasing WT 
SFE (mean fold increase in SFE of 1.38, and a range of 1.17- to 1.70-fold), the increase 
was not statistically significant in any independent experiment by ANOVA. Changes in 
KO SFE between normoxia and hypoxia were also not significant (mean fold change of 
0.94, and a range of 0.35-2.05-fold). 
 
To determine if HIF-1α expression varied in spheres cultured acutely or 
chronically at hypoxia, HIF-1α expression was evaluated by western blotting of HS-WCE 
prepared from WT or KO spheres exposed to prolonged hypoxia (≥ 4 days), or from WT 
or KO spheres that were initially grown in normoxic culture, but were then briefly 
exposed acutely to hypoxia (6 h) prior to harvest (Figure 3-12). In sphere culture 
conditions, HIF-1α was barely detectable in WT cells exposed to chronic hypoxia, 
whereas robust expression of HIF-1α was observed in WT cells exposed acutely to 
hypoxia. Therefore, in contrast to data obtained from monolayer cultured cells, EGF was 
not sufficient to stabilize HIF-1α expression when cells are grown constitutively at 
hypoxia in sphere culture. 
 
One caveat of the tumorsphere assay is that spheres may be derived from 
aggregation of single cells, or even fusions of small spheres. The contribution of cell 
aggregation to sphere formation was assessed by plating single cells labeled with GFP or 
mKate at a ratio of 1:1 in sphere medium supplemented with 0.5% methylcellulose, 
which acts as a physical barrier to impede cellular aggregation. Figure 3-13 shows in 
these conditions, most spheres were not aggregates of each other, only red cells made red 
spheres and green cells made green spheres. 
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Figure 3-12. HIF-1α  expression in tumorspheres cultured acutely or chronically at 
hypoxia.  
WT or KO tumorspheres were originally derived from single cells plated into ultralow 
adhesion dishes and cultured at normoxia.  A subset of WT and KO tumorspheres (80-
100 μm in size) were then transferred from normoxic culture to hypoxia (0.5% O2) for 
the duration of incubation, which was either acute (6h exposure) or chronic (>4 days 
exposure).  Spheres were then isolated, HS-WCE prepared and HIF-1α expression levels 
were evaluated by western blotting (input of 10 μg HS-WCE/lane) using lot M1 of Novus 
100-479, which produced more cross-reactive material (CRM) bands than previously 
observed with lot E2. 
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Figure 3-13. Clonal expansion of tumorspheres.  
Tumorspheres were derived from PyMT WT single cells labeled with either GFP or 
mKate mixed at a ratio of 1:1 and plated into ultralow adhesion dishes in 5% 
methylcellulose. Scale bar represents 100 μm. 
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HIF-1α-Dependent Regulation of CD133 and the Notch Pathway 
 
Since CD133, Notch receptors and Notch target genes may each be modulated by 
the HIF transcription factors [60, 164, 197], the expression of CD133, genes in the Notch  
pathway and classic HIF targets were evaluated in WT and KO tumorspheres by qRT-
PCR. Figure 3-11D presents the mean fold reduction in gene expression observed in KO 
tumorspheres. Only genes that were consistently observed to be downregulated across 
three biological replicate experiments are shown. Expression of Notch4 was 
downregulated an average of 7.24-fold, whereas expression of the Notch 
receptorsNotch1, Notch2 and Notch3 did not vary by more than twofold. The Notch 
ligand Delta-like-1 (Dll1I) was also downregulated in KO spheres an average of 9.73-
fold, and the transcription factors Hey1and Hey2 were downregulated 3.95-fold and 1.9-
fold, respectively. The HEY family of genes has been proposed to function as surrogate 
markers of Notch activity in multiple human breast cancer cell lines [198, 199]. 
 
Although the expression of the Jagged ligands has been reported to be hypoxia-
inducible in breast cancer cell lines [198, 199], we were unable to confirm a consistent 
effect of HIF-1α on the expression of either Jagged1 or Jagged2 by tumorspheres. For 
example, the expression of Jagged1 was upregulated 3.0-fold in two experiments and 
downregulated 3.0-fold in a third experiment, whereas the expression of Jagged2 was 
observed to be upregulated between 3- to 10-fold in two experiments and downregulated 
3.0-fold in a third experiment (data not shown). In addition, the expression of Dll4, Hes1, 
Hes2 or Vegf, which is a known direct HIF target gene, did not vary between WT and KO 
spheres by more than 1.5-fold. The most striking difference in gene expression was 
observed for Prom1 (CD133), which was consistently downregulated > 9.0-fold in KO 
spheres (Figure 3-11). 
 
On the basis of the qRT-PCR results, the expression of CD133 was then evaluated 
by immunostaining monolayer-cultured WT and KO MTECs grown at normoxia or 
hypoxia (Figure 3-14A). Compared to WT cells, CD133-positive cells were not readily 
detectable by immunostaining of KO cells following culture at normoxia or hypoxia  
(Figure 3-14A). These results were validated by flow cytometry following staining of 
WT and KO cells cultured at normoxia with CD133-PE antibodies. As shown in  
Figure 3-14B, the expression of CD133 was reduced in KO cells more than 9.0-fold. 
CD133 expression was also compared by immunostaining tumorspheres derived from 
WT and KO cells that were grown constitutively at normoxia (Figure 3-14C). As in 
cultured cells, the expression of CD133 was increased in WT spheres relative to KO 
spheres (Figure 3-14C), although in contrast to monolayer culture, CD133-positive cells 
were observed in KO spheres. Culture conditions influenced the expression of CD133 
mRNA levels because expression increased by a mean of 5-fold in WT cells spheres 
relative to the same passage of WT cells cultured in monolayer in 2% FBS (data not 
shown). 
 
To test whether CD133 expression influences SFE, spheres were derived from the 
CD133hi or CD133neg subpopulations of late-stage carcinomas arising in PyMT+ 
transgenic females. Live Linneg single cells were studied by flow cytometry after being  
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Figure 3-14. CD133 expression in PyMT MTECs is regulated by HIF-1.   
A. Sub-confluent WT or KO cultured cells were exposed to acute hypoxia (6h), then 
immunostained for CD133 (green) and counterstained with DAPI.  Images were captured 
at 200x magnification; the scale bar represents 50 μm.  B. Representative CD133-PE 
staining profiles of WT (red histogram) and KO (blue histogram) cells cultured at 
normoxia and subjected to FACS analysis. The isotype only antibody control is also 
plotted (green histogram). The percentage of cells that were CD133 positive was 
determined based on the live, singlet, Linneg parent population using FlowJo. C. 
Secondary WT or KO tumorspheres cultured at normoxia were harvested at study 
endpoint from ultralow adhesion wells, dried onto glass slides, stained with CD133-PE, 
counterstained with DAPI and imaged by confocal microscopy. The highlighted area 
(white boxes) shows a higher magnification image, which demonstrates that CD133 is 
localized to the cell surface/membrane. D. Histogram of CD133-PE (red) in the live, 
singlet, Linneg parent population of cells isolated from tumors that arose in the PyMT 
transgenic mouse, as compared to the isotype antibody control (green); approximately 6% 
of cells were defined in this experiment as CD133hi. D. A representative experiment 
showing the mean SFE/well ± S.E.M of CD133hi vs. CD133neg sub-populations that were 
isolated by flow sorting and cultured at normoxia at a density of 10,000 cells/well in 6-
well format (n≥8 wells/genotype, unpaired Student’s t-test). The SFE was determined as 
the percentage of cells capable of forming spheres per the total number of single cells 
plated. 
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stained with CD133-PE. Among replicate experiments, the tumor epithelial cells 
identified as highly positive for CD133-PE ranged from 5% to 12%. A representative 
histogram is presented in Figure 3-14D, showing that 5.99% of cells were isolated as the 
CD133hi fraction. The mean increase in SFE in the CD133hi subpopulation compared to 
the CD133neg fraction among replicate experiments was > 4.0-fold (a representative 
experiment is shown in Figure 3-14E), suggesting that CD133 may be a useful cell 
surface marker to enrich for TICs in the PyMT model. 
 
 
HIF-1α Promotes Tumor-Initiating Cell Frequency in vivo 
 
On the basis of the dramatic differences in growth rates of WT and KO tumors 
and the reduction in SFE by HIF-1α-KO cells in tumorsphere assays, the ability of WT 
and KO cells to form tumors in recipients under limiting dilution transplantation 
conditions was evaluated. To permit estimation of TIC frequency due exclusively to loss 
of HIF-1α activity, TIC potential was compared using unsorted WT or KO MTECs to 
avoid the physical stress encountered during sorting that reduces cell viability and 
therefore affects the calculation of TIC frequency [119]. The ability of WT or KO 
MTECs to form a palpable tumor mass > 5 mm was evaluated using a broad range of cell 
dilutions (10 to 500 cells: 10, 25, 50, 100, 200 and 500) (Table 3-1). At each cell density 
evaluated, there was a statistically significant enrichment in TIC activity in WT cells, 
which was indicated by the percentage of FVB/Nj recipients positive for a palpable tumor 
(Figure 3-15A and Table 3-1). ELDA analysis [189] revealed a 35-fold reduction in TIC 
frequency from KO to WT cells at day 36 posttransplant (Table 3-1). Data were also 
statistically significant on the basis of the Fisher's exact test (Table 3-1). The difference 
in TIC potential remained statistically significant at day 62 posttransplant in the fold 
enrichment of TIC frequency at day 62 may be that the data from the 500- and 200-cell 
recipients were excluded from the ELDA analysis [127]. All recipients in these two 
cohorts were euthanized at day 36 to compare the histological and gene expression 
profiles of early-stage lesions. Notably, WT recipients in the 50- and 100-cell input 
cohorts required surgical intervention or euthanasia based on tumor volume by day 62, 
whereas no intervention was required for KO recipients until day 96 posttransplant [127]. 
 
The mean volume of KO tumors derived under limiting dilution conditions was 
reduced, and this difference was maintained over several months. None of the KO tumors 
derived from transplantation of 50 or fewer cells exceeded a volume of 100 mm3 by day 
62 (Figure 3-15B). By day 112 posttransplant, 96% of recipients that received 10 WT 
cells had developed measurable tumors, whereas 55% of recipients that received 10 KO 
cells had not. The mean tumor volume among the tumor-positive 10-cell KO recipients 
was < 250 mm3. The difference in TIC potential in the 10-cell cohort remained 
significant until day 244, when all animals were euthanized (Supplementary Data, [127]). 
 
HIF-1α-dependent changes in gene expression were evaluated in early-stage WT 
and KO masses (75 to 200 mm3; five tumors per genotype). Similar to results obtained 
from spheres, Notch4, Hey1 and Hey2 mRNA levels were decreased in KO tumors 2.25-, 
4.27- and 2.3-fold, respectively (Figure 3-15C), whereas Notch1-Notch3 mRNA levels  
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Table 3-1. Estimation of TIC frequency of HIF-1α  WT and KO MTECs. 
 
 Tumor-Positive  
Number of Cells 
Injected HIF-1α  WT HIF-1α  KO 
Fisher’s Exact 
Test 
500 78% (7/9) 0% (0/8) p=0.0023 
200 90% (9/10) 10% (1/10) p=0.0011 
100 77% (10/13) 9% (1/11) p=0.0003 
50 69% (11/16) 6% (1/16) p=0.0006 
25 30% (6/20) 0% (0/20) p=0.0202 
10 35% (8/23) 0% (0/22) p=0.0038 
    
Estimated TIC 
Frequency by 
ELDA (95% C.I.) 
1/82 
(1/57-1/117) 
1/2915 
(1/925-1/9193) p = 5.79e
-21 
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Figure 3-15. HIF-1α  regulates tumor-initiation potential in vivo.   
A. Evaluation of the percentage of recipients (number of recipients positive for a palpable 
mass/number of recipients successfully transplanted x100) that developed a tumor mass 
by day 36 post-injection of unsorted WT and KO tumor cells. The asterisks indicate a 
significant difference between genotypes for a given cell density by Fisher’s exact test.  
B. Comparison of WT and KO mean tumor volume ± SEM over time when 10, 25 or 50 
cells are injected into the mammary fat pad. C. The mean fold change ± S.E.M. in gene 
expression profiles of early-stage tumor masses was evaluated by qRT-PCR; all genes 
displayed were down-regulated in KO tumors as compared to WT tumors (n=4 
tumors/genotype/experiment). 
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decreased by less than 50%. All other genes in the Notch pathway that were previously 
found to be differentially expressed in spheres were not differentially expressed among 
WT and KO tumors, except for Vegf, which was downregulated by a mean of 7.3-fold. 
As observed in end-stage tumors, WT and KO Glut1 and Pgk1 mRNA levels were 
reduced in tumors < 200 mm3. 
 
No gross changes in WT or KO tumor histopathology were observed in recipients 
transplanted with 500 tumor cells. None of the KO masses within this cohort were 
detectable by manual palpation, but microscopic analysis of H & E-stained sections 
revealed lesions < 5 mm in five of eight recipients. Since Vegf mRNA was differentially 
expressed, microvessel density was evaluated by Chalkley scoring of sections 
immunostained with anti-CD34 antibodies. Decreased Vegf mRNA levels corresponded 
with a concomitant decrease in mean Chalkley score in KO tumors (Figure 3-15D). In 
summary, deletion of Hif1a reduced TIC potential as well as neoangiogenesis. 
 
 
Discussion 
 
Although the role of hypoxia and the HIF-1α transcriptional response in 
promoting tumor progression and metastasis is well-established, the direct contribution of 
the HIF family to the regulation of TICs in breast cancer is unknown. HIF-1α rather than 
HIF-2α is believed to be the predominant regulator of the hypoxic response in breast 
cancer [22]; therefore, we sought to determine the effect of Hif1a deletion in the MMTV-
PyMT model of breast cancer. In this study, by using an ex vivo genetic deletion 
approach, we generated constitutive HIF-1α-KO and control (WT) MTECs isolated from 
a pool of MMTV-PyMT tumors. One distinct advantage of this approach is that the 
MTECs are transplantable to immunocompetent hosts, preserving any host-derived 
effects on TIC potential following limiting dilution transplantation, in contrast to the 
xenograft of human cells into immunocompromised mice. Herein we show for the first 
time that HIF-1α positively regulates TIC activity in breast cancer as suggested by sphere 
formation assays in vitro and validated through limiting dilution transplantation of WT 
and KO cells. 
 
Additional advantages of the exogenous transduction and transplantation 
approach versus crosses to MMTV-Cre-transgenic mice include avoiding the mosaic 
nature of MMTV-Cre expression, because not all epithelial cells harboring floxed alleles 
of Hif1a undergo recombination [50], and avoiding the use of a mixed genetic strain 
background by utilizing mouse models backcrossed to a single strain (FVB/Nj). 
Because Hif1a deletion impairs cell proliferation [193], an effect we also observed in 
cultured KO MTECs (Figure 3-2B), incomplete recombination could permit nontargeted 
cells to outgrow the recombined (KO) cells. Additionally, it had not previously been 
assayed whether the lung metastases originating in the MMTV-Cre-derived conditional 
KO females were derived from the recombined tumor cells or were generated from cells 
that had escaped recombination [126]. In addition, the prior use of a mixed strain 
background may have introduced genetic modifier effects that could influence tumor 
incidence and lung metastasis. In particular, both tumor burden and lung metastasis in the 
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MMTV-PyMT model are enhanced on the FVB/N background as compared to C57BL/6 
[200]. 
 
In agreement with the findings of previous studies, our study results confirm that 
HIF-1α promotes the growth of MTECs cultured at hypoxia and enhances lung 
metastasis in vivo [126]. However, there were some differences observed between the 
two model systems. For example, we found that deletion of Hif1a repressed the growth of 
cells at normoxia as well as at hypoxia (by 48 hours of culture). In addition, the 
magnitude of the decrease in KO cell invasion was similar, regardless of whether cells 
were cultured at normoxia or hypoxia, whereas Liao et al. reported a difference only at 
hypoxia [126]. No statistically significant increase in invasion potential between WT 
cells cultured at normoxia and hypoxia was observed, as reported previously [126]. In 
contrast to observations from either PyMT model system in which Hif1a was deleted, 
short hairpin RNA-mediated knockdown of HIF1A in MDA- MB-231 breast cancer cells 
does not significantly change cell number at either normoxia or hypoxia (1% O2) [72]. It 
is possible that the effects of loss of HIF-1α activity on PyMT cell growth in monolayer 
culture would be attenuated if cells were cultured at higher serum levels since MDA-MB-
231 cells were cultured in medium containing 10% FBS whereas PyMT cell lines were 
cultured in medium containing 2% or 5% FBS. We further demonstrate that primary 
tumor growth and survival from distant metastases are dependent upon epithelial cell 
intrinsic HIF-1α expression. In stark contrast to results obtained previously [126], we 
found that HIF-1α plays a significant role in the control of primary PyMT-induced 
mammary tumor growth under either standard (50,000-cell input) or limiting dilution cell 
transplantation conditions (50- to 500-cell input). The cause of the control of net 
mammary tumor growth by HIF-1α is unclear, although our data suggest that HIF-1α-
dependent control of TIC activity may be a primary mechanism driving tumorigenesis. 
The significant changes in Vegf mRNA expression and microvessel density observed in 
early-stage KO tumors may also contribute to the phenotype by further restricting tumor 
growth once tumors are initiated. In agreement with our observations, a HIF-1α-
dependent effect on tumor growth was demonstrated recently in both MDA-MB-231 and 
MDA-MB-435 breast cancer xenografts [71, 72]. 
 
Characterization of the expression of luminal (K8/K18) and myoepithelial 
(K14/K5) lineage markers in WT and KO PyMT cells and tumors revealed that fewer KO 
cells than WT cells coexpressed K8/K14, primarily due to loss of K14-positive cells. 
These results suggest that loss of HIF-1α activity corresponds with a reduction in 
bipotent, stemlike cells in PyMT tumors. The most dramatic phenotype was the absence 
of K5-positive cells in KO cultures and the loss of both K14- and K5-positive cells in KO 
tumors. These data are of interest, given the stratification of triple-negative breast cancers 
(TNBCs) into non-basal-like or basal-like subtypes, based on the expression of both K5 
and epidermal growth factor receptors (EGFRs) in tumors within the basal-like 
subtype [201]. 
 
TNBC patients with a basal-like classification have shorter disease-free or overall 
survival [202, 203] and tumors from TNBC patients with metastatic disease exhibit 
higher levels of K5 and EFGR [204]. A potential influence of HIF-1α on the ability of the 
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K5 and EGFR biomarkers to predict disease-free survival in basal-like TNBC is 
intriguing in light of our observations that, in cultured cells, EGF stabilizes HIF-1α 
expression at normoxia and further potentiates hypoxia-inducible expression of HIF-1α. 
Although the PyMT model is classified as a luminal-like cancer [125], late-stage tumors 
such as the ones utilized to generate HIF-1α WT and KO cells are ER- [124]. 
Subpopulations of both WT cells and WT tumors were positive for K5. 
 
It has also been observed in luminal breast cancer cell lines (T47D and MCF7), 
which contain subpopulations of ER-/PR-/K5+ cells, that the K5+ cells are enriched for 
TIC activity and are resistant to conventional chemotherapies compared to ER+/PR+/K5- 
cells [205]. Of additional relevance to our results regarding the decreased expression of 
K5, K14 and markers of EMT, including Slug, by KO tumors is that hypoxia-dependent 
elevation in K5 mRNA levels occurs in a SLUG-dependent manner in MCF7 cells [194]. 
Furthermore, a statistically significant correlation was found to exist between tumors with 
high SLUG expression and PROM1 (CD133) expression. These tumors also expressed 
high levels of carbonic anhydrase IX (CAR9), which is a known HIF-1 target gene [194]. 
 
Recent whole-genome expression profiling of breast cancers has revealed that the 
hypoxic response (predominantly through HIF-1α), the EGFR and signal transducer and 
activator of transcription 3 (STAT3) pathways are positively correlated together in 
TNBCs as compared to luminal cancers [92]. In support of a functional association 
between the HIF-1α and EGFR pathways in TNBCs, MDA-MB-231 cells treated with 
gefitinib were found to exhibit downregulation of HIF-1α transcriptional activity that 
corresponded with decreases in cell viability and migration, whereas resistance to 
cetuximab or lapatinib therapy was hypothesized to be due to the inability of either drug 
to downregulate HIF-1α activity [205]. Taken together, these observations suggest that 
targeting the HIF pathway may be beneficial to TNBC patients, particularly those 
patients diagnosed with basal-like TNBC. 
 
Based upon the HIF-1α-dependent control of CD133 expression in MTECs and 
tumorspheres, as well as the enrichment of sphere formation in the CD133hi versus 
CD133neg populations, we have identified CD133 as a cell surface marker that may enrich 
for TICs in the PyMT model. Antibodies to epitope 2 of CD133 (CD133/2) have been 
utilized extensively to enrich for TICs in other solid tumors, particularly in human colon 
cancer and gliomas. In contrast, in the normal mammary gland, CD133 is expressed by 
differentiated ER+ luminal cells, and CD133+ cells exhibit lower regenerative capacity 
than CD133- cells [206]. Notably, deletion of Prom1 in a knockout mouse model did not 
impair the regenerative capacity of the normal mammary gland, but did reduce ductal 
branching during morphogenesis by increasing the ratio of luminal to basal cells [146]. 
Yet, in the NKI 295 data set, PROM1 expression levels were found to be lower in ERα+ 
tumors than in ERα- tumors [146]. The association of HIF-1α and PROM1 expression in 
ER- breast cancers is not surprising, given that hypoxia is a potent stimulator of ERα 
degradation [207, 208]. 
 
In contrast to observations in the normal mammary gland, Meyer and colleagues 
have recently shown that, in the context of ER- breast cancers, CD133 enriches for TICs 
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when used in conjunction with CD49f (integrin α6) and CD44 [209]. Specifically, the 
CD49f+/CD44+/CD133hi population identified tumor cells with enriched sphere-forming 
and xenografting potential. Likewise, CD133 has also been shown to enrich for TICs in 
the Brca1 conditional mouse [120]. That a marker of a differentiated normal mammary 
epithelial cell could enrich for cells with TIC activity in the context of breast cancer is 
also supported by recent evidence from multiple laboratories that, inBRCA1 basal-like 
tumors, the TIC population arises from the luminal lineage [210-212]. Interestingly, 
basal-like BRCA1 tumors have previously been shown to overexpress HIF-1α and higher 
HIF-1α levels have been found to be correlated with decreased disease-free survival [213, 
214]. Moreover, Proia et al. found that SLUG promoted a basal-like phenotype before 
and after transformation in BRCA1 tumors [212], which is consistent with our 
observation that expression of Slug decreased more than threefold in HIF-1α-KO PyMT 
tumors that did not express the basal markers K5 and K14. 
 
Furthermore, accumulating evidence suggests that differentiated cells (lineage-
restricted progeny) may reacquire stem cell-like potential and tumor-initiating capacity 
rather than follow a strict linear hierarchy as originally proposed for the normal 
mammary gland. The plasticity involved in breast stem cell biology is emerging. Two 
independent groups have observed the spontaneous conversion of non-stem cells into 
stem cells [215, 216]. Likewise, the results of recent lineage-tracing experiments by 
researchers in the Blanpain laboratory have challenged the requirement for a bipotent 
stem cell in the postnatal normal mammary gland [217]. Under the limiting cell 
conditions routinely used to document the regenerative capacity of a given cell 
population, these authors found that the disruption of the normal luminal-to-
myoepithelial cell ratio is sufficient to stimulate a unipotent myoepithelial progenitor cell 
to reacquire a bipotent progenitor activity that is normally restricted to the embryonic 
gland [217]. Yet, how, or if, this model derived from lineage-tracing experiments can be 
applied to TICs during breast tumorigenesis remains unknown. 
 
One mechanism of HIF-1α-dependent control of TIC may be through regulation 
of the Notch pathway. Interactions of HIF-1α with the Notch intracellular domain 
enhances the regulation of Notch transcriptional targets, such as the HEY genes, and 
promotes EMT in breast cancer [60, 158, 218]. In addition, in breast cancer, NOTCH1 
and NOTCH4 have been positively correlated with stemness, and blocking antibodies to 
NOTCH4 reduces mammosphere formation [218]. In KO tumorspheres and early-stage 
KO tumors, decreased expression of several members of the Notch pathway, 
particularly Notch4 and Hey1, was observed. Changes in Notch4 are of particular interest 
because previous studies have shown that blocking NOTCH4 receptor activity inhibits 
tumor formation of xenografted breast cancer cells, whereas blocking NOTCH1 has less 
of an effect [218]. Although a positive correlation between hypoxia 
and NOTCH3 expression was previously described in breast cancer [169], no HIF-1α-
dependent changes in Notch3 were observed in our studies. 
 
HIF-1α-dependent effects on sphere formation efficiency in vitro and TIC 
activity in vivo were observed using parental tumor cells without first enriching for a 
putative CSC subpopulation based on cell surface markers. One rationale for this 
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approach is the lack of comprehensive information on the markers that define TICs in the 
PyMT model. In a similar PyMT tumor cell transplant paradigm to ours, the population 
of CD24 (heat stable antigen)hi/CD29(β1-integrin)+/CD61(β3-integrin)+ cells was found 
to significantly increase during tumor progression, specifically at the transition from 
hyperplasia to carcinoma. Greater than 90% of cells were characterized as 
CD24hi/CD29+/CD61+ in late-stage carcinomas, and this population also had enhanced 
invasive potential in vitro [118]. In addition, researchers in the Visvader laboratory have 
shown that, in cells derived from PyMT adenomas (early-stage lesions), CD14 and c-kit, 
along with CD49f/CD24, enriches for cells with colony-forming potential [219]. More 
recently, it was shown that CD24/CD90 enriches for stem cells in the PyMT model as 
only the CD24+/CD90+ cells were able to form pulmonary metastases following tail vein 
injection as compared to the CD24/CD90 depleted cells [220]. Moreover, whereas there 
was no significant difference in proliferation between the populations in primary 
tumorigenesis, there was a large and significant increase in proliferation of the CSC 
population during lung colonization, suggesting it is the stem cell population that initiates 
lung metastasis in the PyMT model. 
 
In addition, the physical stress of flow sorting decreases cell viability, which 
therefore directly influences the estimated TIC frequency as determined through limiting 
dilution transplantation. As observed for the MMTV-Neu model, the TIC frequency of 
unsorted cells was 1 in 61, decreasing to 1 in 177 for cells enriched by sorting [119]. 
Likewise, for cells isolated from PyMT adenomas, the TIC frequency was estimated to be 
1 in 556 for unsorted cells, whereas the TIC frequency in Linneg cells following sorting 
for CD24 was 1 in 648 [219]. Using unsorted cells isolated from late-stage carcinomas of 
the PyMT model, we observed a TIC frequency of 1 in 82. It is possible that the TIC 
frequency in the PyMT model may vary based upon both the stage of progression and 
subtle differences in technical procedures among laboratories. 
 
The specific cell surface markers that enrich for breast tumorsphere or TIC 
activity are also likely to vary in each mouse model. In the Balb/C p53-/- model, 
mammary tumor cells double-positive for CD24 and CD29 were found to exhibit TIC 
activity [121]. In contrast, in the MMTV-Neu model Sca-1+ cells were found to correlate 
with sphere formation [221], and CD61 was also described as a marker that enriched for 
TICs [119]. How HIF-1α directly affects various tumor cell subpopulations defined 
through flow cytometric profiling for the known murine mammary stem cell markers, or 
whether HIF-1α is preferentially expressed in a given subpopulation requires further 
extensive investigation. 
 
 
Conclusion  
 
Tumor hypoxia profoundly affects all aspects of tumorigenesis, including tumor 
growth, angiogenesis, metastasis and response to chemotherapy and radiation. Although 
HIF's effects are pleiotropic, evidence for the role of HIF-dependent TICs in controlling 
these phenotypes and the solid tumor stem cell niche is increasing. Notably, a recent 
report indicated that oxygen tension can profoundly influence TICs because repetitive 
cycles of hypoxia and reoxygenation promoted breast cancer cell lines to permanently 
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acquire stemlike properties [222]. Our studies demonstrate that the hypoxic response, 
specifically through HIF-1α, is important for controlling breast cancer stem cell behavior 
through the regulation of CD133 and the Notch pathway. These data, together with 
previous observations that the HIFs directly mediate glioma, lymphoma and AML TIC 
activity [60, 115], suggest that attenuation of HIF activity may effectively eradicate TICs 
in a variety of cancers, leading to improved therapeutic response and overall survival. 
 
We acknowledge the possibility that HIF-1α may regulate activity of TICs and 
differentiated cell lineages simultaneously within a tumor. For example, HIF-1α may 
regulate breast TIC activity in a stemlike cell population expressing CD133, but HIF-1α 
activity may also be required by differentiated cells that may act to support TICs through 
paracrine signaling, perhaps via a HIF-dependent secreted growth factor such as VEGF. 
Whether the EGFR pathway is required for HIF-1α-dependent regulation of TIC activity, 
particularly in basal-like TNBC, also requires further investigation. Given the pleiotropic 
role of HIF-1α in tumorigenesis and metastasis, as well as the increasing evidence that 
stem cells may evolve de novo from non-stem cells, targeting both the TIC and non-TIC 
("bulk") populations in breast cancer is likely necessary to successfully treat primary 
breast cancer and to prevent metastasis. 
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CHAPTER 4.    ITGA6 (CD49F) IS DIRECTLY REGULATED BY HYPOXIA-
INDUCIBLE FACTORS (HIFS) AND PROMOTES TUMOR INITIATION 
AND LUNG METASTASIS 
 
 
Introduction 
 
One of the most widely used approaches to enrich for cells with stem-like features 
is the use of antibodies against cell surface markers followed by FACS cytometry. 
Several cell surface markers routinely used to enrich for CSCs were recently reported to 
be regulated by hypoxia in a HIF-1-dependent manner, including CD44 and CD24 (heat 
stable antigen) [223, 224]. Notably, the combination of CD44 and CD24 was the first 
marker set used to enrich for CSCs/TICs in solid tumors, identifying a sub-population of 
TICs (CD44hi/CD24lo) in breast cancers [225]. In a variety of transgenic mouse models of 
breast cancer, CD24 is used along with other cell surface markers to enrich for mammary 
cells with TIC potential [121, 220, 226]. As discussed previously, hypoxia also induces 
expression of Prominin-1 (CD133) [117], a marker which has been widely used to enrich 
for putative CSCs in a variety of solid tumors, particularly in gliomas [227].  
 
Several integrin subunits that function as receptors for extracellular matrix (ECM) 
proteins also serve as common cell surface markers to enrich for normal mammary 
stem/progenitor cells or breast CSCs. These include integrin beta 1 (ITGB1; CD29), 
integrin beta 3 (ITGB3; CD61) and integrin alpha 6 (ITGA6, CD49f), as reviewed in 
[228]. In breast cancers, the CD49fhi population also identifies a sub-population of breast 
epithelial cells with basal/myoepithelial characteristics that is thought to be the origin of 
luminal cancers [212, 229].  
 
ITGA6 heterodimerizes with either ITGB1 or integrin ß4 (ITGB4, CD104) to 
bind to laminin, an abundant component of the mammary gland ECM. In particular, the 
α6/ß4 heterodimer has been implicated as key factor in mediating breast cancer cell 
motility and metastasis [230]. Moreover, increased ITGA6 immunoreactivity was 
previously shown to correlate with reduced survival of breast cancer patients [231]. 
Moreover, chronic hypoxia increases the cell surface expression of CD49f in MDA-MB-
231 cells through a Rab11-dependent mechanism [232]. Finally, as will be presented in 
Chapter 5, CD49f was identified in our microarray profiling screen as being up regulated 
in Hif1a WT cells more than 2-fold. 
 
Since CD49f expression and the HIF transcriptional core signature are both 
enriched in basal-like breast tumor cells relative to luminal (ER+) tumors [92, 93, 229], 
we sought to determine if CD49f might also be a direct HIF target gene. In this Chapter, I 
will demonstrate that ITGA6 is a direct transcriptional target of either the HIF-1 or HIF-2 
transcription factors. ITGA6 mRNA and protein expression decreases upon deletion or 
knockdown of Hif1a alone in PyMT cells, or in response to knockdown of both 
HIF1A/HIF2A in human MDA-MB-231 cells. At least three hypoxic response elements 
(HREs) were identified in the human ITGA6 promoter that bound either HIF-1 or HIF-2. 
In the PyMT model, CD49fhi cells enriched for TIC potential as shown by limiting 
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dilution transplantation. Furthermore, enriching for CD49fhi cells in MDA-MB-231 cells 
potentiated lung metastasis in a tail vein assay. The reduced tumor-initiating and 
metastatic-initiating potential in the CD49flo tumor cells partially recapitulates the 
phenotypes observed upon deletion of Hif1a in the PyMT model [127]. Together, these 
results suggest that HIF-dependent transcriptional regulation of CD49f is partially 
responsible for HIF’s promotion of TIC activity, ultimately resulting in enhanced breast 
tumor growth and metastasis. 
 
 
Methods 
 
 
Animals 
 
MMTV-PyMT transgenic mice (FVB/Nj) were originally obtained from Dr Kent 
Hunter (National Cancer Institute). FVB/Nj and homozygous NOD.Cg-
PrkdcscidIl2rgtm1Wjl/SzJ (Nod/Scid/Gamma, NSG) mice used as recipients for tumor cells 
were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) or bred in-house. 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee at the University of Tennessee Health Science Center. 
 
 
Cell Culture  
 
PyMT WT and KO MTECs were generated and propagated in cell culture as 
described in Chapter 3 and [127]. MDA-MB-231 cells in which HIF1A, HIF2A, or both 
genes, were stably knocked down by targeting with shRNAs generated as in [233] and 
characterized as in [1]. Parental MDA-MB-231 cells were authenticated by DDC Medical 
and results compared to the ATCC STR database. Cells were grown in DMEM-Hi, 
supplemented with 10% FBS, 1x antimycotic-antibiotic (AA) (Sigma, St Louis, MO, 
USA), 25 mM HEPES and shRNA selection antibiotics [single knockdown (KD): 
shHIF1A or shHIF2A cells, 4 μg/ml puromycin, or double knockdown (DKD): 8 μg/ml 
puromycin and 2 mg/ml hygromycin B]. Spent media from confluent cells were routinely 
screened for mycoplasma using the MycoAlert kit (Lonza, Basel, Switzerland). 
 
 
Flow Cytometry and Sorting 
 
Cells grown in monolayer were detached with 2.5% trypsin/EDTA, washed 
several times with HBSS and resuspended in flow buffer (HBSS containing 2% FBS, 10 
mM HEPES, and 1 mg/mL DNase I). Cell number and viability were verified by trypan 
blue staining prior to staining. Cells (1 x 106 in 200 μl flow buffer) were stained with the 
indicated primary antibodies (BD Biosciences, San Jose, CA) on ice for 1 hour: biotin-
conjugated mouse lineage panel (cat#559971), CD31biotin (cat#553371) CD49f-FITC 
(cat#555735). Samples were rinsed once with 2 mL flow buffer, pelleted and kept on ice 
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until analysis at the UTHSC Flow Cytometry core on a LSR II flow cytometer. All raw 
data exported from DIVA were analyzed using FlowJo software. 
 
For FACS analysis of cells from digested tumors, cultured HIF-1 WT and KO 
PyMT MTECs were transplanted into the right inguinal mammary fat pad of 3-week old 
FVB/Nj female recipients (50,000 cells input), as described in [127]. Tumors (350-750 
mm3) minced to a fine paste and digested with collagenase type III (Worthington 
Biochemical Corp, Lakewood, NJ, USA) to prepare single cells for staining prior to 
FACS analysis. For cell sorting, 40 x 106 cells derived from either cultured PyMT or 
MDA-MB-231 cells, or digested PyMT tumors, were stained as above, rinsed with flow 
buffer, and sorted for purity using the 100 μm nozzle on a FACSAria cytometer using the 
gating strategy described in [127]. 
 
After exclusion of dead cells and doublets, cells were sorted into either of two 
gates: for PyMT, CD49f+/CD24high or CD49fneg/CD24low, or for MDA-MB-231 cells 
CD49fhigh or CD49flow. Sorted cells were collected into 4.5 mL tubes pre-coated with 
100% FBS and filled with 1 mL of DMEM + 20% FBS. Post-sort analysis was performed 
to verify purity and viability (7-AAD) of sorted populations. Cell viability was re-
confirmed in the laboratory by trypan blue staining and hemacytometer analysis just prior 
to cell culture or to injection into live mice.  
 
 
 Limiting Dilution Transplantation  
 
Four cell inputs (25, 50, 100 or 200 cells) per sorted cell population 
(CD49f+/CD24hi or CD49fneg/CD24low) were injected into the cleared mammary fat pads 
of 3-wk old FVB/N recipients (n= at least 8 mice/cohort) in a volume of 10 μl of 1:1 
HBSS: growth-factor reduced Matrigel, BD Biosciences, San Jose, CA). Mice were 
palpated 1-2x/week and tumors measured with digital calipers. Lesions were scored 
positive for tumor initiation when the diameter of the lesion was ≥ 5mm in diameter. Data 
was input into the Extreme Limiting Dilution Analysis (ELDA) software for estimation 
of CSC frequency, as in [127]. 
 
 
Tail Vein Injection of MDA-MB-231 Cells into NSG Recipients 
 
MDA-MD-231 cells were mock-sorted (no primary antibody), or stained with 
CD49f-FITC and either not sorted or sorted for CD49fhi vs. CD49flo sub-populations (10-
20% high versus low gates). Post-sort, cells were counted by hemacytometer and adjusted 
to 150,000 to 185,000 cells/100 μl HBSS. Cells were injected into the pre-warmed tail 
vein of NSG recipient mice (n=7/cohort) and euthanized 7 weeks later. Lungs of 
anesthetized mice were harvested and processed for histology as in [127]. Image J 
analysis software was used to calculate the mean area of lungs occupied by metastases.  
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Tumorsphere Assay  
 
Single cells derived from digested PyMT+ tumors were FACS-sorted based on 
the expression of CD49f and CD24 into two populations: CD49f+/CD24hi and 
CD49fneg/CD24lo. A subset of sorted cells from each population was immediately plated 
at a density of 15 cells/ ml into ultra low adhesion (ULA) tissue culture plates (Corning, 
NY, USA) containing tumorsphere medium and tumorsphere formation efficiency 
(TSFE) calculated as in [127]. Data shown is representative of three independent 
experiments. 
 
 
Gene Expression  
 
Total RNA quality was assessed by the Agilent 2100 Bioanalyzer (Santa Clara, 
CA, USA) and converted to cDNA using the High-Capacity cDNA reverse Transcription 
kit (Applied Biosystems, Foster City, CA, USA). Optimized primer and probe sets were 
designed with the Universal Probe Library Assay Design Center software (Roche 
Applied Science, Indianapolis, IN). Ints3 (integrator complex subunit 3) or CYPA 
(cyclophylin A) were used as a loading control for murine or human samples, 
respectively. The advanced relative quantification algorithm of the Roche LightCycler 
480 system was used to calculate Itga6 expression relative to the loading control. 
 
 
Immunofluorescence  
 
PyMT MTECs or MDA-MB-231 cells were plated onto tissue-cultured treated 
glass chamber well slides in standard culture media. At 80% confluence, cells were 
placed at normoxia or hypoxia (0.5% O2) for 6 additional hours. Slides were fixed with 2-
4% paraformaldehyde (PFA) for 10 minutes at room temperature followed by 
immunostaining with anti-CD49f-FITC (BD Biosciences) or anti-CD49f (Chemicon) 
followed by anti-rat IgG Alexa Fluor® 488. For tumorspheres, endpoint spheres were 
dried onto glass slides for 15 minutes at 37ºC, post-fixed with 4% PFA for 15 minutes 
and immunostained with CD49f-FITC.  
 
 
Promoter Analysis and Chromatin Immunoprecipitation (ChIP) 
 
The promoter of ITGA6 was scanned for the presence of putative HIF response 
elements (HREs) using Transcription Factor Matrix (TFM) Explorer. A 2500 bp 
sequence (-2000 to +500) was scanned for the consensus HRE sequence using weight 
matrices available from JASPER and TRANSFAC. Primers were designed to three 
independent HREs in the human ITGA6 promoter. MDA-MB-231 shEmpty (empty 
pLKO.1 vector) or shHIF1A transduced cells were cultured at 21% (normoxia) or 0.5% 
O2 (hypoxia) for 6-24 hours, and ChIP performed using primary antibodies against 
Histone H3 (AbCam 1791), HIF-1α (AbCam 2185 or Santa Cruz sc-10790X), HIF-2α 
(Novus NB100-122), or rabbit IgG, as the non-specific control.  
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Breast Tumor Subtype Analysis  
 
ITGA6 mRNA expression across breast cancer subtypes was analyzed using two 
independent data sets. The Cancer Genome Atlas [93] data was obtained from http://tcga-
data.nci.nih.gov/tcga/tcgaHome2.jsp. The GSE1992 [234] data set was downloaded from 
the Gene Expression Omnibus website (GEO, http://ncbi.nlm.nih.gov/projects/geo). 
Boxplots depicting ITGA6 mRNA expression stratified by PAM50 classification were 
generated in Prism, and p-values calculated following ANOVA analysis with Bonferroni 
correction.  
 
 
Kaplan-Meier Curves  
 
 Survival analysis data was derived from the GSE1992 microarray data set. 
Normalized ITGA6 expression values were divided into four equal quartiles based on 
distribution frequencies. Forty-nine tumors were identified in the top quartile (≥75% 
percentile) with “high” ITGA6 expression (≥0.484), and 49 tumors were identified in the 
lowest quartile (≤25% percentile) with “low” ITGA6 expression (≤-0.813). Survival 
analyses were performed in Prism and p-values derived using the log-rank test. 
 
 
Results 
 
 
Deletion of HIF1A Down-Regulates CD49f Expression 
 
To assess if HIF-1 regulates expression of CD49f, Hif1a WT and KO MTECs 
derived late stage PyMT carcinomas were grown at normoxia or hypoxia and CD49f 
levels evaluated by quantitative real-time PCR (qRT-PCR) and immunostaining. 
Expression of Itga6 mRNA increased 2-fold in WT cells in response to hypoxia (6h), and 
this hypoxic induction was reduced in HIF-1 KO cells. At normoxia, expression of Itga6 
mRNA was decreased by 50% in KO cells (Figure 4-1A). Similarly, examination of 
CD49f protein levels by immunofluorescence (IF) staining of WT and KO cells revealed 
a decrease in CD49f signal in normoxic KO cells relative to WT cells; this effect was 
more striking at hypoxia (Figure 4-1B). However, FACS cytometry profiling using the 
same antibody as used in IF (CD49f-FITC) did not reveal any significant changes in the 
mean fluorescence intensity of CD49f between WT and KO PyMT cells.  
 
To determine whether CD49f is differentially expressed in WT and KO tumors in 
vivo, WT and KO MTECs were implanted into syngeneic FVB hosts to generate tumors. 
Single cells from digested tumors were stained with CD49f-FITC and subjected to FACS 
profiling (n ≥5 tumors/genotype). As compared to the isotype control, the mean 
enrichment in CD49f MFI was 1.8 fold higher in WT versus KO tumors (Figure 4-1C). 
When total RNA from these same tumors was analyzed by RT-PCR, the mean expression 
level of Itga6 mRNA was decreased ~2-fold in KO tumors. Although this effect was 
small, it was statistically significant and consistent with data from cultured cells  
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Figure 4-1. ITGA6 (CD49f) is down-regulated upon deletion of Hif1a in PyMT 
cells, tumors and in HIF-1α  KO tumorspheres. 
A. HIF-1α WT or KO cultured cells were analyzed for relative Itga6 mRNA levels at 
normoxia or following 6 hours hypoxia (**p<0.01, ***p<0.001, ANOVA with 
Bonferroni post-test, n=3 biological replicates/genotype, representative of one 
experiment). Fold change is relative to KO mRNA levels at normoxia which was set to 
1.0. B. WT and KO cultured cells were exposed to normoxia or 6 hours hypoxia, then 
immunostained for CD49f-FITC and counterstained with DAPI.  Images were captured at 
200x magnification; the scale bar represents 20 μm.  C. Representative CD49f FACS 
staining histograms of WT (black histogram) and KO (blue histogram) tumors subjected 
to FACS analysis. The isotype only antibody control is also plotted (red histogram). Data 
is representative of n≥5 tumors/genotype. The percentage of tumor cells that were CD49f 
positive was determined based on the live, singlet, Linneg parent population using FlowJo. 
D. Average fold change CD49f mean fluorescence intensity (MFI) between replicate 
FACS analyses (p < 0.01, Student’s t-test, n≥5 tumors/genotype) E. Average fold change 
in Itga6 mRNA in HIF-1α WT and KO tumors, each relative to control (p < 0.01, 
Student’s t-test). F. End-point HIF-1α WT and KO tumorspheres were dried onto glass 
slides, stained with CD49f-FITC, counterstained with DAPI and imaged by confocal 
microscopy. Scale bar represents 50 μm. 
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(Figure 4-1E). Together, these results suggest that hypoxia/HIF-1 regulate CD49f at both 
the mRNA and protein levels. 
 
Previously we showed that deletion of HIF-1 significantly decreased tumorsphere 
formation efficiency (TFE) in the PyMT model and reduced expression of CD133 in 
tumorspheres [127]. Tumorspheres derived from KO MTECs, also exhibit reduced 
expression of CD49f as compared to WT tumorspheres (Figure 4-1F).  
 
 
Deletion of HIF1A Alone or Together with HIF2A, Results in Decreased Expression 
of CD49f by the Human Breast Cancer Cell Line MDA-MB-231 
 
To confirm that the effect of HIF1A deletion on CD49f was not restricted to the 
PyMT model, we analyzed the effect of HIFα deletion on CD49f expression in the 
human breast cancer cell line MDA-MB-231. MDA-MB-231 cells were previously 
shown to be CD49f+/CD24Neg [229]. CD49f expression was profiled in these cells 
(Figure 4-2A) in 5 independent experiments by flow cytometry. Knockdown of HIF1A 
alone decreased CD49f by a mean of 1.58-fold, which increased to 2.27 fold in DKD. 
Knock down of HIF2A alone did not reduce CD49f expression (Figure 4-2B). 
 
Immunofluorescence staining of MDA-MB-231 cells cultured on coverslips 
revealed a modest hypoxic induction of CD49f. While there was a slight decrease in 
CD49f signal intensity in the shHIF1A cells as compared to EV or shHIF2A cells, the 
combination of both HIF1A and HIF2A knockdown resulted in almost no CD49f 
expression (Figure 4-2C). These data suggest that CD49f expression is regulated by the 
HIF transcription factors, but is more sensitive to HIF-1α than HIF-2α loss. Of note, IF 
staining is still being optimized to repeat and verify these results.  
 
 To determine if the HIFs regulate expression of CD49f, we cultured all four 
MDA-MB-231 genotypes at normoxia and hypoxia and analyzed the expression of 
ITGA6 mRNA. Hypoxia did not increase baseline mRNA levels of ITGA6 in control cells 
(shEmpty). Expression of ITGA6 mRNA was ~50% lower in shHIF1A cells as compared 
to shEmpty cells at normoxia or hypoxia. In contrast, decreased ITGA6 mRNA relative to 
shEmpty cells was only observed at 6 or 24 hours of hypoxia. Independent of oxygen 
concentration, there was a >3-fold decrease in ITGA6 expression when HIF1A and 
HIF2A were simultaneously knocked down (Figure 4-2D). In agreement with results 
from cultured cells, mammary gland tumors derived from all four MDA-MB-231 
genotypes transplanted into NSG mice also showed decreased expression of ITGA6 
mRNA upon knock down of HIF1A alone or in conjunction with HIF2A. There was no 
change in ITGA6 mRNA in tumors derived from shHIF2A cells compared to shEmpty 
tumors (Figure 4-2E). 
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Figure 4-2. CD49f expression is reduced in HIF1A and HIF2A double knockdown 
MDA-MB-231 cells and tumors. 
A. MDA-MB-231 EV, shHIF-1α, shHIF-2α and DKD cultured cells were stained for 
CD49f-FITC and subjected to FACS analysis. Plots represent the maximum fluorescent 
intensity of stained cells (red) versus the isotype control (blue, representative of 4 
individual experiments). B. Multiple cytometry analyses were combined to determine the 
average fold change in mean fluorescence intensity (MFI) among the four genotypes (n=4 
independent experiments). C. Cells were plated on tissue culture glass slides and cultured 
until 90% confluent prior to being subjected to normoxia or hypoxia for 6 hours. Cells 
were fixed with 4% PFA and stained for CD49f. Scale bar represents 20 μm. D-E. Mean 
fold change in ITGA6 mRNA expression in cultured MDA-MB-231 cells (n=3/genotype) 
and end-stage tumors (n=3 tumors/genotype). mRNA expression was evaluated after 6 
and 24 hours of hypoxic exposure. shEmpty at 24 hours normoxia (0 hours hypoxia) was 
set to represent a fold change of 1. 
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ITGA6 (CD49f) Is a Direct HIF Transcriptional Target Gene  
 
Due to the apparent HIFα-dependent regulation of ITGA6 mRNA we observed in 
both PyMT and MDA-MB-231 cells, we hypothesized that ITGA6/CD49f was a direct 
HIF target. Upon examination of the ITGA6 promoter, three potential HIF Response 
Elements (HRE) were identified upstream of the transcriptional start site (TSS) in human 
ITGA6 (Figure 4-3A). The three sites were located at -170, -1333, and -1762 base pairs 
from the TSS. One potential conserved HRE site was identified in the mouse Itga6 
promoter at -1690 from the TSS. To examine HIF-1α recruitment to the CD49f promoter, 
we performed chromatin-immunoprecipitation (ChIP) assays using MDA-MB-231 
shEmpty (EV) and shHIF1A cells cultured at hypoxia for 6 hours. HIF-1α was strongly 
recruited to both the -170 and -1762 HRE sites in EV cells relative to shHIF1A cells 
(Figure 4-3B, upper panel). In contrast, there was very weak enrichment of HIF-1α 
bound to the -1333 site. A previously characterized HRE site in the HIF- 1α target gene 
erythropoietin (EPO) was used a positive control for HIF-1α binding (Figure 4-3), and 
histone H3 as a general active transcription control. To determine if HIF-2α could 
compensate for loss of HIF-1α during CD49f transcription, ChIP assays were repeated 
using an anti-HIF-2α antibody. The same putative HRE sites were analyzed by qRT-
PCR. At both the -170 and -1762 sites, HIF-2α was weakly bound in WT cells  
(Figure 4-3B, lower panel). However, in the shHIF1A cells, HIF-2α binding increased, 
suggesting a compensatory role for CD49f regulation with loss of HIF-1α. These data are 
consistent with our prior observations that loss of HIF-1α in MDA-MB-231 cells results 
in up-regulation of HIF-2α protein [1]. 
 
 
CD49f Promotes Primary Tumor Formation and Increases TIC Frequency in the 
PyMT Model  
 
Individual tumors harvested from a PyMT transgenic female mouse were 
combined and digested to obtain a single cell preparation that was used to sort MTECs 
based on expression of CD49f in combination with CD24. Sorted cells were injected into 
mice in a limiting dilution transplantation assay or plated for a tumorsphere formation 
assay. The tumorsphere formation efficiency (TSFE) of CD24high/CD49f+ cells was 3.5 
times higher than the CD24low/CD49fneg cells (representative of n=2 biological replicates, 
p=0.0001) (Figure 4-4A). When transplanted into FVB hosts, CD24high/CD49f+ MTECs 
resulted in primary tumors that were larger in volume at study endpoint than tumors 
derived from CD24low/CD49fneg MTECs (Figure 4-4B). In addition, when analyzed by 
ELDA, CD24high/CD49f+ derived tumors showed a significantly higher frequency for 
TICs than the CD24low/CD49fneg derived tumors (1 of 99 vs. 1 of 578, respectively, 
p=0.00043) (Table 4-1). These data indicate that MTECs with high expression of 
CD24/CD49f have a higher tumor initiating potential than CD24low/CD49f cells. 
 
At experiment endpoint, primary tumors derived from the transplanted sorted 
cells were harvested, digested to a single cell preparation and analyzed by flow cytometry 
(Figure 4-4C). Tumors derived from CD24high/CD49f+ MTEC were composed of 2 
distinct cell populations: CD24high/CD49f+ MTECs and CD24low/CD49fneg MTECs, 
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Figure 4-3. ITGA6 (CD49f) is a direct HIF target gene in MDA-MB-231 cells. 
A. A schematic representation of HREs in the proximal promoter of ITGA6 that were 
assessed for HIF-1α and HIF-2α recruitment. B. MDA-MB-231 EV and shHIF-1α cells 
were cultured at hypoxia (0.5% O2) for 6 hours. ChIP assays were performed with HIF-
1α (upper panels) and HIF-2α (lower panels) and qRT-PCR conducted on the isolated 
DNA to determine HIFα recruitment. ChIP for the EPO promoter was conducted as a 
positive control. Binding enrichment for each antibody (site fold enrichment) represent 
antibody binding at each HRE site over IgG control. Each panel represents the 
combination of replicate biological experiments (n=3 for HIF-1α and n=2 for HIF-2α for 
each comparison).  
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Figure 4-4. PyMT CD24hiCD49f+ cells are enriched for TIC activity in vitro and 
in vivo. 
A. PyMT transgenic tumors were harvest, digested, and stained with CD49f and CD24 
antibodies prior to being subjected to FACS analysis. CD24hi/CD49f+ (double positive, 
DP) and CD24low/CD49fneg double negative (DN) cells were collected and plated for 
tumorsphere formation efficiency (A) or (B) used in a limiting dilution transplantation 
assay. Mean SFE/well ± S.E.M. Cells were plated at a density of 30,000 cells/well in 6-
well format and mean SFE/well ± S.E.M. determined (n≥8 wells/genotype, unpaired 
Student’s t-test). B. Comparison of DP and DN mean tumor volume ± SEM over time 
when 25, 50, 100 or 200 cells are injected into the mammary fat pad. C. CD49f/CD24 
expression was analyzed in tumors derived from initial transplantation of DP (right panel) 
and DN (left panel). D. DP and DN recipient mice (n=5/genotype) were evaluated for 
lung metastases at time of primary tumor removal. Graph represents mean number of 
metastases ± S.E.M. While the data trended toward significance, there were not enough 
animals within each cohort to power the study to detect smaller changes in metastatic 
potential.  
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Table 4-1. ELDA analysis of TIC frequency in CD24high/CD49f+ or 
CD24low/CD49fneg  derived tumors at day 51 post transplant.  
 
 MTEC Phenotype  
Number of Cells Injected CD24Low/CD49fNeg C24High/CD49f+ p-Value 
200 2/7 (29%) 5/7 (71%)  
100 1/6 (17%) 4/6 (67%)  
50 1/8 (12%) 6/9 (67%)  
25 0/8 (0%) 1/8 (12%)  
Estimated TIC Frequency 1/578 1/99 0.00043 
 
 
suggesting that CD24high/CD49f+ MTEC are able to regenerate not only the same cell 
population from which they were derived, but also the weakly tumorigenic 
CD24neg/CD49fneg MTECs. When lungs from mice bearing either CD24high/CD49f+ 
MTEC or CD24low/CD49fneg  MTEC derived tumors were scored for number of 
metastatic lesions, mice transplanted with CD24high/CD49f+ MTECs had on average 50% 
more total lung metastases than mice transplanted with CD24low/CD49fneg MTEC  
(Figure 4-4D). These data suggest that CD49f not only plays a role in primary tumor 
initiation, but also promotes metastatic potential from the primary mammary tumor site to 
the lung. 
 
 
CD49f Promotes Lungs Metastases Induced by Tail Vein Injection of MDA-MB-231 
Cells  
 
To further investigate if metastatic potential is driven by CD49f, MDA-MB-231 
shEmpty cells were FACS sorted based on CD49f expression levels into CD49fhigh and 
CD49flow populations. When CD49fhigh cells were injected into the tail vein of NSG 
hosts, the area of the lungs occupied by metastases was 25% higher than the metastatic 
area induced by CD49flow cells (p=0.001), and >50% higher than ‘mock sorted’ 
(unstained cells subjected to the mechanical stress of passing through the cell sorting 
nozzle, p=0.0001) (Figure 4-5A-B). These data suggest that the presence of CD49f 
enriches for a cell phenotype with an elevated ability to colonize the lungs. Since this was 
only a single experiment, we aimed to replicate these results by repeating the FACS 
sorting and tail vein study. However, in contrast to the initial experiment, in the second 
experiment we stained all cells with CD49f-FITC. Cells were then sorted based on 
CD49fhigh, CD49flow or mock sorted (subjected to sorting without selecting for a sub-
population). Cells were again injected into the tail vein of NSG hosts and metastatic area 
of the lung analyzed after 7 weeks. In contrast to the first experiment, in which the mock 
sorted lungs produced very few metastases compared to either the CD49fhigh or CD49flow 
sorted samples, this time the lung of mock sorted injected cell lungs produced a range of 
metastases (Figure 4-5C-D), with the majority of lungs filled at least 50% with 
metastases. This result is more consistent with our prior observations that by flow 
cytometry 96-98% of the MDA-MB-231 shEmpty cells are positive for CD49f. It would  
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Figure 4-5. FACS-sorted CD49fhigh cells exhibit increased lung metastatic 
potential in a tail vein assay. 
MDA-MB-231 EV cells were stained with CD49f-FITC antibody and subjected to FACS 
sorting. Cells collected for CD49fhigh were gated as the top 20% of CD49f expressing 
cells, and cells collected for CD49flow were gated as the lower 20%. Mock sorted cells 
not exposed to antibody but subjected to sorting serve as the non-enriched control. Cells 
(185,000 cells/100 μL) for each genotype were injected into the tail vein of NSG mice 
and lungs were harvested for NBF fixation and H&E staining 7.5 weeks later. A. Graph 
of mean area of lung occupied by metastases per population (**p<0.01, ***p<0.001, 
ANOVA with Bonferroni post-test). B. Representative H&E stained images of lungs 
from each genotype (n=5 lungs/cell population). The experiment was repeated, this time 
collecting for CD49fhigh by gating for the top 10% of CD49f expressing cells, and 
collecting for CD49flow by gating for the lower 10% of CD49f expressing cells. Mock 
sorted cells were stained with antibody and subjected to sorting without gating for CD49f 
expression. C. Graph of the mean area of lung occupied by metastases per population. B. 
Representative H&E stained images of lungs from each genotype.  
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be expected that injecting the mock cells, which contain a mixture of high- and low-
expressing CD49f cells would give rise to a wide range of lung metastases, with some 
lungs having more metastases compared to others. These data also suggest that the CD49f 
antibody (clone GoH3) may activate integrin signaling to stimulate metastasis.  
 
CD49f Expression Is Enriched in Specific Subtypes of Human Breast Cancers and 
Correlates with Decreased Survival 
 
Breast cancer has been classified into five major subtypes on the basis of global 
gene expression [86]. We sought to determine the expression of the HIF regulated TIC 
marker, CD49f in human breast cancers. By examining previously published microarray 
analyses of primary breast tumor sample [236] [234], we found that CD49f is 
significantly upregulated in basal-like breast cancers compared to HER2 enriched or 
luminal breast cancers (Figure 4-6A). As expected, increased levels of ITGA6 correlated 
with increased levels of HIF1A across all subtypes. However, there was no correlation 
between HIF2A and ITGA6 expression (Figure 4-6B-C). We also discovered that ITGA6 
expression is prognostic for survival in patients with breast cancer. Patients with tumors 
with high ITGA6 levels have significantly reduced overall and recurrence free survival  
(Figure 4-6D).   
 
Discussion 
 
After examining the HIF-dependent expression of several cell surface markers in 
the PyMT model that were previously reported to enrich for CSC activity in various 
transgenic models of breast cancer (CD24, CD29, CD133, CD49f), we identified CD49f 
as a HIF-1α regulated CSC marker in PyMT tumors and in MDA-MB-231 cells. We 
demonstrated that upon deletion of Hif1a in the PyMT murine model of breast cancer, the 
expression level of CD49f mRNA and protein decreases. This HIF-1α effect on CD49f 
was observed not only in vitro, but also in vivo since mammary gland tumors derived 
from Hif1a KO MTECs also expressed less CD49f than WT tumors. We validated these 
findings in the commonly used human metastatic breast cancer cell line, MDA-MB-231. 
HIFα knockdown in these cells revealed that knockdown of HIF1A had a more 
prominent effect on CD49f than knockdown of HIF2A, while simultaneous knockdown  
of both HIFα subunits has the most significant impact on CD49f expression, decreasing 
expression by >75%. 
 
Additionally, we identified 3 putative HRE sites within the human ITGA6 
proximal promoter, and demonstrated that HIF-1α directly binds to at least 2 of these 
sites. The use of the HIF1A knockdown (KD) cells in this experiment provides 
compelling evidence that HIF-1α is direct transcriptional regulator of ITGA6, since little 
to no HIF-1 binding was observed in the HIF1A KD cells. Additionally, in terms of HIF-
2α binding, there was only moderate enrichment observed at these HRE sites in the EV 
cells, while in the HIF1A KD cells there was a strong enrichment. These data suggest that 
while HIF-1α may be the main regulator of ITGA6, upon HIF-1α loss, HIF-2α can play a  
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Figure 4-6. Correlation between ITGA6 and HIF1A expression and survival in 
breast cancer patients. 
A. ITGA6 mRNA is differentially expressed in human breast cancer subtypes. Publically 
available datasets [93, 234] were used to compare levels of ITGA6 mRNA in breast 
cancer samples classified by PAM50 (*p<0.05, **p<0.01, ***p<0.001, ANOVA with 
Bonferroni post-test). B. In the TCGA dataset, ITGA6 mRNA positively correlates with 
HIF1A (p<0.05, correlation coefficient r2 = 0.0078) mRNA but not HIF2A mRNA (p = 
0.08) (C). D.Kaplan-Meier curves depict the probability of breast cancer survival and 
recurrence based on relative ITGA6 mRNA expression in the Hu data set [234] (n=75 
tumors for high CD49f and n=75 tumors for low CD49f, Log rank test, p<0.05).  
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compensatory role and also induce CD49f transcription. These conclusions are in 
agreement with qRT-PCR, FACS, and immunofluorescence experiments, which revealed 
little to no CD49f expression or activity in DKD cells. ChIP experiments are currently in 
progress between shEmpty and DKD cells to further validate these data. 
 
Upon further investigation into the role CD49f plays in primary mammary tumor 
formation and lung colonization, we discovered that PyMT MTECs enriched for high 
levels of CD49f (CD49+) by FACS analysis had significantly increased tumorsphere 
formation in vitro and had enriched TIC potential in vivo as compared to cells not 
enriched for CD49f (CD24low/CD49Neg). These data revealed that CD24high/CD49+ PyMT 
cells are enriched >5-fold for TIC frequency than CD49fNeg cells. Additionally, analysis 
of the metastatic potential of PyMT CD24/CD49f enriched cells revealed that the average 
number of metastatic lesions present in the lungs was higher in the mice transplanted with 
CD24high/CD49f+ cells than in the mice that received CD24low/CD49fNeg cells. However, 
the variability of the metastases among cohorts and the small sample size did not provide 
enough power for sufficient statistical analyses for this experiment. It should also be 
noted, that after this experiment was completed, Bryan Welm shared unpublished data 
that he found that only CD24high PyMT tumor cells retain TIC activity. Therefore it is 
possible that in these experiments, the absence of CD24high cells in the CD49fneg 
population may be confounding the results that CD49f enriches for TICs. Therefore, 
repeating the experiment with CD24high/CD49+ and CD24high/CD49fneg, would provide 
further insight into the exact role of CD49f in promoting tumor growth and metastasis. 
 
However, using the MDA-MB-231 cell line, we found that high CD49f 
expression augments lung metastases in the tail vein assay when MDA-MB-231 cells 
enriched for CD49High and CD49fLow populations are compared. The metastatic lesions in 
the lungs of mice injected with CD49fHigh cells were so numerous and large that it was 
not possible to discern the number of individual foci. Instead, the total area of metastatic 
burder lung was determined by ImageJ analysis, revealing a 50% increase in total lung 
area occupied by metastases in mice that received CD49High cells as compared to those 
that received CD49Low cells. In agreement with our data, when 4T1 breast cancer cells are 
injected in a tail vein assay, knock down of CD49f resulted in decreased metastasis to the 
lung [237]. These combined data suggest an important role for CD49f not only in 
promoting stem-like activity in vitro, primary tumor growth and TIC potential in vivo, 
but also in promoting lung metastases in multiple models of breast cancer. 
 
Integrins such as ITGA6/CD49f are essential for invasion and migration of tumor 
cells during metastasis. In order for cancer cells to break through a target tissue’s basal 
membrane, they must attach to the tissue’s cell surface receptors, most of which are 
integrins. Integrins are crucial, not only for physically tethering cells to the matrix, but 
also for sending and receiving molecular signals that regulate these processes during 
tumorigenesis. In breast cancer, specifically, an increase in ITGA6 corresponds to an 
increase in intermediate filaments keratin and vimentin to increase tumor cell migratory 
potential [238]. Additionally, in advanced breast carcinomas ITGA6, in combination with 
integrin beta 4 (ITGB4), has been found at the leading edge of invasive cells, where it 
cooperates with ErbB2 and ErbB3 to promote aberrant cell signaling [239]. Moreover, 
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ITGA6/ITGB4 regulates expression of SPARC (secreted protein acidic and rich in 
cysteine), which is involved with matrix remodeling and enhanced SPARC expression 
promotes invasion [240]. 
 
To determine if our experimental results have any direct relevance to human 
disease, we performed bioinformatic analyses of publically available data sets in regard 
to ITGA6 mRNA expression among human breast cancer subtypes. The basal-like 
subtype of breast cancer, including TNBCs, have the highest levels of ITGA6 mRNA as 
compared to all other subtypes. Additionally, high ITGA6 expression positively 
correlated with high HIF1A expression across all subtypes of breast cancer. Whole 
genome expression profiling of the breast cancer subtypes has revealed that TNBCs, and 
to a lesser extent, HER2-enriched tumors, have an enriched hypoxic gene signature as 
compared to luminal breast cancers [92]. The HIF pathway has also been identified as 
one of three key pathways enriched in basal versus luminal cancers in The Cancer 
Genome Atlas data set [93]. In addition, in a variety of solid tumors, HIF-1α or HIF-2α 
expression has been linked to increased activity of TICs [156]. As HIF protein expression 
is enriched in TNBCs, and HIFs regulate breast TICs, the hypoxic response influence 
may directly influence the increased aggressive nature and chemotherapy resistance 
phenotypes observed in TNBCs. Finally, elevated expression of ITGA6 is prognostic, 
predicting a decrease in overall and recurrence free survival patients with breast cancer, 
indicating its potential usefulness as a biomarker to predict metastasis. 
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CHAPTER 5.    IDENTIFYING NOVEL OR UNDERSTUDIED HIF-
REGULATED GENES 
 
 
Rationale 
 
As discussed in Chapter 3 and in [127], we have extensively characterized HIF-1α 
wild type (WT) and knockout (KO) mammary tumor epithelial cells (MTECs) derived 
from late stage, ER-/PR-/Neu+ carcinomas of MMTV-PyMT transgenic mice also 
harboring Hif1a floxed alleles. Two microarray screens were performed to identify HIF-
1α-regulated candidate genes that may promote tumor growth and/or lung metastasis. 
Differential gene expression profiles were compared between WT and KO cells cultured 
at normoxia (21% O2) and hypoxia (0.5% O2) and between end-stage WT and KO 
mammary tumors derived from transplantation of the parental cell lines into the 
mammary fat pad. Several genes were down-regulated in response to deletion of Hif1a 
that are predicted to regulate primary tumor growth and/or the metastatic switch. HIF-1α 
is known to promote multiple steps in metastasis and we found HIF-1 regulates 
expression of many uncharacterized hypoxia-inducible genes in PyMT mammary tumor 
cells. Characterization of the roles that genes downstream of HIF-1 play in driving 
metastatic potential may identify additional pathways that are amenable to therapeutic 
intervention and that may be more specific to the metastatic program than globally 
repressing HIF-1 activity using HIF inhibitors. 
 
 
Methods 
 
 
Gene Expression Microarray Analysis 
 
PyMT HIF-1α WT and KO cells were plated in triplicate in standard growth 
media (Chapter 3). As we found that addition of EGF to the culture media super induces 
HIF-1α expression, even at normoxia (Figure 3-2, [127]), cells were cultured either in 
the presence of absence of 10 ng/mL mouse recombinant EGF (Invitrogen). Each 
condition (WT±EGF, KO±EGF) was plated in triplicate (technical replicates) for both 
normoxic and hypoxic exposure (summarized in Table 5-1). At approximately 90% 
confluence, cells were placed at either normoxia (21% O2) or hypoxia (0.5% O2) for 6 
hours. This time point was chosen as HIF-1α protein expression begins to peak at 3 hours 
of hypoxic exposure (Figure 3-3) and mRNA levels of classic hypoxia-inducible genes, 
such as Vegf and Glut1 are highest at 6 hours. Additionally, three HIF-1α WT and three 
HIF-1α KO end-stage tumors were harvested and size matched based on volume and 
weight. Total RNA was harvested from flash frozen cells and from end-stage tumors as 
described in Chapter 3. All samples were analyzed for RNA integrity (RIN) by an 
Agilent Bioanalyzer and only samples with a RIN greater than 9 were hybridized on a 
MouseRef-8 v2.0 Expression BeadChip Kit (Illumina) at the UTHSC Molecular 
Resource Center. This BeadChip contains approximately 25,600 well-annotated RefSeq 
transcripts for ~19,100 unique genes in the mouse genome. Raw data was transformed to  
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Table 5-1. Summary of culture conditions used for cells harvested for 
microarray profiling. 
 
Genotype O2 Exposure EGF Addition 
Hif1a WT Normoxia, 6 hrs None 
Hif1a WT Hypoxia, 6 hrs None 
Hif1a WT Normoxia, 6 hrs 10 ng/mL 
Hif1a WT Hypoxia, 6 hrs 10 ng/mL 
Hif1a KO Normoxia, 6 hrs None 
Hif1a KO Hypoxia, 6 hrs None 
Hif1a KO Normoxia, 6 hrs 10 ng/mL 
Hif1a KO Hypoxia, 6 hrs 10 ng/mL 
 
 
the log2-scale, and intensity values were quantile normalized using Expander [free 
download, Tel-Aviv University, Israel (2003)]. Normalized log-scale intensity values 
were analyzed for differential expression using the Expander software. Seven pairwise 
comparisons were made from the cell data (Table 5-2) in order to obtain a complete 
image of gene changes either in the presence or absence of EGF and in response to 
exposure to hypoxia. All genes with a mean fold differential ≥ 2, and with a p-value less 
than 0.05 among technical replicates were included in gene lists. However, data obtained 
from the three tumors/genotype revealed that one WT and one KO tumor were distinct 
outliers compared to the other tumors for nearly all of the genes. These tumors were 
removed from the analysis and only two tumors/genotype were compared, therefore, 
mean fold changes did not have p-values associated with them. Additionally, since gene 
expression changes in vivo were not as robust as in vitro, a fold change cut off of 1.5 was 
used to assess gene expression changes in the tumors. 
 
 
Functional Analysis  
 
 In order to obtain a comprehensive set of functional annotations from the list of 
genes we identified as being differentially regulated, we used DAVID (the Database for 
Annotation, Visualization and Integrated Discovery, http://david.abcc.ncifcrf.gov). From 
this analysis we were able to identify functionally related gene groups. Additionally, the 
KEGG database (Kyoto Encyclopedia of Genes and Genomes, 
http://www.genome.jp/kegg/) was used to place predicted HIF-1α-target genes into 
molecular pathways. Gene Set Enrichment Analysis (GSEA,  
http://www.broadinstitute.org/gsea/index.jsp) was used to determine if the gene sets 
identified with our arrays significantly correlated with other published pathway and  
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Table 5-2. All pairwise comparisons from datasets from cells. 
 
Comparison  Data Set 1 Data Set 2 
1 WT Normoxia plus EGF WT Normoxia without EGF 
2 WT Normoxia without EGF WT Hypoxia without EGF 
3 WT Hypoxia plus EGF WT Hypoxia without EGF 
4 WT Normoxia plus EGF KO Normoxia plus EGF 
5 WT Normoxia without EGF KO Normoxia without EGF 
6 WT Hypoxia plus EGF KO Hypoxia plus EGF 
7 WT Hypoxia without EGF KO Hypoxia without EGF 
 
 
functional gene sets. Dr. Fan was instrumental in advising our lab in how to access and 
utilize these tools. 
 
 
Results 
 
 
Effects of EGF on HIF-1α-Dependent Gene Expression 
 
As discussed in Chapter 3 (Figure 3-2), exposing PyMT MTECs to EGF 
increases HIF-1α protein levels at normoxia, and further increases HIF-1α levels at 
hypoxia as compared to cells grown in 2% FBS alone. When WT normoxia plus EGF 
samples were compared to WT normoxia without EGF, 99 genes were found to be up 
regulated in cells treated with EGF. When exposed to 6 hours of hypoxia this number 
decreased to only 83 genes that were-up regulated in the presence of EGF. This result is 
interesting as it was expected the combination of hypoxic exposure and the presence of 
EGF would increase the number of up-regulated genes versus EGF alone. Furthermore, 
comparison of the genes in each of these groups revealed only 6 genes that overlapped 
(Figure 5-1A), further suggesting that EGF treatment primarily regulates genes in a HIF-
α/hypoxia-independent manner. In the absence of EGF, hypoxic exposure up-regulated 
141 genes and only a few of these genes (Figure 5-1B) overlapped with genes in either of 
the previous two comparisons, resulting in 128 genes that were hypoxia-inducible only, 
and 90 that were EGF-inducible only.  
 
At normoxia, 95 genes were found to be up regulated in HIF-1α WT versus HIF-
1α KO cells in the presence of EGF (Figure 5-2A). However, in the absence of EGF 308 
genes were found to be up-regulated in WT versus KO cells. Comparing the two groups 
there were 61 genes in common, suggesting that most genes are HIF-1α, but not EGF-
dependent. As expected, upon hypoxic exposure the number of genes up-regulated in WT  
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Figure 5-1. Comparison of up-regulated genes in HIF-1α  WT cells in the presence 
of EGF ± hypoxia. 
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Figure 5-2. HIF-1α-dependent genes in the presence and absence of EGF and 
hypoxia. 
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versus KO cells increases from 95 to 183 in the presence of EGF and from 308 to 545 in 
the absence of EGF, with 130 overlapping genes (Figure 5-2B). We have shown that not 
only does EGF treatment induce HIF-1α protein stabilization, but that it also induces 
gene expression independent of HIF-1α. Therefore, the observation that more genes are 
differentially regulated in the absence of EGF could be a result of the presence of EGF 
masking the full effects of HIF-1α-dependent gene expression. Therefore, we chose to 
focus on the data generated from cells cultured without EGF for further comparisons. 
Since the cells are cultured in low serum without additional growth factors, we felt that 
the comparison 7 data set would reveal genes most dependent upon HIF-1 in the hypoxic 
environment. 
 
 
HIF-1α-Dependent Gene Expression in PyMT MTECs and Tumors 
 
Comparing HIF-1α WT to HIF-1α KO cells with no EGF, we found 512 
differentially regulated genes at normoxia and 820 differentially regulated genes at 
hypoxia (Figure 5-3). At normoxia, there were 369 genes that were up-regulated in WT 
cells and 143 genes that were down-regulated. At hypoxia, there were 545 genes up 
regulated in WT cells and 275 genes that were down regulated.  
 
Analysis of the data obtained from tumors revealed that 696 genes are down-
regulated in WT tumors and 782 genes up regulated in WT tumors. Comparing up 
regulated genes in cells and tumors, 68 genes were found to be in common. For down-
regulated genes, 26 genes were in common (Figure 5-4). These numbers suggest that the 
in vivo tumor microenvironment plays a large role in regulation of HIF-1-dependent gene 
expression. Table 5-3 lists the top 10 up and down regulated genes that are in common 
between cells and tumors. Some of the genes identified as up-regulated are already 
known to be HIF target genes, such as pyruvate dehydrogenase kinase 1 (Pdk1) [241]. 
Others, such as Creatine Kinase brain isoform (Ckb), Vitamin D receptor (Vdr), and 
Embigin (Emb), do not have a clear published role as to their relationship with HIF or the 
hypoxic response. Differential expression of Vdr was not validated at the protein level 
(data not shown). We decided to focus on Ckb due to dearth of publications on Emb, and 
a lack of robustly tested commercially available reagents (such as antibodies to Emb). 
 
DAVID functional annotation clustering analysis revealed the 7 top functional 
pathways dependent upon HIF-1 (Table 5-4). Specifically, cytokine and growth factor 
signaling pathways are strongly affected; both are important pathways not only in cell 
growth and survival, but also in tumor growth and progression. Not surprisingly, 
angiogenesis is also enriched as the HIFs regulate a main angiogenesis gene, VEGF [175, 
242]. Additionally, extracellular matrix, cell-cell adhesion and cell migration and motility 
are also enriched pathways, and each is important for tumor growth, progression and 
metastasis [243] [101, 244]. KEGG pathway analysis revealed similar pathways to 
DAVID (Table 5-5) and also implicated additional cancer pathways that were enriched in 
our HIF-1α differentially regulated gene set. Gene set enrichment analysis (GSEA) 
correlated with DAVID and KEGG and showed that both cell cycle and EMT pathways 
are enriched (Table 5-6). In addition, GSEA suggested that breast cancer pathways and  
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Figure 5-3. Differentially regulated genes between HIF-1α  WT and KO cells at 
normoxia and hypoxia. 
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Figure 5-4. Differentially regulated genes in common between PyMT MTECs and 
end stage tumors. 
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Table 5-3. Top 10 differentially regulated genes between cells and tumors. 
 
 Fold Change Fold Change 
Genes Up-
Regulated in WT 
Cell 
FC 
Tumor 
FC 
Genes Down-Regulated 
in WT 
Cell 
FC 
Tumor 
FC 
Creatine kinase 
brain isoform (Ckb) 
23.64 1.50 Cation transport regulator 
homolog 1 (Chac1) 
10.32 1.76 
Vitamin D receptor 
(Vdr) 
16.76 2.35 Caspase recruitment 
domain-containing 
protein 14 (Card14) 
6.12 1.69 
Embigin (Emb) 11.71 2.40 B-cell linker (Blnk) 5.82 1.23 
Pyruvate 
dehydrogenase 
kinase, isozyme 1 
(Pdk1) 
8.27 1.60 DTW domain containing 
1 (Dtwd1) 
5.26 1.60 
Nuclear prelamin A 
recognition factor 
(Narf) 
8.04 3.21 Bifunctional 
methylenetetrahydrofolate 
dehydrogenase/cyclo-
hydrolase, mitochondrial 
(Mthfd2) 
4.93 1.51 
Peptidyl-prolyl cis-
trans isomerase C 
(Ppic) 
7.23 2.58 Insulin-like growth factor 
2 (Igf2) 
3.97 1.53 
Insulin-like growth 
factor-binding 
protein 4 (Igfbp4) 
6.57 3.30 Glypican (Gpc1) 3.58 1.54 
A disintegrin and 
metalloproteinase 
with 
thrombospondin 
motifs 4 (Adamts4) 
5.74 2.03 DNA damage-inducible 
transcript 3 (Ddit3) 
3.20 3.07 
Milk fat globule-
EGF factor 8 protein 
(Mfge8) 
5.39 2.44 Coiled-coil-helix-coiled-
coil-helix domain 
containing 10 
(Chchd10/Ndg2) 
3.07 1.56 
Surfactant, 
pulmonary-
associated protein D 
(Sftpd) 
5.30 2.84 Nuclear pore 
glycoprotein-210 
(Nup210) 
2.83 1.58 
 
FC = Fold Change  
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Table 5-4. DAVID functional analysis of differentially regulated HIF-1α  genes. 
 
DAVID Annotation Cluster Enrichment Score 
Cytokine and Growth Factor Signaling 14.32 
Extracellular Matrix 8.45 
Blood Vessel Development/Angiogenesis 3.2 
Cell-Cell Adhesion 2.9 
Growth Factor Binding 2.51 
Glucose Metabolism 2.45 
Cell Migration and Motility 2.11 
 
 
 
Table 5-5. Top 10 KEGG Pathway Analysis. 
 
KEGG Pathway p-Value 
ECM-receptor interaction 2.50E-04 
Cytokine-cytokine receptor interaction 4.20E-04 
Focal adhesion 2.60E-03 
Pancreatic cancer 4.10E-03 
Dilated cardiomyopathy 6.90E-03 
Alanine, aspartate and glutamate metabolism 9.20E-03 
Melanogenesis 1.20E-02 
Pathways in cancer 1.50E-02 
Metabolism of xenobiotics by cytochrome P450 2.50E-02 
Galactose metabolism 2.90E-02 
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Table 5-6. GSEA Analysis of HIF-1α  regulated genes enriched in WT cells and 
tumors.  
 
Gene Set Name (MsigDB) Description p-Value 
RAS_ONCOGENIC_SIGNATURE Genes selected in supervised 
analyses to discriminate cells 
expressing activated H-Ras 
oncogene from control cells 
expressing GFP. 
8.60E-11 
BRCA_ER_NEG Genes whose expression is 
consistently negatively correlated 
with estrogen receptor status in 
breast cancer - higher expression 
is associated with ER-negative 
tumors 
7.40E-09 
EMT_UP Up-regulated during the 
TGFbeta-induced epithelial-to-
mesenchymal transition (EMT) 
of Ras-transformed mouse 
mammary epithelial (EpH4) cells 
(EMT is representative of late-
stage tumor progression and 
metastasis) 
2.11E-08 
ABBUD_LIF_UP Genes that increased after LIF 
treatment (10 ng/ml, overnight) 
in AtT20 cells 
9.04E-06 
MAPK_SIGNALING_PATHWAY Genes involved in MAPK 
signaling pathway 
1.09E-05 
HSC and PROGENITORS_SHARED Up-regulated in mouse 
hematopoietic stem cells and 
progenitors from both adult bone 
marrow and fetal liver (Cluster 
iii, HSC and Progenitors Shared) 
1.15E-05 
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Table 5-6. (Continued). 
Gene Set Name (MsigDB) Description p-Value 
EMT_DN Down-regulated during the 
TGFbeta-induced epithelial-to-
mesenchymal transition (EMT) 
of Ras-transformed mouse 
mammary epithelial (EpH4) cells 
(EMT is representative of late-
stage tumor progression and 
metastasis) 
3.53E-05 
BRCA_ER_POS Genes whose expression is 
consistently positively correlated 
with estrogen receptor status in 
breast cancer - higher expression 
is associated with ER-positive 
tumors 
6.93E-05 
HYPOXIA_REVIEW Genes known to be induced by 
hypoxia 
9.28E-05 
WNT_SIGNALING_PATHWAY Genes involved in Wnt signaling 
pathway 
5.96E-03 
HSA04110_CELL_CYCLE Genes involved in cell cycle 1.15E-02 
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hypoxia pathways are enriched in WT cells and tumors. 
 
 
Discussion 
 
 Microarray analysis of HIF-1α WT and KO cells and tumors produced data 
implicating hundreds of genes as being differentially regulated by HIF-1α expression in 
PyMT late stage carcinomas and cell lines. Some of the genes identified have long been 
known to be HIF-1α target genes, such as Vegf, Glut1, Phd3/Egln3, Aldoc, Ldha, Gapdh 
and many more [24]. Furthermore, genes were identified that have recently been shown 
to be direct HIF-1α-target genes, including Axl [245], Angptl4 [72], and multiple 
jumonji-domain histone demethylases [246]. Additionally, analysis of the gene lists 
revealed enrichment of several genes in WT cells that are either involved in stem cell 
maintenance, or are commonly used stem cell surface markers including CD133/Prom1 
[117], which has been shown to a HIF-1α target gene, Gata3 [247], Wnt signaling 
pathway genes such as Wnt10a, Wnt5b, Lrp5, and Fzd7 [248], Notch pathway genes such 
as Dll1 and Hey1 [164], and Itga6/CD49f.  However, there are still many genes on these 
lists that have yet to be identified as direct HIF-1α target genes, or to have a direct 
implication in HIF-1α-dependent tumor growth and progression. Investigating the role of 
one of these genes, Ckb, in breast tumor growth and development is the focus of the next 
chapter.  
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CHAPTER 6.    CREATINE KINASE B (CKB) ACTIVITY IS HIF-1-
DEPENDENT AND IS ESSENTIAL FOR PRIMARY TUMOR GROWTH, 
CELL INVASION AND METASTASIS TO THE LUNG 
 
 
Introduction 
 
As we have previously shown, HIF-1α expression is required for mammary tumor 
growth and metastasis in the MMTV-PyMT mouse model of breast cancer [127]. In order 
to identify genes that are required for this phenotype that act downstream of HIF-1α, we 
performed microarray profiling on both Hif1a WT and KO cells as well as late stage 
mammary carcinomas derived from these cells.  We found 94 genes differentially 
regulated by HIF-1α in both settings (Chapter 5).  Many of these genes, including Vegf, 
Egln3 (PHD3), Aldoc and Pdk1 were known HIF-1α target genes and are involved in 
cancer cell migration and invasion, tumor initiation and growth, and metastasis [61, 154] 
[72, 116].  One of the genes we found to be the most differentially up-regulated in WT 
cells and tumors is the enzyme creatine kinase brain isoform (Ckb). 
 
 
The Creatine Kinase System  
 
CKB is a member of a family of creatine kinases (CKs) that reversibly transfer a 
high-energy phosphate group between ATP and creatine to generate phosphocreatine 
(PCr) and ADP (Figure 6-1). There are two cytoplasmic CK isoforms, CKB and CKM 
(muscle isoform), which dimerize to form CKB-B or CKM-M homodimers or a CKB-M 
heterodimer, and two mitochondrial isoforms, CKMT1 and CKMT2 [249]. CKs are 
expressed at high levels in tissues with high and rapidly changing energy demand, such 
as brain and muscle [250]. Ischemia and hypoxia are two conditions in which ATP 
production via oxidative phosphorylation is inhibited due to the lack of oxygen; 
therefore, CK metabolism supplements energy produced by oxidative phosphorylation 
and glycolysis, i.e., PCr serves an energy reservoir for CKs to re-generate ATP from 
ADP in highly metabolic tissues [251].  
 
 
CKB and Cancer 
 
Although named “brain” isoform, CKB is expressed in virtually all cell types, and 
CKB over-expression has been documented in a variety of solid tumors as compared to 
normal cells [251]. Particularly, CKB has been found to be overexpressed in several 
types of cancers including breast cancer, colorectal cancer, colon cancer, and ovarian 
cancer [252-256]. Although not much is known about the direct function of CKB in 
cancer progression and metastasis, one study found that CKB knockdown inhibited cell 
proliferation of the ovarian cancer cell line Skov3 and induced apoptosis under hypoxia 
or hypoglycemic conditions [257]. These data suggest that CKB is linked to oxygen 
consumption and glycolysis. The authors also found that CKB depletion sensitized Skov3 
cells to chemotherapeutic agents. Another study suggested that the role CKB plays in 
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Figure 6-1. Overview of creatine kinase enzymatic activity. 
Creatine kinase catalyzes the reversible reaction to generate phosphocreatine (right), or to 
generate creatine (left) from phosphocreatine to produce ATP. 
Image reproduced from Sigma-Aldrich, Cyclocreatine 377627_technical datasheet. 
 
 
cancer progression could be its localization along actin filaments within the cell, 
facilitating cell spreading and migration [258], though this hypothesis was not tested in 
vivo. 
 
Inhibition of CKB by the phosphocreatine analog cyclocreatine in pre-
clinical models.  In 1994, a variety of creatine analogs were synthesized and analyzed for 
their ability to block ATP production through the CK system [259]. Several analogs were 
found to be active, however, cyclocreatine (cCr) was the most active, resulting in 160-
fold less efficient ATP production through CK [260]. In initial studies of the effect of cCr 
as an anti-cancer agent, in 1993, Lillie et al found that not only did cCr inhibit tumor cell 
growth in vitro in a variety of cancer cell lines, but it also decreased the rate of tumor 
growth in animals transplanted with cervical cancer line ME-180 that were fed 1% cCr 
daily [261]. In 1995, in a rat mammary adenocarcinoma model, cCr given by daily IP 
injections starting at various intervals post-transplant resulted in a significant tumor 
growth delay in [262]. Furthermore, this delay was extended when cCr was given in 
combination with conventional cancer therapies such as Adriamycin and 
cyclophosphamide [262]. In addition, in 1998, an in vitro study of the prostate cancer cell 
line, DU-145, which expresses high endogenous levels of CKB, showed that treatment 
with cCr markedly inhibited motility of the cells to various chemoattractants, as well as 
decreased invasion through a Matrigel matrix [263].  
 
Cyclocreatine (cCr) in phase I studies. When administered in a phase I/II dose 
escalation study to terminal cancer patients by i.v. infusion, the primary adverse side 
effects of cCr therapy were reversible hypoglycemia and fluid retention; the maximum 
tolerated dose (MTD) was estimated to be 80 mg/kg [251]. Despite an initial burst of 
reports touting cCr as an anticancer agent in the 1990s [259, 261-263], no current clinical 
trials are testing cCr (recent clinicaltrials.gov query). However, a recent high-profile 
report that cCr therapy ameliorated neurological symptoms and improved cognition in a 
mouse model of X-linked retardation may spark renewed interest in clinical use of GMP-
grade cCr [264]. A web search has revealed that at least four companies are developing 
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cCr, or cCr analogs, in their pipelines (Pantox Laboratories, Avicena, ALR Industries, 
and Lumos Pharma). Of these, Lumos Pharma has FDA approval to test cCr (Lum-001) 
in clinical trails as an orphan drug to test whether Lum-001 can ameliorate mental 
retardation in patients with a creatine transport deficiency. In addition, Lumos has an 
inactive investigational new drug application with the FDA to use Lum-001 in solid 
tumors. We are in the process of contacting Lumos to establish a collaborative agreement 
to obtain Lum-001 for research purposes, and for possibly initiating new clinical trials for 
MBC patients who have failed conventional therapy.  
 
Despite evidence that cCr reduces primary mammary tumor mass, the efficacy of 
cCr to block or to treat established metastatic breast cancer has not been systematically 
evaluated. Moreover, limited pre-clinical studies have evaluated cCr therapy using mouse 
models in which the tumors develop at the appropriate orthotopic site (i.e. mammary 
gland, rather than subcutaneous) and that will metastasize to distant organs from the 
breast in immunocompetent rodent models. 
 
In this Chapter, I will show that HIF-1α KO PyMT cells and KO tumors express 
significantly less CKB mRNA and protein than WT cells and tumors. In WT cells 
transduced with lentivirus expressing either of two independent Ckb shRNAs  
(Figure 6-2), there is a significant decrease in primary tumor growth, an increase in 
survival from lung metastases induced by primary tumor resection, as well as a decrease 
in the incidence of lung metastases induced by tail vein injection. In addition, the 
formation of lung metastases in the CKB WT cells introduced into the circulation by tail 
vein injections into FVB mice was blocked by daily treatment with cCr without any 
apparent gross or organ cytotoxicities. These data, along with the above previous clinical 
data, indicate that cyclocreatine may be not only a beneficial anti-cancer agent but also as 
a potent anti-metastatic agent in breast cancer. 
 
 
Methods 
 
 
Cell Culture 
 
Hif1a wild-type and knockout mammary tumor epithelial cells (MTECs) were 
established as previously described in Chapter 2 and in [127], and maintained in medium 
containing DMEM/F-12 (DMEM/F-12; Invitrogen, Carlsbad, CA, USA) with 2% FBS. 
For subcultivation, cells were rinsed twice with Puck's A saline, then incubated for up to 
60 minutes at 37°C in a 3:1 solution of dispase II/0.25% trypsin reconstituted in Puck's A. 
All cells were grown either at normoxia in an air-jacketed CO2 incubator (5% CO2; 
SANYO, Wood Dale, IL, USA) or at hypoxia (0.5% O2, 5% CO2) in a multigas incubator 
(SANYO) in which N2 gas displaces O2. Cells were exposed acutely (≤6 hours) or 
chronically (> 6 hours to several days) to hypoxia and were removed from chronic 
hypoxic exposure only for brief periods to change the media. Due to the sensitivity of the 
PyMT cells to immediate serum withdrawal, cells were slowly weaned to 0.5% FBS-
containing medium by decreasing the percentage of FBS by 0.5% after every cell  
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Figure 6-2. Structure of Ckb and location of shRNA targeting sequences. 
Ckb is located on Chromosome 12 of the mouse genome. The RNA transcript has 7 exons 
and the two shRNA targeting sequences we chose for knockdown are in different exons. 
shc59 is located in the middle of exon 2 and shc61 is located at the 5’ end of exon 5. An 
shRNA resistant Ckb was recently generated by mutating 4 nucleic acids in the targeting 
sequence of shc61 (base pairs highlighted in red). These silent mutations do not change 
the protein sequence, or presumably the function of wild-type Ckb.  
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subcultivation in order to perform invasion assays. Cells were then serum starved 
overnight for no longer than 16 hours prior to using in the invasion assay experiments. 
 
 
Generation of Ckb Cell Line Variants 
 
PyMT WT cells were used to create stable knockdown of Ckb via lentiviral 
transduction. A Ckb shRNA library containing 3 independent Ckb targeting sequences 
designed by The RNAi Consortium (TRC) and cloned into the pLKO.1 vector was 
purchased from Open Biosystems (RMM4534-EG12709, Figure 6-3A). Cells were 
transfected using a Nucleofector (Lonza, Basel Switzerland) with cell-specific kit T and 
program setting 24 to evaluate each construct’s knockdown efficiency. Two of the three 
pLKO.1 plasmid constructs produced >75% knockdown (shc61 and shc59, Figure 6-2) 
by western blot and qRT-PCR. These two shRNA vectors were packaged into lentivirus 
particles by the UTHSC viral vector core for transduction of WT cells to generate stable 
Ckb knockdown (KD) cell lines following puromycin selection. WT cells were 
transduced with virus particles at an MOI of 50 with shc59, shc61 or empty vector (EV) 
and pools of positive clones (representing several hundred clones for each construct) 
were established and maintained in culture as described above with normal growth media 
plus 2 μg/mL puromycin.  
 
To generate an shRNA-resistant Ckb expressing cell line, a full-length Ckb coding 
sequence was purchased from Open Biosystems (MMM1013-202770188, Accession: 
BC106109, Clone ID: 6395794) in the pCMV-Sport6 plasmid. Using the Not1 and Sal1 
restriction enzyme site, Ckb was cloned into a modified entry vector, pENTR4-FLAG 
(Figure 6-3B) [265], purchased from Addgene (17423) to create an N-terminal FLAG-
tagged Ckb. Using a site directed mutagenesis kit (QuikChange Lightning Multi Site-
Directed Mutagenesis Kit, Agilent Technologies 210515), four silent mutations were 
introduced into the target sequence for shc61 (Figure 6-2) following the manufacturer’s 
protocol. FLAG-tagged, WT Ckb containing mutant shc61 targeting sites was then 
shuttled into a modified destination lentiviral expression vector, pLenti- PGK-Neo 
(Figure 6-3C) [265], using LR recombinase technology (LR Clonase® II Plus, 
Invitrogen, 12538120). Vectors have been packaged into lentiviral particles by the 
UTHSC viral vector core, and experiments to transduce virus into PyMT KO cells as are 
in progress. Following transduction, pools will be selected using neomycin to select for 
transduced cells. 
 
 
Protein Extraction and Western Blotting 
 
Whole cell extracts (WCE) were prepared as described in chapter 4 and in [41]. 
WCE were resolved on 4% to 12% Tris-Base gels (100 μg/lane; Invitrogen) and 
transferred onto polyvinylidene fluoride (PVDF) or PVDF Fluorescent (PVDF-FL) 
membranes prior to blocking with 5% milk. Antibodies for CKB, β-tubulin, and SMA 
detection were purchased from Epitomics (2830), Abcam (6046) and Sigma-Aldrich 
(A2547), respectively. Primary antibodies were probed with secondary antibodies  
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Figure 6-3. Vectors used to create Ckb cell line variants. 
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conjugated to HRP or infrared dye, 680 or 800. Antibody complexes were detected with 
chemiluminescence for complexes with HRP or imaged using a LiCor Odyssey infrared 
imaging system. 
 
 
RNA Extraction and Real Time PCR 
 
Total RNA was preparation and cDNA quantification were performed as 
described in Chapter 3. 
 
 
Invasion Assay 
 
Invasion assays were preformed as in Chapter 3.  
 
 
Cell Proliferation Assay 
 
MTECs were grown in normoxic culture (ambient air; 5% CO2) or hypoxic 
culture (0.5% O2, 5% CO2) in medium buffered with 25 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES). On the day before enumeration, 5,000 cells/ 100 
μL were plated into 96-well plates in normal growth medium (2% FBS medium). The 
medium was changed 24 hours post-plating, which coincides with the 0 time point (t = 0) 
and the first cell harvest for cell number analysis, but medium was not replenished for the 
duration of the experiment. All cells were plated in triplicate per genotype/oxygen 
tension/time point. For each time point, 10 μL of WST-1 (Chemicon, 2210) reagent was 
added to cells and incubated for 2 hours at 37°C prior to measuring absorbance on a 
microplate reader. An absorbance of 440 nm was used for all samples, with a reference 
wavelength of 600 nm. Background absorbance detected in blank wells was subtracted 
from sample wells and proliferation was measured as change in absorbance over time (in 
days).  
 
 
ATP Assay 
 
 Intracellular ATP was measured from cultured MTECs following the protocols 
provided with the high sensitivity ATP bioluminescence assay kit (Roche, 11699709001). 
Briefly, MTECs were grown to 80% confluence prior to incubation in normoxic culture 
(ambient air; 5% CO2) or hypoxic culture (0.5% O2, 5% CO2) for 24 hours. All cells were 
plated in triplicate per genotype/oxygen tension. At 24 hours cells were harvested by 
scraping from the plate with a cell lifter and transferred into a 1.5 mL microcentrifuge 
tube. Samples were pelleted at 1,000 g for 10 minutes prior to lysis using the lysis reagent 
provided in the kit plus a protease and phosphatase cocktail inhibitor. Luciferase reagent 
was added 1 second prior to a 10 second integrated reading on a single-tube luminometer. 
A blank (reagent only) reading was obtained and subtracted from all sample readings. For 
the ATP standard curve, serial dilutions were made from the kit’s ATP standard ranging 
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from 10-5 to 10-12 M. Bioluminescence versus molarity was plotted on a log-log scale and 
used to calculate intracellular ATP concentrations in cell samples. DNA concentrations 
for each individual sample were measured using a Qubit® fluorometer (Invitrogen), and 
all ATP concentrations were normalized to total DNA for each individual sample. 
 
 
Tumor Transplant 
 
Tumor transplants were performed as described in Chapter 3. Briefly, MTECs 
dissociated into single cells with 0.05% trypsin-EDTA were counted using a 
hemacytometer and diluted 1:1 (vol:vol) with growth factor reduced Matrigel-Hank's 
balanced salt solution (HBSS) at a density of 50,000 cells per 10 μl. Cells were kept on 
ice until injection into the right inguinal mammary fat pads (10 μl) of 3-week old female 
FVB/Nj recipients (The Jackson Laboratory) using a 26-gauge PT2 needle mounted on a 
Hamilton syringe, followed by clearing of the endogenous epithelium. Recipients were 
palpated one or two times per week, and outgrowths were measured with digital calipers 
to calculate tumor volume as described previously in Chapter 2. 
 
 
Tail Vein and Cyclocreatine Experiments 
 
For studying of late stage metastatic events, PyMT EV, shc59 and shc61 Ckb KD 
single cells were injected directly into the circulation via the tail vein at a density of 
1x106 cells per 100 μl. Mice were sacrificed after 21 days, and lungs were harvested for 
evaluation of metastases as described in Chapter 4.   
 
For cyclocreatine experiments, PyMT EV cells were injected into the tail vein as 
above, and cells allowed to seed the lungs for 24h. Mice were then treated daily with 1 
g/kg of cyclocreatine (cCr) or vehicle (0.9% saline) i.p. for 21 days; dosing was based on 
[262]. In an independent experiment, a third cohort was added wherein PyMT EV cell 
micrometastases were allowed to form for 7 days prior to initiation of cCr therapy, which 
was then administered for 14 days. On day 21 all mice were sacrificed for lung 
harvesting, formalin fixation overnight and H&E staining. 
 
 
Tissue Harvest, Histology and Immunostaining 
 
Tumors were harvested from anesthetized mice and flash-frozen in liquid nitrogen 
for preparation of RNA or protein, or they were fixed in 10% neutral buffered formalin 
(NBF) for 6 hours at room temperature for histological staining (H & E) and 
immunostaining. Paraffin-embedded sections (5 to 7 μm) were immunostained after 
antigen retrieval (1 × citrate buffer) using a rabbit monoclonal antibody to Ckb 
(Epitomics 2830), followed by development with a VECTASTAIN Elite ABC Kit and 
ImmPACT DAB (diaminobenzidine) substrate (Vector Laboratories). Lungs were 
inflated with 10% NBF and fixed in NBF overnight. Paraffin-embedded sections (7 μm) 
representing every 100 μm of lung tissue were obtained for each paraffin block, and all 
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sections were stained with H & E. The individual H & E-stained section containing the 
highest number of metastases per recipient, as evaluated by counting each slide under a 
light microscope at × 50 original magnification, was used to determine the mean number 
of metastases per genotype. 
 
 
Chromatin Immunoprecipitation  
 
The promoter of Ckb was scanned for the presence of putative HIF response 
elements (HREs) using Transcription Factor Matrix (TFM) Explorer [266]. A 2500 bp 
sequence (-2000 to +500) was scanned for the consensus HRE sequence using weight 
matrices available from JASPER and TRANSFAC. PyMT Hif1a WT and KO cells were 
cultured at 21% (normoxia) or 0.5% O2 (hypoxia) for 6 hours, and ChIP performed using 
primary antibodies against Histone H3 (AbCam 1791), HIF-1α (Santa Cruz sc-10790X), 
or rabbit IgG, as the non-specific control. Primers were designed to flank the -1800 HRE, 
5’-GTGCCTCCTGTGCACTTTTT-3’ and 5’-AGCCTAGCTTCAGAGAACTAATGG-
3’, the -1300 HRE, 5’-CAGGGCTGTTCTGGACTCTC-3’ and 5’-
CCTCACAAGTFCTGGGATTA-3’, and a region in a Ckb intron with no identified 
HRE, 5’-CCACAACAGCACATGACTGG-3’ and 5’-GGCCTTAGATCACACCCAAG-
3’. Quantitative RT-PCR was performed on the isolated DNA. Site fold-enrichment was 
calculated as the fold change in HIF-1α binding over the IgG control after normalization 
to the input DNA. 
 
 
Bioinformatics Analysis 
 
The level of CKB mRNA expression in clinical breast tumor subtypes was derived 
from the TCGA data portal (http://cancergenome.nih.gov/). Level three normalized data 
were used for mRNA expression, and samples (n=804 total tumors) were stratified by 
tumor subtype based on the PAM50 method. Plots were generated using Prism 5.0 
(GraphPad Software, Inc.) and p-values (ANOVA with Bonferroni correction) ≤ 0.05 
were considered significant.  As the current TCGA data set provides limited survival 
data, survival analysis was also conducted using data derived from [267]. Normalized 
log-ratio expression values for CKB were divided into 3 equal tertiles: 96 tumors with the 
highest CKB level (>499.7), 95 tumors with intermediate levels of CKB (between 315.5 
and 499.2) and 95 tumors with lowest CKB levels (<309.6).  For the data analyzing CKB 
together with HIF1A, 33 tumors expressed high levels of both HIF1A and CKB, 37 
tumors low levels of both genes, and 32 tumors expressed intermediate levels of both 
genes. The y-axis (probability) is defined as the frequency of survival events.  Data were 
analyzed using Prism 5.0 (Graph Pad San Diego, CA). 
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Results 
 
 
Ckb Expression Is Decreased in Hif1a KO Cells and Tumors 
 
PyMT MTEC Hif1a WT or KO cells were exposed to 21% O2 (normoxia) for 24 
hours or 0.5% O2 (hypoxia) for 6 or 24 hours. In contrast to expectations, hypoxia did not 
induce CKB protein expression as analyzed by western blot (Figure 6-4A). However, 
there was a dramatic decrease in CKB protein in either normoxic or hypoxic Hif1a KO 
cells. This same pattern was observed for Ckb mRNA levels; there was a significant 
decrease in Ckb expression in the Hif1a KO cells at both normoxia and hypoxia  
(Figure 6-4B). Cell extracts and RNA were extracted from whole tumor samples. The 
reduction of CKB protein between Hif1a WT and KO end-stage tumors was modest with 
a 37% decrease in CKB protein expression in Hif1a KO tumors (analyzed by Odyssey 
infrared western blot, Figure 6-4C). However, similar to cultured cells, Ckb mRNA 
expression showed a significant decrease in Hif1a KO tumors as compared to WT. The 
discrepancy between the protein and mRNA results could be due to the fact that mRNA 
levels were first normalized to the epithelial cell marker, cytokeratin 18 (Krt18), to 
account for epithelial cell content in whole tumor samples, whereas the western blot was 
not normalized for cytokeratin expression. Therefore, we propose that the modest 
difference in CKB expression observed in the tumor samples could be due to CKB 
expression derived from infiltrating stromal cells in the whole tumor sample. 
Experiments are in progress to co-stain WT and KO tumor sections with antibodies to 
CKB and to either cytokeratin 18, or to CD68, a marker of macrophages, or to CD45, a 
pan-leukocyte marker.  
 
 
Knockdown of Ckb Reduces Tumor Cell Invasion in vitro 
 
To assess the effect of loss of Ckb expression in vitro, Hif1a WT cells were 
transfected with 3 independent pLKO.1 shRNA vectors targeting Ckb. Of these 3 
plasmids, two shRNA sequences produced >75% knockdown at both the protein and 
mRNA level (Figure 6-5, shc59 and shc61) and these were then used to produce 
lentivirus particles to transduce PyMT HIF-1α WT cells. Each stably transduced cell line 
produced >80% reduction of Ckb protein and mRNA as compared to an empty vector 
(EV) control (Figure 6-6A and B).  Next, cell proliferation was analyzed by the WST-1 
assay over time in cells cultured at either normoxia or hypoxia. Neither shc59 nor shc61 
produced any significant change in 2-D growth rate as compared to EV control cells 
cultured at normoxia or hypoxia (Figure 6-6C). However, when assayed for invasion 
potential in a trans-well assay, there was a significant reduction in the ability of each 
knockdown cell line to invade through a Matrigel layer as compared to EV cells  
(Figure 6-6D). This reduction was even more pronounced at hypoxia. 
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Figure 6-4. Ckb expression in PyMT Hif1a WT and KO cells and end-stage 
tumors.  
A. PyMT MTECs grown to 80% confluence were subjected to hypoxia culture for the 
indicated number of hours for up to 24h, or cells were continuously cultured at normoxia, 
such that the t=0 sample was harvested on the same day as the t=24h hypoxic sample. 
WCE were resolved on 4-12% Tris-Base gels and blotted to PVDF membrane and blotted 
for CKB. B. The mean fold-change ± S.E.M. in Ckb mRNA gene expression observed in 
WT and KO cells and end-stage WT and KO tumors as determined by quantitative real-
time PCR (n=3 tumors/genotype). C. Western blotting for CKB comparing four 
independent tumors (500-750 mm3) per genotype (mouse brain WCE was used as a 
positive control). Extracts were resolved on 4-12% Tris-Base gels and blotted to PVDF-
Fluorescent membrane which was divided horizontally at approximately 50 kDa. The top 
half of the blot was blotted for CKB and the lower portion was blotted for β -tubulin 
(loading control). Blots were imaged on a LiCor Odyssey infrared imaging system and 
CKB expression was determined in WT versus KO tumors after normalization to β-
tubulin levels (right panel). The difference in CKB expression trended toward 
significance (p = 0.13), but additional samples (n>4) will need to be analyzed to increase 
statistical power. 
  
  124 
 
 
 
Figure 6-5. Evaluation of 3 independent Ckb shRNA vectors to efficiently 
knockdown CKB in cells transfected with pLKO.1 viral vector DNA.  
PyMT HIF-1α WT cells were transfected with 4 μg of pLKO.1 shRNA vector DNA by 
nucleofection. Cells were subjected to puromycin selection 24 hours after transfection 
and resulting colonies were pooled to create stable knockdown cell lines. WCE were 
resolved on 4-12% Tris-Base gels and blotted to a PVDF-FL membrane which was 
blotted for CKB and α-SMA (loading control). Blots were imaged on an Odyssey 
infrared imaging system and CKB expression was determined in WT versus KD cells 
after normalization to α-SMA levels.  
  
  125 
Figure 6-6. Effect of Ckb knockdown upon growth and invasion.  
A. PyMT MTECs grown to 80% confluence were subjected to normoxic or hypoxia 
culture for 6 hours. WCE were resolved on 4-12% Tris-Base gels and blotted to PVDF 
membrane which was divided horizontally at approximately 50 kDa. The top half of the 
blot was blotted for CKB and the lower portion was blotted for β-tubulin (loading 
control) to avoid the need to strip and reprobe the blot. B. The mean fold-change ± 
S.E.M. in Ckb gene expression observed relative to EV as determined by qRT-PCR. C. 
Growth curve of MTECs cultured at normoxia or hypoxia in growth medium 
supplemented with 2% FBS. For both conditions, the mean absorbance ± S.E.M. is 
presented, calculated as an average of the mean cell number observed per replicates per 
time point, as observed in two replicate experiments.  All data was analyzed by two-way 
ANOVA and was not significant at any time point (p>0.05). D. The mean fold-change in 
invasion was normalized to the invasion index observed for EV cells cultured at 
normoxia (FC=1.0). Data represent the mean fold change in invasion observed in two 
independent experiments. All columns were compared to each other using one-way 
ANOVA analysis with a Bonferroni post-test, *p<0.05, ***p<0.001. E. MTECs were 
plated in triplicate and grown to 80% confluence prior to being subjected to 24 hours 
normoxic or hypoxic culture. Cells were harvested and immediately lysed for analysis of 
intracellular ATP. ATP concentrations were determined from a standard curve of serial 
dilutions of ATP protein and normalized to total DNA. The mean ATP concentration per 
ng of DNA ± S.E.M. is presented calculated as an average of the 3 technical replicates 
per cell type. Data was analyzed by one-way ANOVA with a Bonferroni correction post-
test, *p<0.05, ***p<0.001 and represents the mean from two independent biological 
replicates.  
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Loss of Ckb Significantly Delays Tumor Formation and Inhibits Lung Metastases in 
vivo 
 
To study the effects of Ckb knockdown in vivo, we first chose to compare 
primary tumor growth rate.  HIF-1α WT (EV), HIF-1α KO, shc59 and shc61 cells were 
transplanted into the inguinal fat pad of FVB mice at a density of 50,000 cells. Tumors 
were palpated at least once per week over time and measured to calculate tumor volume. 
As shown previously [127], Hif1a KO cells exhibited a significant delay in tumor onset 
and decreased tumor volume maintained over time. A similar pattern of growth and size 
was observed in both Ckb knockdown cell lines (Figure 6-7A). At day 35 post transplant, 
the tumor volume of EV tumors was ≥1000 mm3, whereas all other genotypes had 
reached a maximum mean volume of only 250 mm3 (p < 0.001). At endpoint there was 
also a significant difference in tumor wet weight among EV, shc59, and shc61 
(Figure 6-7B, p < 0.001). To investigate if loss of Ckb blocked or delayed metastasis 
from the primary tumor, in a small independent pilot experiment all tumors were resected 
at a volume of ~750 mm3, and animals were housed until moribund due to lung 
metastases. Recipients of shCkb tumors survived >2x longer than recipients of EV cells 
(7.5 wks vs. 3.5 wks, hazard ratio 19.66 by log-rank test, Figure 6-7C). To explore if 
Ckb knockdown also blocked late-state metastatic events, a tail vein assay was utilized. 
One million cells were injected directly into the circulation and mice were harvested 21 
days later.  The lungs of all FVB recipient mice injected with WT or EV cells were filled 
with large metastases, whereas no surface mets were observed for the shc61 cells and a 
maximum of 10 metastases were observed for shc59 cells (Figure 6-8). 
 
 
Inhibition of Ckb with Cyclocreatine Blocks Lung Metastasis  
 
Next, PyMT EV cells were injected into the tail vein, and allowed to seed the 
lungs for 24h. After 24 hours mice began receiving daily treatment with cyclocreatine 
(cCr), a phosphocreatine analog, at a dosing of 1 g/kg of cCr or vehicle (0.9% saline) i.p. 
for 21 days. Whereas surfaces of lungs from vehicle-treated mice were filled with 
metastases, very few metastases were visible in the cCr cohort (Table 6-1). These results 
were replicated in an independent experiment, in which a third a cohort was added; 
micrometastases were allowed to form for 7 days prior to initiation of cCr therapy for 14 
days. In this cohort, 2/5 mice developed >50 surface metastases, whereas all (5/5) 
vehicle-treated mice developed >50 metastases and 1/5 mice treated from day 1 with cCr 
developed >50 metastases (Figure 6-9, Table 6-2, χ2 < 0.05). 
 
 
CKB Expression Correlates with HIF1A mRNA Expression and with Decreased 
Relapse Free Survival in Patients with Breast Cancer 
 
To gain insight into the clinical relevance of CKB gene expression in breast 
cancer, we examined its expression in a collection of primary tumor samples. By 
evaluating the TCGA breast cancer data set, we found that CKB mRNA levels are 
significantly upregulated in HER2-enriched breast cancers compared to basal-like or  
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Figure 6-7. Ckb knockdown decreases primary tumor growth and end point 
tumor wet weight and increases survival time from lung metastases. 
A. The growth rate of PyMT HIF-1α WT (EV), KO, shc59 and shc61 tumors at 50,000 
cells input (*p <0.05 at day 23 and ***p <0.001 from day 27 to end point, two-way 
ANOVA with Bonferroni correction). B. All tumors were harvested at day 34 to evaluate 
tumor weight (***p <0.001, ANOVA with Bonferroni correction). Data in A-B are 
representative of two independent experiments. C. The impact of Ckb expression in 
tumor cells on the survival of recipients following tumor resection. A pilot experiment of 
a subset of animals subjected to primary tumor resection and allowed to survive until 
moribund due to metastasis. The morbidity hazard ratio is 3.68 times higher when hosts 
bear Ckb WT tumors (n=4 mice/genotype, log-rank test, p=0.0124). 
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Figure 6-8. Knockdown of Ckb decreases lung metastasis burden. 
EV, shc59 or shc61 MTECs at a density of 1x106 cells/100 μL were injected directly into 
pre-warmed tail veins of FVB/Nj recipient mice. After 21 days mice were sacrificed and 
lungs harvested for metastasis evaluation. Images were captured at 40x magnification. 
The total number of surface metastases (n = 5 mice/genotype ***p<0.001) were counted 
under a dissecting scope. H&E analysis revealed metastasis size was reduced in response 
to Ckb knockdown. This experiment is representative of 4 biological experiments with a 
grand total of n > 40 mice/genotype.  
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Table 6-1. Summary of surface lung metastases in mice treated with saline 
versus cyclocreatine for 21 days. 
 
Metastatic 
Event 
Saline Cyclocreatine 
No Mets 1/8 5/7 
<50 Mets 2/8 2/7 
>100 Mets 5/8 0/7 
 
χ2 = 7.634, p = 0.022 
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Figure 6-9. Inhibition of Ckb by cyclocreatine (cCr) treatment blocks the 
formation of lung metastases. 
EV MTECs were injected directly into pre-warmed tail veins of FVB/Nj recipient mice at 
a density of 1x106 cells/100 μL. Mice were divided into three groups and after 24 hours, 
one group (n=5) began receiving daily IP injections of saline (Saline) and another (n=5) 
began receiving daily IP injections of 1g/kg cyclocreatine (cCr D1). After 7 days, when 
micrometastases have formed, the third group of mice (n=5) began receiving daily 
injections of 1g/kg cyclocreatine (cCr D7). Three weeks (21 days) after initial cell 
injection, all mice were sacrificed and lungs harvested for metastasis evaluation. Images 
were captured at 40x magnification. Each lung harvested was analyzed for total number 
of surface metastases (n = 5 mice/genotype) and H&E sections were also evaluated to 
compare metastasis size. This experiment represents one pilot experiment of 2 different 
starting points. However, the saline versus day 1 start point data in this second 
experiment, replicate the results shown in Figure 6-8.  
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Table 6-2. Summary of surface lung metastases in mice treated with saline 
versus cyclocreatine for 21 days (day 1 start) or cyclocreatine for 14 days (day 7 
start). 
 
Metastatic 
Event 
Saline Day 1 Start Day 7 Start 
No Mets 0/5 3/5 0/5 
<10 Mets 0/5 2/5 2/5 
11-50 Met 0/5 0/5 2/5 
>50 Mets 5/5 0/5 1/5 
 
χ2 = 17.43, p = 0.0078 
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luminal breast cancers (Figure 6-10A). As expected, based on data from the PyMT 
model, increased levels of CKB mRNA also correlated with increased levels of HIF1A 
mRNA across all subtypes (Figure 6-10B). We also investigated how CKB expression 
related to survival in breast cancer patient. Patients with high CKB expression had 
significantly shorter times for recurrence free survival as compared to those with low or 
intermediate levels of CKB (Figure 6-10C). Relapse time was further decreased in 
patients who had both high levels of HIF1A and CKB (Figure 6-10D). 
 
 
Is Ckb a Direct HIF-1α  Target? 
 
 Since Ckb expression is dependent upon HIF-1α expression in PyMT WT and 
KO cells and tumors, and because CKB mRNA expression correlates with HIF1A mRNA 
expression in primary breast cancer samples, we sought to determine if Ckb is directly 
regulated by HIF-1α. Upon examination of the mouse Ckb promoter, we identified two 
potential hypoxia response elements (HREs) within 2 kb of the transcriptional start site 
(0) (Figure 6-11, top panel). To examine HIF-α recruitment to the Ckb promoter, we 
performed chromatin-immunoprecipitation (ChIP) assays with PyMT HIF-1α WT and 
KO cells cultured at hypoxia for 6 hours. We observed that HIF-1α did not appear to be 
recruited to either HRE (Figure 6-11, bottom panel). HIF-1α recruitment to the VEGF 
promoter was included as a positive control, but also did not appear to recruit HIF-1α to 
its promoter region, suggesting a technical problem with the ChIP procedure. Previous 
control experiments using a different ChIP grade antibody (Abcam 2185), produced a site 
fold enrichment of >5 for HIF-1α binding at the VEFG HRE, whereas in the experiment 
presented here (using the Santa Cruz antibody), there was a fold enrichment of <1. This 
suggests that the Abcam antibody may have a higher binding affinity to mouse HIF-1α 
than the Santa Cruz antibody, while the Santa Cruz antibody binds well to human HIF-1α 
(Figure 4-3). As a functional correlate of transcriptional activity associated with the 
VEFG HRE, we assessed the recruitment of Histone H3 to this region and observed 
robust recruitment of this enzyme following exposure to hypoxia. These data suggest that 
HIF-containing transcriptional complexes present at the VEFG HRE, further suggesting 
there may be a problem with the HIF-1α antibody used for this experiment being 
recruited. The first intron in the Ckb promoter served as a negative control (Figure 6-11). 
As this experiment served only as a preliminary examination into HIF-1α-dependent 
regulation of Ckb, and the results were inconclusive as judged by the failure of the 
positive control, additional experiments are needed to ascertain the exact mechanism of 
HIF-1α regulation of Ckb. 
 
 
Discussion 
 
Although multiple roles for HIF-1α in mediating breast cancer phenotypes have 
been well described [68, 126, 127, 198, 268-271], there are still many HIF-1α-dependent 
genes that remain to be characterized for the role they play in tumor progression and 
metastasis. We have identified one such gene, creatine kinase brain isoform (Ckb) to be a  
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Figure 6-10. CKB correlates with HIF1A in primary breast cancer samples. 
A. CKB mRNA levels were compared using the Cancer Genome Atlas (TCGA) dataset 
across breast cancer subtypes based on PAM50 classification. B. Normalized CKB 
mRNA was compared to HIF1A mRNA for all samples to determine correlation of the 
two in the TCGA dataset (r2 = 0.00669, p < 0.05). C. Kaplan-Meier curves were derived 
from data analyzed from 286 primary human breast tumor specimens [267] for 
recurrence-free survival, stratified by high, intermediate (medium) and low CKB 
expression. D. Stratification incorporating both CKB and HIF1A expression levels. 
Significance was determined by Mantel-Cox Log-rank test. 
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Figure 6-11. Preliminary ChIP analysis of the Ckb promoter. 
Top panel: schematic representation of HREs in the proximal Ckb promoter that were 
assessed for HIF-1α recruitment. Lower panels: PyMT HIF-1α WT and KO cells were 
cultured at hypoxia (0.5% O2) for 6 hours. Formaldehyde-fixed lysates were subjected to 
ChIP with HIF-1α or Histone H3 antibodies and qPCR was performed on the isolated 
DNA to determine HIF-1α and H3 recruitment to the HREs. As controls, ChIP for HIF-
1α was performed for the mouse Vegf promoter or an intron within Ckb with no 
identified HRE sites. Data are derived from a pilot experiment and are representative of a 
single experiment. 
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HIF-1α-dependent gene necessary for mammary tumor growth and lung metastasis in the 
PyMT model of breast cancer. We have demonstrated that HIF-1α KO cells and tumors 
express much lower levels of both Ckb protein and mRNA. Interestingly, while Ckb was 
highly HIF-1α dependent in these experiments, it was not hypoxia-inducible. One 
explanation for this could be that since most breast cancers over express HIF-1α, no 
hypoxic stimulation is needed to induce expression of Ckb. Furthermore, as HIF 
expression can be induced independently of hypoxia by growth factor pathways such as 
EGF and HER2, the HIF-1α-dependent expression of Ckb may be through one of these 
pathways. Additionally, cell stressors such as low glucose, change in pH and 
theproduction of reactive oxygen species (ROS), all increase HIF-1α expression and 
could up-regulate Ckb expression independent of hypoxia.  
 
 Analysis of Ckb levels in HIF-1α WT and KO tumors showed a robust decrease 
in both mRNA and protein expression in KO MTECs. However, in tumors this difference 
was not as dramatic. A significant difference in mRNA expression was only observed 
after data was normalized to the epithelial cell maker, Krt18. In tumors the difference was 
not significant. However, this could be due to the fact that protein extracts were derived 
from whole tumor samples including both stromal and epithelial cells, and samples were 
not normalized to Krt18 expression for epithelial cell content only. Therefore, some of 
the Ckb expression observed in tumors may be from invading stromal cells. To identify if 
Ckb is highly expressed in invading stromal cells in KO tumors, whole tumors could be 
sorted for based on Krt18 expression to isolate epithelial cells from stromal cells and Ckb 
expression analyzed in these isolated cells. This could indicate if the increase in HIF-1α 
KO tumor growth over time may be due to the increase in infiltrating stromal cells that 
express high levels of Ckb over time. 
 
Knockdown of the Ckb gene produced decreased mammary tumor growth, similar 
to data derived from HIF-1α KO cells. However, in contrast to HIF-1α KO cells, tail vein 
assays to model late state metastasis revealed a significant decrease in lung metastases 
produced either by knocking down Ckb or inhibiting its activity with the chemical 
inhibitor, cCr. Together these results suggest Ckb acts downstream of HIF-1α to promote 
late stage metastatic breast cancer. This finding is particularly relevant to breast cancer 
subtypes that exhibit high constitutive expression of HIF-1α, including basal-like and 
HER2-enriched tumors which are both enriched for the hypoxic core signature [92, 93].  
 
Initial ChIP assays to determine if Ckb is a direct HIF-1α transcriptional target 
gene did not produce conclusive results. While the assay control for H3 binding to the 
Vegf promoter was clear, no assays performed with the HIF-1α antibody displayed 
enrichment for binding of HIF-1 to the Vegf HRE or to the Ckb regulatory region (-2000 
to +500 bp). Prior control studies performed with a different HIF-1α antibody (Abcam 
2185) produced a site enrichment of at least 2-fold in HIF-1α WT cells at the Vegf 
promoter, however in Figure 6-11, the Santa Cruz sc-10790X HIF-1α antibody was used 
and produced less than a 1-fold site enrichment. These data suggest that the Santa Cruz 
antibody may not display a strong affinity for mouse HIF-1α. To confirm whether or not 
HIF-1α can bind to the Ckb promoter, additional experiments need to be performed 
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utilizing either a different HIF-1α antibody or a different positive HIF-1α control such as 
Phd3, which was shown on our microarray data to be more HIF-1α dependent than Vegf. 
Additionally, a human cell line that expresses high endogenous levels of CKB, such as 
MCF7 cells that have been knocked down for HIF-1α, HIF-2α, and DKD for both [26], 
could be tested, as there were HREs identified in the human CKB promoter as well. Of 
note, we have screened the MDA-MB-231 knockdown cells for Ckb expression and no 
detectable levels of Ckb protein were observed in any genotype, so these cells are not 
useful for CKB evaluation.  
 
The commercial availability of the creatine kinase (CK) inhibitor, cyclocreatine 
(cCr) [272], provides an excellent chemical tool to ascertain the effects of loss of Ckb 
activity upon the formation of metastases, as an alternative to genetic manipulation. 
Blocking CK activity by daily treatments with cCr resulted in a significant decrease in the 
ability of Ckb expressing PyMT WT cells to form metastases in the lungs of recipient 
mice. Additionally, conversion of micrometastases to macrometastases was also blocked 
by cCr treatment, as was demonstrated by starting cCr treatment 7 days after cells were 
injected into mice. One caveat to these studies however, was the lack of additional dosing 
regimens. Our single dose of 1 g/kg was based on data published from almost 20 years 
ago that investigated cCr effects on rat mammary adenocarcinomas [262]. There were no 
adverse side effects or obvious gross toxicities using the 1 g/kg dose in FVB mice. 
However, this dose may not be the maximum effective dose. Studies are needed that 
determine the maximum tolerated dose tolerated by FVB mice bearing tumor cells, as 
well as more thorough cytotoxicity studies of mouse organs following treatment with 
escalating doses of cCr to determine if a higher dose could also be used to block 
metastases. Furthermore, no studies were completed to examine the effects of cCr on 
primary tumor growth, or if cCr could also block metastatic events following removal of 
the primary tumor. Both are future experiments I plan to complete.  
 
Another caveat to the cCr experiments was the use of a single model, the PyMT 
model. A screen of CKB protein expression in a panel of the HCI patient derived 
xenograft tumors demonstrated that while all tumors express CKB, a subset of TNBC 
tumors express higher levels of the protein, including the TNBC tumor HCI-10. As will 
be discussed in the next chapter, HCI-10 tumors metastasize to the axillary lymph node 
and because the tumor cells are labeled with Luc2, mice bearing HCI-10 tumor cells can 
easily be monitored for not only primary tumor growth, but also metastatic events. With 
this system we can evaluate two areas in which cCr therapy could be beneficial; 1) 
inhibiting tumor progression after the formation of a measurable tumor mass and 2) 
blocking the formation of macrometastases after surgical resection of the primary tumor. 
The second of these would be most useful in evaluating cCr as a clinically relevant 
therapy as most patients with breast cancer will undergo surgery to remove the primary 
mass, and are at a high risk of metastatic recurrence and death. 
 
Furthermore, I found that CKB is a prognostic factor in breast cancer. High CKB 
mRNA expression in primary human breast tumors is significantly correlated with a 
decrease in recurrence free survival, and survival further decreases when high CKB 
expression is paired with high HIF1A expression. This is not surprising as high CBK 
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expression correlates with high HIF1A expression in human breast cancers, and HIF1A 
has previously been shown to be a negative prognostic factor associated with increased 
likelihood of metastasis in breast cancer patients [21, 76, 85]. Additional studies are 
needed to ascertain exactly how HIF-1α-dependent signaling of Ckb contributes to the 
stepwise process of metastasis, particularly if Ckb is not a direct HIF-1 transcriptional 
target.  
 
Our findings suggest that Ckb is a major effector of in vivo HIF-mediated breast 
tumorigenesis and metastasis, indicating that targeting Ckb alone, or in addition to HIF-
1α, as part of combinatorial breast cancer treatment strategies may more effectively 
disrupt HIF-driven processes that contribute to aggressive tumor progression. 
  
  139 
CHAPTER 7.    USING HUMAN MODELS TO ELUCIDATE HIF-1 VERSUS 
HIF-2 CONTRIBUTION IN BREAST CANCER 
 
 
Introduction 
 
A critical aspect of tumor physiology is the sensation of oxygen in the 
microenvironment. Over-expression of the oxygen-responsive Hypoxia-Inducible Factor 
(HIF) alpha subunits in breast cancer correlates with poor prognosis, increased risk of 
metastasis and decreased survival. Up to 17% of patients are diagnosed with triple 
negative breast cancer (TNBC; ER/PR/HER2-negative), however TNBC tumors account 
for at least 25% of breast cancer deaths [88]. In contrast to the luminal or HER2+ 
subtypes, no targeted therapies exist for TNBC. Additionally, the rapid onset of 
resistance to chemotherapy along with the spread of cancer to the liver, lung or brain is 
more common in women with TNBC. Comprehensive comparison of gene expression 
profiles among breast cancer subtypes has revealed that the hypoxic response 
transcriptional core signature is highly enriched in TNBCs as compared to luminal breast 
cancers [92, 93]. 
 
Recent studies from our laboratory have demonstrated an essential role of HIF-1 
in promoting tumor growth and metastasis in a “luminal-like”, ER negative, Neu/HER2 
positive mouse model of breast cancer (Chapter 3). Yet, whether HIF1A and HIF2A 
perform different roles among the subtypes of human breast cancer remains unknown. 
Using human models of breast cancer, we are testing whether the HIF pathway promotes 
tumor growth and metastasis in luminal and triple negative breast cancers through 
differential regulation of HIF-1α and HIF-2α activity.  
 
 
Methods 
 
 
Human Xenograft Maintenance  
 
The novel human tumor xenograft system developed in the laboratory of Dr. 
Alana Welm of the Huntsman Cancer Institute at the University of Utah authentically 
reflects the same tumor histopathology and the clinical patterns of metastasis observed in 
the patients from which the sample originated [132]. We have obtained cryopreserved 
tumor fragments from multiple sub-lines of tumors maintained in this tumor bank, 
including three triple negative (HCI-1, HCI-2 and HCI-10) and three luminal breast 
cancer (HCI-3, HCI-7 and HCI-11) lines, all of which have been successfully passaged in 
our laboratory into immunocompromised NOD/SCID gamma (NSG, NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) female recipient mice. Frozen tissue chunks, obtained from Dr. 
Alana Welm, were briefly thawed and washed 3 times with DMEM, then briefly stored in 
DMEM/F12 media until time of transplant. An approximately 1 mm x 2 mm sized piece 
of tissue was implanted into the inguinal fat pad of 3-6 week old female NSG mice. For 
ER+ tumors, an estrogen pellet was implanted subcutaneously behind the neck at the 
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same time as transplant surgery. Mice were monitored weekly for tumor growth. When 
tumors grew to ~1,000 mm3, mice were euthanized and tumors harvested. Tumor 
fragments were either immediately used for re-transplant into another cohort of mice, 
cryopreserved for future use, frozen in liquid nitrogen for DNA, RNA and protein 
extraction or fixed in NBF and analyzed for histology. At necropsy, lungs and axillary 
lymph nodes were examined for gross metastases, and then fixed overnight in NBF.  
 
 
Cell Culture  
 
 MDA-MD-231 cell culture was described previously in Chapter 4.  
 
 
Tumor Cell Transplants into NSG Recipients 
 
MDA-MB-231 cells were dissociated into single cells with 0.25% trypsin-EDTA 
and counted using a hemacytometer. Cells were resuspended in HBSS alone at a density 
of 250,000-1 million cells/10 ul. Cells were kept on ice until injection into the right 
inguinal mammary fat pads (10 μl) of 3-6 week old female NSG recipients using a 26-
gauge PT2 needle mounted on a Hamilton syringe, followed by clearing of the 
endogenous epithelium. Recipients were palpated one or two times per week, and 
outgrowths were measured with digital calipers to calculate tumor volume as described 
previously [126]. 
 
For transplant of lentivirus-transfected HCI tumor cells, transduced cells cultured 
in suspension were pelleted at 600 rpm to remove dead cells, washed once with HBSS 
and re-suspended in a 1:1 dilution of Matrigel:HBSS. The number of cells implanted into 
female NSG recipients was determined empirically for each experiment. All cells that 
survived antibiotic selection were transplanted into recipient mice (range of 4,000-45,000 
cells per experiment). Due to the very low cell input, many months were required to 
regenerate tumors after viral transduction.  
 
 
Genetic Modification of HIFs in HCI Tumors 
 
Knockdown of either HIF1Α or HIF2Α (or co-deletion of both alpha subunits) 
was accomplished using pLKO.1 shRNA lentiviral vectors. Vectors used to create shHIF-
1α, shHIF-2α and DKD MDA-MD-231 cells were based on shRNA sequences identified 
by Dr. Roland Wenger [26] and were also used to transduce cells derived from the HCI 
tumors. Tissues harvested from tumor bearing mice were cut into pieces using scalpels 
and minced with razor blades. All necrotic areas were removed prior to mincing of the 
tissue into a paste. The minced tissue was incubated with collagenase III (Worthington) 
and hyaluronidase (Sigma) and enzymatically digested in a 37°C shaker (250 rpm) for 1 
hour. Tissue was further digested to single cells as described in Chapter 3. The final cell 
pellet was resuspended in serum free stem cell media (Chapter 3) plus the addition of 
heparin and allowed to recover overnight at 4°C. The next day cells were plated at a 
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density of 250,000 cells/well into 6-well ultra-low attachment plates. Lentivirus 
expressing firefly luciferase or luciferase and puromycin (pEILuc2 or  
pEIPuro-Luc2, Figure 7-1) was added to the cells at an MOI of 10 in the presence of 8 
μg/ml polybrene. Virus was incubated with cells for 24 hours, and then cells were 
washed and replated in fresh stem cell media. After 48 hours, Luc2 positive cells were 
selected by the addition of 1 μg/ml puromycin (Figure 7-2). Once cells recovered from 
selection (5-7 days) they were pelleted, washed and resuspended in Matrigel for 
transplanting into NSG recipients.  
 
 Once Luc2+ tumors grew to sufficient size, flash frozen and cryopreserved 
fragments were prepared and the remaining tumor tissue was digested with the protocol 
above. Cells were transduced with either shHIF-1α, shHIF-2α or shEmpty (EV) 
lentivirus. Cells were again selected, and live-cells re-transplanted back into the next 
generation of mice. Tumor growth was evaluated between shRNA and EV treated cells 
by caliper measurements and bioimaging. 
 
 
Xenogen Bioimaging 
 
 D-Luciferin firefly potassium salt (Xenogen, XR-1001) was prepared in sterile 
DPBS without calcium and magnesium to a concentration of 30 mg/mL. On imaging 
days, fresh stock solutions were diluted 1:2 with sterile DPBS to a final concentration of 
15 mg/mL. Mice received a dose of 10 μL luciferin per gram of body weight by IP 
injection 10-15 minutes prior to imaging. Mice were anesthetized using isoflurane. The 
Xenogen Living Image software system was used to capture images. The camera settings 
were set to detect luminescence on auto exposure. Amount of luciferase signal was 
determined by total flux (photons/second) for each animal. Imaging was completed twice 
per week.  
 
 
Immunofluorescence 
 
Human xenografted tumors were harvested from mice and fixed in 10% neutral 
buffered formalin (NBF) for 6-8 hours at room temperature for immunostaining. Paraffin-
embedded sections (5 to 7 μm) were immunostained after antigen retrieval (1 × citrate 
buffer) using a rabbit polyclonal HIF-1α antibody (Abcam 2185) at a dilution of 1:5000 
followed by tryamide signal amplification (TSA) with Alexa Fluor®-488 according to the 
manufacturer’s protocol. (Invitrogen, T-20922). All sections were counterstained with 
DAPI and coverslipped using VECTASHEILD hard set mounting medium (Vector 
Laboratories). 
 
 
MDA-MB-231 Tumorsphere Assays 
 
MDA-MB-231 cells were prepared for tumorsphere assays as described in 
Chapter 3. Single cells were resuspended in serum-free 0.5% methylcellulose media  
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Figure 7-1. Maps of vectors used for luciferase labeling. 
The parent vector, pEILuc2 (top) was derived from the pEIZ vector previously obtained 
from Dr. Bryan Welm. The vector contains a multiple cloning site (MCS) and firefly 
luciferase coding sequence (Luc2, derived from the pGL4.13 vector from Promega) 
downstream of IRES, driven by the eIF-1α promoter. Using this pEI parent vector 
backbone, the puromycin resistance gene (Puro) was PCR cloned downstream of the 
IRES, and Luc2 was cloned into the MCS to create pEIPuro-Luc2 to allow for selection 
of cells expressing Luc2. All constructs have been reposited to Addgene by Dr. Bryan 
Welm.  
  143 
 
Figure 7-2. Schematic of lentivirus transduction of HCI tumors in stem cell 
conditions. 
Fresh primary tissue chunks were transplanted into female NSG mice. At a tumor volume 
of ~750 mm3, tumors were resected and digested to single cells for transduction with a 
luciferase expressing virus. Following transduction, live cells were transplanted into a 
new generation of female NSG mice, tumors were evaluated for growth by Xenogen live 
bioimaging. 
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containing DMEM/F-12 plus 20 ng/ml mouse recombinant EGF, 20 ng/ml basic 
fibroblast growth factor, 1 × B27 (all from Invitrogen) and 4 μg/ml heparin (Sigma- 
Aldrich, St Louis, MO, USA), as described previously [188]. Primary tumorspheres were 
derived by plating 500 single cells/well into 24-well ultra-low-adhesion dishes. Dishes 
were cultivated at normoxia for 10 to 14 days prior to enumeration of spheres. Individual 
spheres ≥ 100 μm from each replicate well (n ≥ 12 wells/genotype) were counted. The 
percentage of cells capable of forming spheres, termed the "sphere formation efficiency" 
(SFE), was calculated as follows: [(number of spheres formed/number of single cells 
plated) × 100].  
 
 
Results 
 
 
HIFα  Expression in Triple Negative Breast Cancer Models  
 
 To determine level of expression of the HIFα proteins in various breast cancer 
subtypes, protein extracts from seven primary breast cancer PDX xenografts obtained 
from the HCI tumor bank were analyzed (Figure 7-3). The four TNBC tumors (HCI-1, 2, 
9 and 10) expressed the highest levels of both HIF-1α and HIF-2α, while the luminal 
tumors (HCI-5, 3 and 11) expressed lower levels of both proteins [1]. These data are 
consistent with previous findings that the HIF transcriptional core signature is enriched in 
TNBC [93]. To study the specific contribution of the HIFα subunits in the HCI samples, 
we procured 3 different TNBC and 3 different luminal cryopreserved tumor xenograft 
fragments from Dr. Alana Welm. Tumors were chosen based on levels of HIFα 
expression and considering the sites of distant metastases. Of the 3 TNBC tumors, 2 
metastasize to lung and 1 metastasizes to axillary lymph nodes (AxLN). Of the 3 luminal 
tumors, 1 metastasizes to lung (HCI-11), 3 to the AxLNs and 1 to the bone (HCI-7). It 
has already been established that MDA-MD-231 cells express high levels of HIF-1α as 
compared to other breast cancer cell lines [175].  
 
 
Transduction of HCI Tumor Cells with Lentivirus for Live Bioimaging and 
Evaluation of Metastatic Spread over Time 
 
 In order to readily observe the growth rate of primary tumors and dissemination 
from the primary site to distant organs, we labeled HCI tumor cells with firefly luciferase 
(Luc2) by lentiviral transduction of cells cultured in stem cell conditions. Whole tumors 
were harvested from mice and digested to single cells in the absence of serum prior to 
transduction in stem cell culture conditions. The absence of serum and inability of cells to 
attach to tissue culture plastic has been reported to preserve gene expression and SNP 
profiles and histopathology of the primary patient samples [115, 273]. The first tumor I 
chose to label with Luc2 was the HCI-2 TNBC tumor, which expresses the highest levels 
of HIFα among all HCI TNBCs (Figure 7-2 and Figure 7-4). Live cells were injected 
into the 4R fat pad of 4 independent female NSG mice (passage 1, P1). Tumors were 
monitored weekly for growth and were harvested from mice when tumors reached a  
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Figure 7-3. HIFα  expression in HCI tumors of specific subtypes. 
HS-WCE protein extracts were prepared from fresh frozen tumor tissues obtained from 
the laboratory of Dr. Alana Welm and probed for HIF-1α, HIF-2α or β-tubulin (loading 
control).  
Adapted from Anderson, T.M.R., et al., Breast Tumor Kinase (Brk/PTK6) is a mediator 
of hypoxia-associated breast cancer progression. Cancer Res, 2013. [1] 
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Figure 7-4. Xenogen bioimaging of HCI-2 Luc2+ tumor cells. 
Tumors were harvested from mice bearing HCI-2 xenografts and digested to single cells 
prior to being plated in stem cell culture conditions for lentiviral transduction with 
pEILuc2. Twenty-four hours after transduction, cells were washed and replated in fresh 
stem cell medium and ultra-low attachment plates. After 14 days of growth in stem cell 
conditions, cells were pelleted and resuspended in a 1:1 mixture of HBSS:Matrigel, and 
injected into the inguinal fat pad of 3-6 week only NSG mice to generate parental (P1) 
tumors. Tumors were both palpated and imaged twice per week for a total of 9 weeks. 
Day 10 represents the first day Luc2 signal was detected by IVIS imaging, although no 
tumor masses were palpable. Day 58 represents the final Luc2 signal intensity just prior 
to tumor harvest; caliper measurements revealed a final tumor volume of 583.77 mm3 in 
this mouse. Images are representative of 4 individual mice. 
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volume of 500-750 mm3. The individual HCI-2 Luc2+ tumor with the brightest Luc2 
signal on the final day of bioimaging was used for digestion and transduction of cells 
with either pLKO.1-shHIF1A or empty pLKO.1 (EV) lentiviral particles. Following 
selection of shRNA targeted cells with puromycin, cells were transplanted back into the 
mammary fat pad of recipient NSG mice (P2). Due to the stress associated with virus 
transduction and antibiotic selection, very few cells were recovered for transplant from 
either the shHIF1A and EV cells. As a result only 2 recipient mice were used; each 
mouse received shHIF1A cells into the 4R fat pad and EV cells into the 4L fat pad 
(Figure 7-5A). Moreover, the shHIF1A cells were recovered with >5x the yield 
compared to EV cells. Therefore, it was not expected tumors would grow at the same 
rate. 
 
Evaluation of end-stage tumors revealed HIF-1α protein levels were knocked 
down (as compared to EV controls in both mice) (Figure 7-5B). qRT-PCR analysis of 
HIF1A mRNA levels revealed a mean of >80% knockdown for shHIF1A tumors  
(Figure 7-5C). Once tumors grew to approximately 750 mm3, they were harvested for re-
transplant into recipient mice to evaluate HIF-1α knockdown on tumor growth in a larger 
cohort (n=6 tumors/genotype, P3). 
 
 Tumors were measured and imaged twice per week. Analysis of tumor volume 
over time indicated no obvious difference in the time palpable or measureable tumor 
onset between EV and shHIF-1α tumors (Figure 7-6A). However, by day 30 post 
transplant, EV tumors began to grow at a faster rate then the shHIF-1α tumors. Analysis 
of end-stage tumor volume revealed a significant reduction in tumor weight wet in the 
shHIF-1α tumors as compared to the EV tumors (Figure 7-6B). Immunoblotting for HIF-
1α protein levels among the individual end stage tumors suggested that knockdown of 
HIF-1α with shRNA was not efficient as there was a large variation in the amount of 
HIF-1α protein present among each knockdown tumor as compared to the EV control 
tumors. This finding was confirmed by immunofluorescence imaging which showed 
similar amounts of HIF-1α protein in the various tumors as detected by western blotting 
(Figure 7-6D). Analysis of HIF-2α protein levels by western blot did not reveal any 
significant change in expression between EV and shHIF-1α tumors (data not shown). 
 
Based on the relatively modest decrease in mean tumor growth and mean tumor 
wet weight in shHIF-1α tumors as compared to EV controls, likely due to the high 
variability in HIF-1α knockdown efficiency, we hypothesized that selecting the tumor 
with the best HIF1A knockdown would increase the difference in tumor growth between 
genotypes. Based on western blot results, EV #1 and shHIF-1α #3 tumors were selected 
for re-passaging into recipient NSG mice (P4). Tumor growth was again evaluated over 
time. In contrast to the previous experiment, in this experiment the shHIF-1α tumors 
grew faster than the EV tumors (Figure 7-7). Given our previous data using the PyMT 
model [127], and that this was our first experiment using a human model of breast cancer, 
we presumed there must have been a mistake in the experimental set-up. Prior to 
returning to using the HCI model, we next set out to evaluate HIF-1α knockdown in a 
commonly used metastatic TNBC breast cancer cell line model, MDA-MB-231 cells. 
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Figure 7-5. Xenogen bioimaging of HCI-2+shHIF-1α  or EV transduced tumors 
over time. 
A. EV cells were injected into the 4L inguinal fat pad and shHIF-1α cells were injected 
into the 4R inguinal fat pad of 3-6 week NSG mice to generate second passage (P2) HIF-
1 wild-type (WT) and shHIF1A tumors, respectively. Tumors were both palpated 
manually and bioimaged twice per week for 9 weeks. Day 13 represents the first day to 
Luc2 signal was observed, although no masses were palpable. Day 28 shows signal 
midway through tumor growth and day 61 represents the final Luc2 signal observed prior 
to tumor harvest with an shHIF-1α average tumor size of 1275.7 mm3 and an average EV 
tumor size of 764.67 mm3. B. Western blot of end-stage tumor HS-WCE probed for HIF-
1α; ** represents under loaded protein for EV#2 tumor. C. qRT-PCR analysis of mean 
HIF1A mRNA levels in tumors.   
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Figure 7-6. Comparison of tumor growth and HIF-1α  protein levels by western 
blotting and IHC in third passage HCI-2 tumors. 
A. The growth rate of third passage (P3) HCI-2-Luc2 EV and shHIF-1α tumors. B. All 
tumors were harvested and evaluated for end stage tumor wet weight (p <0.05, Students t-
test). C. Western blot analysis of individual end stage P3 tumors for HIF-1α protein 
levels D. Immunofluorescence staining of selected P3 tumors for HIF-1α. 
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Figure 7-7. After selecting for the most efficient HIF1A knockdown HCI-2 tumor, 
shHIF1A repassaged P4 tumors grow faster than EV repassaged tumors. 
Growth rate of HCI-2-Luc2 EV (#1) and shHIF-1α (#3) tumors repassaged from P3, now 
P4) selected for highest and lowest HIF-1α expression, respectively. Data show a trend 
that knockdown of HIF1A accelerates tumor growth, but the difference between means is 
not significant at any time point by two-way ANOVA with Bonferroni correction. 
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HIF1A Knockdown in MDA-MB-231 Cells Increases Primary Tumor Growth  
 
 We obtained in collaboration with Dr. Roland Wenger MDA-MB-231 cells, in 
which either HIF1A, HIF2A or both genes had been knocked down to generate shEmpty 
(EV/WT), shHIF-1α, shHIF-2α, and shHIF-1α/shHIF-2α (DKD) cells. We verified that 
all lines had >80% knockdown of either HIFα gene in single or double knockdown cells 
(Figure 7-8A-C). To investigate the invasion potential of cells knocked down for HIFα, 
we performed an invasion assay through a Matrigel layer. While shHIF-1α cells had a 
modest increase in the ability to invade, shHIF-2α cells had a significant increase 
invasion with no change in DKD as compared to EV at normoxia. The ability of the 
shHIF-2α cells to invade further increased when exposed to hypoxia, while the invasion 
potential of the DKD cells decreased. These results were obtained from a single 
experiment and need to be repeated. A tumorsphere assay was then utilized to examine 
the sphere forming ability of each cell line. In 3 independent experiments we observed a 
significant increase in the sphere forming potential of shHIF-1α cells as compared to EV 
controls, while there was only a slight but not significant increase in shHIF-2α cells. 
DKD cells had almost no sphere forming potential; suggesting the ability to form spheres 
is highly dependent on the expression of at least one HIFα subunit. The ability of cells to 
form spheres in stem cell cultures is generally associated with tumor initiation potential, 
therefore these data support our in vivo findings in the HCI-2 tumors.  
 
Next all 4 genotypes of MDA-MB-231 cells of NSG mice were transplanted into 
the mammary fat pad at a density of 250,000 cells. shHIF-1α tumors grew twice as fast 
as all other genotypes and were be harvested 10 days earlier due to reaching a study 
endpoint size of >1000 mm3 tumor volume (Figure 7-9A-B). In contrast, HIF-2α 
knockdown significantly decreased tumor growth as compared to EV, and DKD further 
decreased growth (Figure 7-9C). Analysis of end stage tumors revealed an increase in 
HIF-2α protein and mRNA levels in the shHIF-1α tumors (Figure 7-9D-E), while HIF-
1α levels remained low, leading us to propose that HIF-2α is driving the growth of these 
tumors. However, HIF-2α knockdown was not maintained well in vivo, but shHIF-1α 
and DKD are maintained. These results are in contrast to what we expected to discover 
given our previous data with the PyMT model. However, these results are consistent with 
what we observed when HIF1A was knocked down in the HCI-2 tumors, suggesting 
differing roles for HIF-1α and HIF-2α in promoting tumor growth and progression in 
different subtypes of breast cancer. Construction of stabilized HIF-1α and HIF-2α 
lentiviruses to generate HIF1A and HIF2A overexpression (Pro-Ala mutations) in MDA-
MB-231 cell lines is in process to test this hypothesis. 
 
 
Characterization of Tumor Growth and Metastasis Using the TNBC HCI-10 Tumor 
Line 
 
Our studies performed using the HCI-2 TNBC tumors, suggested that HIF-1α 
knockdown increases tumor growth. Knockdown of HIF-1α in MDA-MB-231 TNBC 
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Figure 7-8. Characterization of HIFα  knockdown phenotypes in MDA-MB-231 
cells. 
A. HIF1A and B. HIF2A mRNA levels in MDA-MB-231 knockdown cells at 24 hours 
normoxia or 6 to 24 hours hypoxia (0.5% O2). Values are relative mRNA levels as 
compared to expression of Cyclophillin A (loading control). B. HS-WCE extracts from 
cultured cells were blotted for HIF-1α, HIF-2α and β-tubulin (loading control) to 
determine HIFα protein levels in the knockdown cell lines. D. The mean fold-change in 
invasion was normalized to the invasion index observed for EV cells cultured at hypoxia 
(FC=1.0). Data represent the mean fold change in invasion observed in a single pilot 
experiment. All columns were compared to each other using one-way ANOVA analysis 
with a Bonferroni post-test, *p<0.05, ***p<0.001. E. The mean sphere formation 
efficiency (SFE) ± S.E.M. was determined when cells were cultured in tumorsphere 
culture conditions. Tumorspheres ≥100 μm were scored positive, and the mean SFE (the 
percentage of cells capable of forming spheres per total number of single cells plated) per 
experiment (n≥12 wells/genotype; p<0.05, unpaired Student’s t-test) was determined. 
Data represents mean of three independent tumorsphere experiments. 
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Figure 7-9. Phenotypes following knockdown of HIF-1α  and HIF-2α  in MDA-
MB-231 cells. 
A. The growth rate of MDA-MB-231 EV, shHIF-1α, shHIF-2α and DKD tumors at 
250,000 cells input. B. Day 34 tumor volume just prior to sacrifice of shHIF-1α tumors 
(***p <0.001, ANOVA with Bonferroni correction). C. Evaluation of tumor volume at 
endpoint without shHIF-1α tumors (**p <0.01, *p <0.05 ANOVA with Bonferroni 
correction). D-E. HIF-1α and HIF-2α protein and mRNA levels in end-stage knockdown 
tumors (**p <0.01, *p <0.05 ANOVA with Bonferroni correction). 
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cells also supported these findings. However, neither of these models demonstrates 
highly efficient spontaneous lung metastases from the primary mammary tumor in the 
mammary fat pad, as we observe in the PyMT model. Therefore we chose to refocus 
efforts to compare the roles of HIF-1 versus HIF-2 in a more metastatic TNBC model. 
The HCI-10 tumors are capable of metastasizing to the axillary lymph nodes from the 
mammary fat pad. In order to perform bioimaging analysis we also revised the Luc2 
labeling process by creating the pEIP-Luc2 vector so that Luc2+ cells could be selected 
by puromycin resistance (Figure 7-1). This refinement should result in a more evenly 
labeled Luc2+ tumor cell populations.  
 
HCI-10 tumor cells were transduced with pEIP-Luc2 lentiviral particles in stem 
cell conditions and Luc2+ cells were selected for with 1 μg/mL of puromycin. Cells 
remained in culture for 14 days prior to being pelleted, washed and resuspended in 
Matrigel for injection into the fat pad of female NSG mice. Approximately 180,000 cells 
were divided evenly and injected into both number 4 fat pads of 2 independent mice 
(n=45,000 cells/injection). Twice weekly bioimaging and palpation revealed Luc2 signal 
as early as 13 days after transplant prior to any palpable mass detected in the fat pad 
(Figure 7-10A-C), indicating bioimaging is more sensitive in monitoring tumor 
progression. By day 57 there was a robust Luc2 signal in each transplanted fat pads, 
although the mammary tumor was only just palpable and not yet measureable with 
calipers (Figure 7-10B-C). Moreover, by day 57 post transplant, the first signal was 
detected in the axillary lymph nodes suggesting that metastasis occurs very early in 
tumorigenesis in the HCI-10 model. By the last day of imaging, a robust signal was 
observed in both axillary lymph nodes of animal #2241. When mice were harvested for 
tumor removal, we observed there were metastases in both axillary lymph nodes at a size 
of approximately 2-3 mm in diameter. Overall, these data demonstrate that we could 
visualize the formation of AxLN metastases before there was a palpable tumor mass, and 
we could correlate a signal intensity with increasing metastatic burden. Upon necropsy, it 
was confirmed that the signal observed by bioimaging was indeed from an AxLN 
metastases and not from lung metastases. In order to confirm that this was not an isolated 
event, we retransplanted tissue chunks from the first passage (P1) HCI-10 Luc2+ tumors 
into recipient NSG mice to generate passage 2 (P2) HCI-10 Luc2+ tumors. We again 
observed the same pattern of tumor growth and AxLN metastasis over time 
(Figure 7-11).  
 
To determine if HCI-10 Luc2+ tumors also increase in tumor growth rate upon 
HIF1A deletion and what the effects of HIF-2α deletion would be, we are currently in the 
process of transducing these HCI-10-Luc2 tumors with shHIF-1α and shHIF-2α 
lentivirus. HCI-10 Luc2+ EV transduced cells have been generated, and tumor fragments 
are cryopreserved for future use. 
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Figure 7-10. HCI-10 Luc2+ P1 tumor growth and metastasis over time. 
A. Tumors were harvested from mice, digested to single cells, transduced with pEIP-
Luc2 and selected for with 1 μg/mL puromycin prior to being injected into the inguinal 
fat of 3-6 week old NSG mice. Tumors were both palpated and bioimaged twice per 
week. Day 13 represents the first day Luc2 signal was observed, with no palpable tumor 
mass. Day 57 represents a middle time point for which tumors were palpable but were not 
measureable with calipers and axillary lymph node metastases were first apparent. 
Day111 represents a late stage HCI-10 Luc2+ signal just prior to harvest with robust 
signal detected in both the primary tumor and the axillary lymph node metastases. B. Plot 
of Luc2 signal (total flux, photons/second, p/s) over time post transplant. C. Plot of tumor 
volume over time post transplant. 
2241 
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Figure 7-11. Characterization of P2 HCI-10 Luc2+ tumor and AxLN metastasis by 
bioimaging. 
HCI-10 Luc2+ tumors were harvested from hosts and tumor fragments were immediately 
repassaged into the inguinal fat pad of 3-6 week old NSG mice. Tumors were both 
palpated and imaged twice per week. Day 13 represents the first day Luc2 signal was 
observed, with no palpable tumor mass. The upper panel shows tumor growth and 
metastasis development over time (images are representative of 4 animals). The lower 
panels display Luc2 signal (total flux, p/s) and tumor volume over time for the duration 
of the experiment. 
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Discussion 
 
We have previously generated evidence to support a positive role of HIF-1α in 
breast cancer initiation, progression and metastasis (Chapters 3, 4, and 6 and Schwab et al 
[127]). However, the exact mechanism of HIF-2α in these processes remains to be 
established. We have demonstrated that in the luminal-like, MMTV-PyMT model of 
breast cancer, deletion of HIF-1α results in a decrease in tumor initiation potential, tumor 
growth and metastasis. However, when we knocked down HIF-1α in the TNBC HCI-2 
tumor, we observed the opposite effect. In these TNBC tumors, sufficient loss of HIF-1α 
(> 80%) is required for increased tumor growth as compared to HIF-1α WT (EV) 
controls. In the triple negative human breast cancer cell line, MDA-MB-231, we verified 
these findings, while also observing that HIF-2α knockdown had only modest though 
statistically significant effects on primary tumor growth. Additionally, tumor sphere 
assays suggested that loss of HIF-1α conferred a more stem-like nature in the cells by 
significantly increasing tumorsphere formation efficiency (SFE), while loss of HIF-2α 
did not affect SFE. These conflicting results obtained from the PyMT model and these 
two different TNBC models of breast cancer suggest that the HIF-1 and HIF-2 may play 
different roles in promoting tumor initiation, progression and metastasis, and that these 
roles may also be dependent on the molecular subtype of the breast tumor (TNBC versus 
luminal).  
 
In order to validate these preliminary findings, we are investigating the effects of 
HIFα knockdown in a third triple negative tumor model, HCI-10. Knockdown of the 
HIFs in this tumor will also allow us to evaluate the consequences HIFα loss has on early 
metastases as these tumors develop lymph node metastases very early during 
tumorigenesis. The HCI-10 tumor line has been robustly labeled with luciferase to 
facilitate observation of HIFα-dependent differences in metastatic phenotypes. 
Additionally, I am in the process of labeling three HCI luminal tumors (HCI-3, HCI-7, 
and HCI-11) with luciferase, and to then be subjected to gene knockdown for the HIFα  
subunits. Once the luminal knockdown tumors are established, we will be able to 
ascertain whether or not these luminal tumors behave like the PyMT model or if they 
portray a different phenotype and behave more similar to HCI TNBC and MDA-MB-231 
cells. With these reagents we will be able to more clearly delineate the exact roles of both 
HIF-1 and HIF-2 in tumor growth and metastasis in different subtypes of human breast 
cancer. 
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CHAPTER 8.    DISCUSSION 
 
 
A considerable body of research has been accumulated relevant to the biology of 
HIF-1α in breast cancer. As early as the 1920’s metabolic maintenance in the presence of 
varying oxygen levels was being described in cancers [274]. Metabolic homeostasis is 
important for expansion under the low oxygen, or hypoxic conditions for tumors [275]. It 
was not until more than half a decade later, however, that HIF-1α was identified as being 
the transcriptional regulator of hypoxia-induced expression of erythropoietin (EPO) [276, 
277]. It was quickly realized that HIF-1 was a master regulator of the hypoxic response  
[190, 278]. Following this discovery, rapid advances were made in delineating the role of 
HIF-1α in tumorigenesis and metastasis. The first demonstrations that HIF1 mediated 
tumor-promoting effects occurred only a few years after it was purified and cloned [41, 
279]. Subsequent studies continued to compile evidence that increased levels of HIF-
1α are directly and positively associated with increased cell invasion, metastasis and 
death [3], as well as resistance to chemotherapy, immunotherapy and radiotherapy [160]. 
Moreover, high HIF-1α expression has been found to independently correlate with poor 
overall survival, increased risk of relapse and increased risk of metastasis in breast cancer 
patients [85]. While significant progress has been made in understanding how hypoxia 
and the HIF-dependent hypoxic response influence tumorigenesis, substantial work is left 
to fully define this complex pathway. In this body of work, I have delineated the role that 
the HIFs play in breast cancer initiation, progression and metastasis through regulation of 
breast cancer TIC activity and gene expression.  
 
 
The HIFs Regulate TICs 
 
 We first characterized the role of Hif1a in regulating breast TICs by using an ex 
vivo genetic deletion approach in the MMTV-PyMT mouse model of breast cancer [127]. 
In this model we generated constitutive HIF-1α KO and WT mammary tumor epithelial 
cells that were useful both for culture in vitro and for transplantation back into 
immunocompetent hosts to generate HIF-1α WT and KO mammary carcinomas. Using 
this approach, we were able to demonstrate that HIF-1α is required for primary 
mammary tumor growth and lung metastasis [127]. Additionally, I was the first to 
demonstrate that HIF-1α regulated TIC activity in breast cancer, in part through up 
regulation of the Notch pathway through assays detailed in Chapter 3. Further 
investigation into the role of HIF-1α in TIC activity, led us to the discovery that HIF-1α 
directly regulates many genes currently used to enrich for cancer stem cells, including 
CD133 and CD24, although other laboratories published these data before our work was 
published [117, 224]. We recently observed that another commonly used marker for stem 
cells, CD49f/ITGA6, was highly dependent upon HIF expression. Furthermore 
enrichment for CD49fhigh/+ cells by FACS not only enhanced primary tumor growth, but 
also increased lung metastases, as described in Chapter 4. These data provide compelling 
evidence that HIF regulates cancer stem cells, as has been shown in lymphomas [60] and 
gliomas [115]. 
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 TICs are believed to modulate phenotypes associated with metastatic breast 
cancer cells, including enhanced migration/invasion and enhanced resistance to 
chemotherapy [163]. Therefore, targeting the CSC/TIC population for eradication could 
have a significant impact on patient prognosis and therapeutic response. Additionally, 
TICs are more resistant to therapy than bulk tumor cells or the surrounding stroma [162, 
280], although the exact mechanisms for this resistance are not well defined. Moreover, 
independent of its role in CSCs/TICs, HIF-1α was previously shown in multiple tumor 
types to contribute to resistance to radiation and chemotherapy [281-284]. A recent study 
suggests one underlying mechanism may involve HIF-1α’s direct regulation of the 
multidrug resistance (MDR) gene [14]. These data, combined with our findings, suggest a 
prominent role for the HIFα subunits in regulating TICs in a variety of solid tumors, 
making this pathway an attractive therapeutic target. Furthermore, the enrichment of 
HIFα protein expression in TNBCs versus luminal cancers [1, 92, 93], may directly 
regulate the increased aggressiveness and chemoresistance phenotypes observed in 
TNBCs, in part by directly regulating the TICs. Treating patients diagnosed with TNBC 
is challenging, since tumors are typically high grade, patients do not response to 
endocrine therapies or Herceptin, and onset of chemotherapy resistance to conventional 
chemotherapies is rapid, leading to a higher risk of recurrence and decreased 5-yr 
survival [88]. To date no FDA-approved targeted therapies exist for. Therefore, it is 
possible that HIF inhibitors, or inhibitors to genes downstream of HIF in the hypoxic 
response, may be particularly beneficial to TNBC patients. 
 
As another example, targeting CD49f, which is enriched in TNBC (Figure 4-6) 
[229] and is a direct HIF target (Figure 4-3), within these tumors may provide 
therapeutic benefit. Recently, multiple novel therapeutic systems have been designed 
with the aim of killing CSCs and altering the microenvironment (niches) supporting these 
cells [285]. For example, a monoclonal antibody against CD133 (gemtuzumab 
ozogamicin) has been developed and used to successfully treat patients with AML [286]. 
In addition, targeting Notch, which promotes CSC activity [287, 288], has been effective 
in lowering the CSC population, in addition to lowering the incidence of brain metastases 
from a breast cancer cell line [289]. Utilizing strategies such as these, we may be able to 
target CD49f gene expression or integrin signaling to treat patients diagnosed with TNBC 
whose tumors express high levels of CD49f. Increased expression of CD49f during 
treatment may also be useful as a biomarker that predicts onset of resistance to therapy or 
metastatic relapse. 
 
 
The HIFs Promote Tumor Metastasis 
 
In addition to playing a definite role in regulating TIC phenotypes, the HIFs are 
also involved in breast cancer metastasis. The hypoxic response is clinically relevant to 
metastatic breast cancer since hypoxia stimulates extravasation, anoikis and colonization 
[25]. As described in Chapter 3, I showed that HIF-1α is a key driver of the formation of 
lung metastases originating from primary PyMT mammary tumors [127]. When lungs 
were harvested from mice at the same time as primary tumor removal, very few lung 
metastases were present. However, when lungs were harvested 8-weeks after primary 
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tumor removal, mice bearing HIF-1α KO tumors showed a 90% decrease in the 
formation of lung metastases. In contrast, when cells were injected directly into the tail 
vein, there was no difference in lung metastatic events between mice receiving HIF-1α 
WT or KO cells (unpublished data). These data provide some insight into which of the 
various steps of the metastatic cascade at which HIF-1α is necessary to promote 
metastasis. Only after we remove the primary tumor do we see a significant effect on 
lung metastases, suggesting that the HIF pathway is stimulated by surgery, perhaps 
because surgery activates the wound response. These observations are consistent with 
what has been reported in the clinic, that surgery can induce cancer metastasis [290]. 
However, the distinct lack of a difference in phenotype between WT and KO PyMT cells 
when studying metastasis using the tail vein model, suggests that HIF-1α plays a more 
pronounced role in the early stages of metastasis in this model.  
 
There are multiple steps early in the metastatic cascade where HIF could be 
required. For example, at what point do cells start entering the circulation? Are cells 
being shed from the primary tumor once it reaches a certain volume, and because HIF-1α 
KO tumors grow more slowly, they do not shed as many cells? A recent paper by the 
Semenza laboratory demonstrated that HIF-1-dependent activation of collagen prolyl 
hydroxylases promotes local invasion and intravasasion of breast cancer cells [291]. Are 
there HIF-dependent cytokines or other factors released when the primary tumor is 
removed that amplifies this process? Additionally how well do cells survive once they 
enter the blood stream?  
 
Since disseminated cells are no longer in the breast microenvironment, they may 
require some sort of survival signal to survive long enough to make it to distant organs. 
How does HIF mediate cell survival in this setting? Data from our collaboration with the 
Reginato lab suggests that HIF promotes survival in the blood stream as single cells by 
preventing anoikis [90]. Moreover, cells need to receive a signal from distant organs in 
order to seed them. This process, known as homing, may require different HIF signals at 
different organ sites. For example, Schito et al demonstrated that HIF-1 promotes 
lymphatic metastasis by directly activating platelet-derived growth factor B (PDGF-B), 
and PDGF-B is required for cells to attach to lung endothelium [292]. 
 
While we have not yet studied these exact mechanisms, the HIF-1α WT and KO 
PyMT tumor model may prove to be a useful tool in answering these questions using 
syngeneic, immunocompetent mice. Collecting blood from mice during the course of 
tumor development, from transplant initiation to tumor endpoint, could be used to 
analyze the occurrence and frequency of circulating tumor cells between HIF-1α WT and 
KO tumor bearing mice. Additionally, cytokine and growth factor arrays performed on 
these blood samples or from conditioned media from cultured HIF knockdown cells 
would determine if there are differentially excreted proteins necessary for cell intravasion 
and survival between WT and KO, similar to [293]. Investigation into these processes 
could ultimately lead to the identification of additional HIF pathways amenable for 
therapeutic target for patients with metastatic breast cancer. 
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A Novel HIF-Dependent Gene Involved in Breast Cancer Progression and 
Metastasis 
 
The microarray profiling screen we performed on HIF-1α WT and KO cells and 
the microarray screen on late stage WT and KO tumors took us one step closer in 
answering some of these questions and identified several differentially regulated HIF-1α 
genes and pathways involved in tumor development. Analysis of the array data revealed 
that HIF-1α regulates multiple genes involved in stem cell maintenance, as discussed 
above and in Chapter 5. Many other genes we initially identified have since been 
implicated as being HIF-1α dependent genes such as Angptl4 [72], Jarid1b and the 
Jumanji proteins [246], several pro-collagens [291] and Axl [245]. However, we also 
discovered several genes that still had not been previously explored as hypoxia-
dependent or in the context of breast cancer. One of these genes was Ckb.  
 
My studies into the HIF-1α dependent expression of Ckb (as discussed in Chapter 
6) have shown that while Ckb expression is not necessary for 2D cell growth, it is 
necessary for cell invasion through Matrigel. Loss of Ckb in vivo led to a reduced time to 
primary tumor development and significantly reduced the occurrence of lung metastases, 
both after primary tumor removal and in a tail vein model. Furthermore, mice injected 
with PyMT WT cells treated with the Ckb inhibitor, cyclocreatine (cCr), displayed a 
marked decrease in lung metastases versus control mice treated with saline only.  
 
Further investigation into Ckb revealed that not all breast cancer cell lines express 
Ckb at the protein level. Western blotting for CKB in MDA-MB-231 cells produced no 
detectable CKB signal, while MCF7 cells expressed moderate levels (data not shown). 
Investigation into CKB expression in the HCI tumor series revealed that CKB is highly 
expressed in all samples, although at various levels. Additionally, prior microarray profile 
screening performed on MCF7 HIF-1α and HIF-2α knockout cells has demonstrated a 
substantial decrease in CKB mRNA levels in HIF-1α knockout cells, but not in HIF-2α 
knockout cells [294], In the same dataset, CKB was also found to cluster with other 
known HIF-1α target genes like BNIP3L and LOX (personal observations).  
 
These data are exciting as Ckb is highly expressed in a variety of tumors and is 
HIF-1-dependent. HIF-driven, hypoxic areas are a hallmark of most solid tumors and 
their metastases. Despite advances in early detection and therapies for some types of 
breast cancers, patients with advanced, recurrent metastatic breast cancer (MBC) have < 
20% 5-year survival rates. In phase I, clinical trials, cCr therapy did not demonstrate any 
severe toxicity and, therefore, may not dose-limiting. Additionally, cCr has previously 
been shown to prevent pathological bone loss [295]. Therefore, in addition to its 
chemotherapeutic power, cCr could also be used to ameliorate bone loss due to osteolytic 
lesions. However, no trials testing efficacy of cCr therapy have been performed in breast 
cancer patients. Given that cCr is relatively inexpensive as compared to other mainstream 
chemotherapies, these data provide evidence for the hypothesis that targeting HIF and 
HIF-dependent genes like CKB could be beneficial in the development of new anticancer 
therapeutics, especially for those with metastatic breast cancer. 
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The Differing Roles of the HIFs in Breast Cancer 
 
HIF-1α is important for many aspects of tumor initiation, progression and 
metastasis. As discussed briefly in Chapter 4 and in further detail in Chapter 7, we have 
shown that HIF-2α plays an important role in breast cancer in addition to HIF-1α. We 
found that CD49f, which is involved in both tumor initiation and metastasis, is regulated 
by both HIF-1 and HIF-2. Upon the loss of HIF-1α in MDA-MB-231 cells, HIF-2α is 
able to compensate for loss of HIF-1α and will induce transcription of CD49f. This could 
be explained by our observation that in the TNBC 231 cell line, HIF-2α protein levels 
increase in HIF-1α knockdown cells. However, we did not observe this effect in our 
luminal-like, Neu/HER2+ PyMT cell line, which express relatively low levels of HIF-2α 
versus HIF-1α in contrast to MDA-MB-231 cells (data not shown). These results suggest 
that the roles of HIF-1α and HIF-2α may be breast cancer subtype dependent. This 
hypothesis is further supported by our findings that in both the TNBC HCI-2 tumor 
xenograft model (Figure 7-7) and the TNBC MDA-MB-231 cell line (Figure 7-9), 
knockdown of HIF-1α leads to an increase in tumor growth and metastases as compared 
to HIF-1α WT tumors. These data are again in contrast to our findings in the luminal-like 
PyMT model where knockout of HIF-1α led to decreased tumor growth and metastasis, 
without a compensatory increase in HIF-2α.  
 
Further investigation into the differing roles of the HIFs in different subtypes of 
breast cancer could lead to a better understanding of how these tumors would respond to 
certain therapies, and help to develop more targeted therapies for patients with a 
particular subtype of breast cancer. I predict that use of the HCI model will be most 
useful in delineating these roles since this system most accurately models human breast 
cancer and metastasis. Although we have utilized the TNBC HCI-2 xenograft tumors to 
knockdown HIF-1α, we have not yet studied the effects of HIF-2α knockdown in these 
tumors. It is unknown if loss of HIF-2α would give the same phenotype as we observed 
in the TNBC MDA-MB-231 cell line, or if these primary patient samples would behave 
differently. Furthermore, as HCI-2 and the other TNBC HCI tumors are derived from 
different patients, it is possible that while they are the same subtype, they themselves may 
contain intrinsic differences they may result in different HIF-1α and HIF-2α knockdown 
phenotypes.  
 
Additionally, the luminal HCI tumors still require evaluation of the phenotypes 
resulting from loss of the HIFs. However, we have encountered technical difficulties in 
establishing stem culture and lentiviral transduction conditions in these tumors. One of 
the main caveats is the slow growth these tumors exhibit in vivo. It can take many 
months before tumors are large enough to be harvested and digested. Our first attempts at 
digesting the luminal tumors into single cells resulted in a very low cell yield and after 
only 2 days in stem cell conditions, most cells had died. Furthermore, the nature of some 
of these tumors makes it very difficult to extract single cells, as most of the single cells 
from particular lines, such as HCI-11, are trapped in a mucus-like substance after 
enzymatic digestion. We have take steps to circumvent these problems, such as having 
multiple tumor bearing mice in our animal colony at all times and adding estradiol to the 
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digestion and stem cell medias, since these tumors are highly dependent upon estrogen. 
In addition, forcing cells out of the mucus substance through a filter has aided in 
increasing the final cell yield. Yet, we are still in the process of establishing technical 
parameters to generate HIF-1α or HIF-2α knockdown luminal tumors.  
 
One additional caveat of all of our experimental approaches is the repeated use of 
gene knockdown for the HIFα subunits, when what is actually observed in patients is 
gene overexpression. Therefore, approaches that overexpress the HIFα subunits in human 
breast cancer cell lines or the HCI xenografts could provide additional insight into the 
roles of HIF-1α and HIF-2α in the different subtypes of breast cancer. Our lab has 
obtained pBabe vectors for both HIF-1α and HIF-2α overexpression (OE) in which the 
proline residues hydroxylated by PHD enzymes are mutated to alanine residues [296]. 
These mutations disable the PHDs from being able to target the HIFα subunits for 
degradation, therefore rendering the HIFs stabilized and constitutively active. We have 
successfully transduced the HIF-2α OE lentiviral vector into MDA-MB-231 cells, and 
are working on transducing them with the HIF-1α OE vector. The next step would then 
be to test tumorigenesis and metastatic phenotypes in all of the MDA-MB-231 HIF 
genotype cells. Once all of these tumor lines are established, we would have invaluable 
tools to fully define the differing roles the HIFs play in primary patient breast tumors. 
Moreover, since the HCI tumors replicate the same patterns of metastasis in the mouse as 
the patient, we could also discern distinct roles for the HIFs in the metastatic process of 
these tumors, and if there is a correlation between HIFα expression and subtype in terms 
of metastatic potential.  
 
 
A Role for the HIFs in Stromal Cells in Supporting Breast Cancer Progression and 
Metastasis 
 
In addition to the roles HIF plays in tumor cells, HIF-1 is also required for 
mobilization of mesenchymal stem cells (MSCs) into peripheral blood [269]. MSCs 
produce pro-inflammatory cytokines in response to hypoxia [297], which may potentiate 
breast tumor cell TIC activity. One mechanism is that MSCs produce IL-6, which 
activates STAT3 in the breast tumor cell, stimulating breast TIC activity and the 
production of additional IL-6 in a feed forward loop [297]. A direct or necessary effect of 
the HIF transcription factors in coordinating these pathways in breast cancer in either cell 
type (tumor or MSC) has not been investigated. It is possible that HIF-1 and/or HIF-2 
expression is required in both the tumor cell and in host MSCs for maximal induction of 
tumor-initiation, angiogenesis and metastasis. 
 
To determine if hMSCs co-transplanted with tumor cells promotes tumor 
initiation through HIF-dependent mechanisms, via an IL-6/STA3 loop, or via stimulation 
of tumor angiogenesis, or both, utilization of the HCI model in which the HIFs are 
knocked down would provide an excellent tool. MSCs WT or KD for the HIFs co-
injected into the mammary fat pads in combination with HCI tumors WT or KD for the 
HIFs, would help to determine if HIFα expression is critical in the tumor cell, hMSCs 
host cells, or both cell types. These experiments would not only give insight into hMSC-
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dependent effects on the effect of HIFα deletion on cytokine production, but also if there 
is an enrichment of TICs in the presence of hMSC and if there is an increase in metastasis 
potential. Given our findings on the importance of HIF in breast cancer cells, we would 
expect to find that HIF-1 and/or HIF-2 is also required in hMSCs to promote tumor 
growth through regulation of both TIC activity and angiogenesis, suggesting more than a 
tumor cell-intrinsic role in modeling the tumor microenvironment. In this case, strategies 
to inhibit HIF activity in combination with Stat3 inhibitors may represent a novel, 
targeted therapeutic approach to treat breast cancer by eradicating the population of 
breast cancer TICs that drive relapse and therapeutic resistance and/or by blocking 
positive feedback loops between tumor cells and stromal cells (MSCs). 
 
 
Summary of Major Findings 
 
1. Overexpression of HIF-1α upon VHL deletion is not sufficient to induce 
mammary tumorigenesis during normal mammary gland development. 
 
2. Ex-vivo deletion of Hif1a in mammary tumor epithelial cells in the MMTV-
PyMT model of breast cancer results in delayed primary tumor growth and 
decreased lung metastases originating from the mammary fat pad. 
 
3. HIF-1α regulates breast cancer TIC activity, likely in part through regulation of 
the Notch pathway. 
 
4. HIF-1α directly regulates transcription of the breast cancer stem cell marker 
ITGA6/CD49f, which promotes tumor initiation and metastasis. 
 
5. ITGA6 is an independent prognostic factor for breast cancer patient survival. 
 
6. There are several HIF-1α regulated genes in breast cancer that regulate processes 
such as stem cell maintenance, angiogenesis, cell invasion and metastasis that 
may be useful as therapeutic targets in the future.  
 
7. Ckb, a HIF-1α dependent gene, promotes primary tumor growth, cell invasion 
and metastasis to the lung. Treatment of cells expressing Ckb with cyclocreatine 
inhibits the formation of lung metastases. CCr may be useful therapy for patients 
with MBC. 
 
8. CKB mRNA is an independent prognostic factor for breast cancer patient 
survival. 
 
9. Expanding analysis of HIF-dependent genes in breast cancer to human models, 
including the HCI “living tissue” bank and conventional breast cancer cell lines, 
revealed differing roles for the HIFα subunits in breast cancer development and 
progression. Whether HIF-1α or HIF-2α promotes or attenuates tumorigenesis 
and metastasis in human breast cancer may depend on the molecular subtype 
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classification.  
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CHAPTER 9.    REMAINING QUESTIONS AND FUTURE EXPERIMENTS 
 
 
In Chapters 1-8 I described the role that the HIFs play in breast cancer initiation, 
progression and metastasis. While I have produced valuable insights to further delineate 
the role of HIF-regulated genes in MBC, several questions remain to be answered in the 
models I have created and characterized. In answering the questions posited below, we 
will develop a more comprehensive understanding of the exact function of HIF-regulated 
genes in breast cancer progression and metastasis.  
 
 
Is CD49f Alone a Driver of Tumor Progression and Metastasis, or Does it Require 
the Presence of CD24? 
 
 Dr. Bryan Welm has observed in the PyMT model that only CD24hi cells retain 
TIC activity (personal communication). Therefore it is possible that the absence of CD24 
in our experiment (CD24low paired with CD49flow) may be confounding the results that 
CD49f enriches for TICs. In order to address this issue, CD24hi PyMT cells would be 
used as the parent population to enrich only for the CD49f high or low cell 
subpopulations and the sorted cells used to repeat the limiting dilution transplantation 
assay (as presented in Chapter 4). Given my data using CD49f sorted MDA-MB-231 
cells in a tail vein assay, in which I only enriched for CD49f, I would expect to observe a 
similar phenotype in the PyMT cells enriched only for CD49f, including more metastatic 
burden in a tail vein assay and enriched TIC potential in CD49fhigh cells by the limiting 
dilution transplantation assay.  
 
 
Can Re-Expression of Ckb in PyMT HIF-1α  KO or shc61 KD Cells Rescue the 
Tumor and Metastasis Phenotypes? 
 
 PyMT HIF-1α KO cells, which express low levels of Ckb (Chapter 6), exhibit 
decreased mammary tumor growth and lung metastasis (Chapter 2). Therefore, ectopic 
expression of Ckb in KO cells or re-expression of Ckb in shc61 knockdown cells may 
increase tumor growth and promote metastasis to levels observed in HIF-1α WT cells, 
which express high levels of Ckb. To address this question, a lentiviral expression vector 
expressing the complete coding sequence of murine Ckb with a N-terminal Flag tag 
(FLAG-Ckb) will be introduced in HIF-1α KO cells or shc61 KD cells. These cells will 
then be evaluated for the expression of the Flag protein to ensure induced expression of 
Ckb over residual endogenous Ckb expression. Cells will then be used in a primary tumor 
growth experiment with HIF-1α WT and constitutive HIF-α KO cells. It is expected that 
the HIF-1α KO + FLAG-Ckb tumors will grow at similar rates as the HIF-1α WT 
tumors, providing additional evidence that HIF-1-dependent Ckb is a key driver of 
tumorigenesis. 
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Is the Ckb shRNA Targeting Sequence (c61) Specific to Ckb, or Are There Off-
Target Effects? 
 
 Since off-target effects can be observed when using shRNA mediated knockdown 
technology, additional controls may be required during peer review. Since most of the 
data in Chapter 6 was generated using shRNA knockdown, an additional control to 
support my findings would be to utilize an shRNA-resistant Ckb cDNA. In this 
experiment, translationally silent substitutions have been made in four nucleotides within 
the c61 shRNA targeting sequence in Ckb, therefore inhibiting binding of the c61 
shRNA. This c61-shRNA-resistant Ckb cDNA will be ectopically expressed in PyMT 
HIF-1α KO cells, followed by transduction with the c61 shRNA. If the shRNA targeting 
sequence is specific, then I would expect there to be no knockdown in the cells that 
ectopically express the c61-resistant sequence.  In addition, if these cells do not 
efficiently generate primary tumors or metastases by tail vein assay, then this would 
strongly suggest that the c61 shRNA targets other genes besides Ckb that are responsible 
for the c61 shRNA phenotypes observed using WT cells that express c61 shRNA.  
 
 
Can Treating Primary Tumors with Cyclocreatine Inhibit Primary Tumor Growth 
as well as Lung Metastases? 
 
 I demonstrated in Chapter 6 that as an alternative to Ckb gene knockdown, 
treating cells expressing Ckb with the chemical inhibitor cyclocreatine also results in a 
significant decrease in lung metastases. Therefore, I hypothesize that treating mice with 
primary tumors with cyclocreatine would also result in a decrease in mammary tumor 
growth and potentially inhibit lung metastasis from the primary tumor site. 
Complementary, cyclocreatine could be tested using the HCI xenograft model and 
conventional metastatic breast cancer cell lines for potential primary tumor and 
metastasis anticancer activity. To address this question, I have xenografted recipient NSG 
mice with tumor fragments from the HCI-10 Luc2 model. Once tumors are palpable, 
mice will be treated daily with either saline (n=10) or 1g/kg cCr by i.p. injection (n=15), 
and bioimaged twice a week to monitor tumor growth and AxLN metastases. 
 
 
Is CKB a Direct HIF Target Gene? 
 
 Since no conclusive results could be obtained from initial ChIP experiments using 
the PyMT MTECs and the Santa Cruz ChIP grade antibody, experiments will be repeated 
using the PyMT MTECs immunoprecipitated with the Abcam antibody, which may have 
higher affinity for mouse HIF-1α. Additionally, MCF7 are currently being analyzed for 
HIF-1α binding at two independent HRE sites to further support our findings.  
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Are There Additional Understudied Genes Revealed by Array Profiling That Could 
Provide Additional Targets for Successful Breast Cancer Therapy?  
 
 The identification of Ckb using the microarray data as a novel HIF-dependent 
gene that promotes MBC phenotypes, has led to an exciting potentially clinically useful 
strategy. There are several other genes derived from the analysis of the arrays that have 
not yet been functionally characterized for a role in breast tumorigenesis, such as Emb, 
Elf5 and Mia1, that could also lead to additional insights into the biology of HIF-
dependent tumorigenesis and metastasis. Emb (Embigin) is a member of the 
immunoglobulin superfamily that functions as a cell adhesion molecule [298]. As many 
cell adhesion molecules are disregulated in cancer, further investigation into this gene 
could provide addition insight into cancer cell motility. Elf5 is part of the epithelium-
specific subclass of the Ets transcription factor family, and is involved in regulating many 
epithelial-specific genes [299]. In particular Elf5 is enriched in normal mammary gland 
luminal progenitor cells [300], and also regulates the EMT [301]. Mia1 has previously 
been implicated in regulating invasion and metastasis of malignant melanoma cells [302] 
and also functions as an attachment protein in the extracellular matrix [303]. Further 
investigation into these genes in breast cancer may lead to the discovery of a novel target 
that promotes metastasis. 
 
 
Are There Additional Cells Lines to Use as Models That Would Replicate My 
Results Derived from MDA-MB-231 Cells? 
 
 The conflicting data generated from our PyMT model and the MDA-MD-231 
model with respect to the function of HIF-1 versus HIF-2, suggests that additional cell 
line models must be evaluated for HIFα-dependent activities. Our lab is currently in the 
process of profiling an extensive panel of different breast cancer cell lines available from 
ATCC that are representative of the major molecular intrinsic subtypes by western 
blotting in order to determine if any lines express similar levels of the HIFα proteins as 
MDA-MB-231 cells. If we identify another line with similar expression levels of HIF-1α 
and HIF-2α as the MDA-MB-231 cells, we will determine if the same tumor phenotypes 
are observed in vitro and in vivo following HIF1A and HIF2A knockdown. This approach 
will also be useful to explore the role of HIF-1 versus HIF-2 HER2-enriched tumors, as 
we currently maintain only a single PDX model (HCI-7).  
 
 
Which Additional Studies Can Be Performed to Better Define the Potentially 
Opposing Roles of the HIFα  Proteins in TNBC? 
 
I have generated data showing that HIF-1 and HIF-2 may have different roles in 
TNBCs. Using the four HIFα deletion genotypes created in the MDA-MB-231 cell line, 
two important experiments could be performed. The first would be to perform ChIP-Seq 
on the cells to identify HIF-1 versus HIF-2 specific targets, and to determine if HIF-1 
targets increase with deletion of HIF2A and vice versa. The second would be to perform 
RNA-Seq to profile RNAs, including mRNAs, lncRNAs, microRNAs, that are 
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differentially regulated between genotypes at both normoxia and hypoxia. Data obtained 
from these experiments could help delineate specific pathways and genes that are up and 
down regulated with HIF-1α and HIF-2α expression or deletion.  
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APPENDIX. BREAST TUMOR KINASE (BRK/PTK6) IS A MEDIATOR 
OF HYPOXIA/HIF-ASSOCIATED BREAST CANCER PROGRESSION.§ 
 
 
Abstract 
 
Triple negative (basal type) breast cancers (TNBC) are aggressive and difficult to 
treat relative to luminal type breast cancers. These tumors frequently express abundant 
Met receptors and are enriched for transcriptional targets regulated by hypoxia inducible 
factor 1-alpha (HIF-1α), a principal mediator of cell stress that independently predicts 
cancer relapse and increased risk of metastasis. We recently showed that breast tumor 
kinase (Brk/PTK6) is a critical downstream effector of Met signaling and required for 
HGF-induced cell migration. Herein, we examined the regulation of Brk by HIFs in 
TNBC cell lines and mouse models. Brk mRNA and protein levels are strongly 
upregulated by hypoxia, low glucose and reactive oxygen species in vitro. HIF 
knockdown demonstrated that BRK expression is dependent upon both HIF-1α and HIF-
2α, and chromatin-immunoprecipitation (ChIP) assays revealed that Brk is a direct 
transcriptional target of HIF-1α/2α. Notably, knockdown of HIF-1α/2α in MDA-MB-
231 cells significantly diminished xenograft growth; Brk re-expression reversed this 
effect. Finally, we crossed WAP-Brk (FVB) transgenic mice into the METmut knock-in 
(FVB) model. Expression of the Brk transgene augmented METmut-induced mammary 
tumor formation and metastasis. Surprisingly, mouse mammary tumors that arose in 
either METmut or WAP-Brk X METmut mice expressed abundant Sik, the mouse homolog 
of Brk, which conferred markedly increased tumor formation and decreased survival. 
These results identify HIF-1α/2α as novel regulators of Brk expression and suggest that 
Brk is a key mediator of hypoxia-induced breast cancer progression. Targeting Brk 
expression or activity may provide an effective means to block the progression of 
aggressive breast cancers. 
 
Introduction 
 
Breast tumor kinase (Brk), also known as PTK6, is a soluble protein tyrosine 
kinase typically expressed in differentiated epithelial cells of the skin and gastrointestinal 
tract [304]. While Brk is not found in normal mammary tissue, it is aberrantly expressed 
in up to 86% of breast tumors, with the highest levels in advanced tumors, suggesting a 
tumor-specific role of this kinase in breast cancer [305-307]. Other cancers, such as 
melanoma, lymphoma, ovarian, prostate and colon cancer also exhibit overexpressed 
and/or mislocalized Brk (reviewed in [308]). 
 
Brk contains N-terminal src homology 2 (SH2), src homology 3 (SH3) and C-
terminal kinase domains. It is distantly related to Src family kinases as they share 56% 
                                                
 
§ Adapted with permission. Anderson, T.M., Peacock, D.L., et al (2013). “Breast Tumor 
Kinase (Brk/PTK6) Is a Mediator of Hypoxia-Associated Breast Cancer Progression.” 
Cancer Res. 2013 Aug 8. [Epub ahead of print]. 
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homology within the kinase domain [309]. One notable difference between Brk and Src 
family kinases is that Brk lacks a myristoylation site, and is present in both the cytoplasm 
and the nucleus. Many Brk substrates, both cytoplasmic and nuclear, have important 
functions in cancer, including signal transducer and activator of transcription (STAT) 
molecules, Akt, and Sam68 (reviewed in [308]). Brk is activated downstream of ErbB 
family receptors and Met receptors and is required for EGF-, heregulin-, and hepatocyte 
growth factor (HGF)-enhanced cell migration [310-312]. Although Brk and ErbB2 have 
distinct gene loci, they are coamplified in some breast cancers [313], potentially leading 
to enhanced MAPK signaling and cell proliferation. Brk expression in ErbB2-induced 
tumors correlates with shorter latency and resistance to the ErbB2 inhibitor, Lapatinib 
[313]. Moreover, elevation of Brk expression in breast cancer cells confers resistance to 
the EGFR-blocking antibody, cetuximab, by inhibiting EGFR degradation [314]. Brk also 
mediates anchorage-independent growth in breast cancer cells through modulation of the 
IGF receptor [315]. Indeed, Brk upregulation appears to be an early event associated with 
growth factor-dependent tumor progression [311, 313-315]. While significant 
advancements have been made toward understanding the mechanisms of Brk signaling 
[308], little is known about the regulation of Brk expression in breast cancers.  
 
Hypoxia-inducible factors (HIFs) are the principal mediators of transcriptional 
responses to cellular hypoxia [316]. Hypoxia-inducible factors (HIF-1 and HIF-2) are 
heterodimers of two oxygen-regulated subunits, HIF-1α or HIF-2α and HIF-1β. HIF-1β 
is constitutively expressed, whereas HIFα subunits are continually degraded through the 
ubiquitin pathway under normal oxygen tensions (normoxia). In contrast, in response to 
hypoxia, HIFα subunits are stabilized and translocate to the nucleus, where they can 
heterodimerize with HIF-1β. HIF transcription factors recognize a core hypoxia-response 
element (HRE) consensus motif of 5’-RCGTG-3’ within enhancer regions of target genes 
[317, 318], and act as master regulators of many cellular functions relevant to cancer 
progression, including angiogenesis, glucose metabolism, and tumor growth and 
metastasis [316]. Indeed, HIF-1α is overexpressed in many human cancers (reviewed in 
[25]), and over-expression in breast tumors predicts relapse and indicates a higher risk of 
metastasis [85]. HIF-1α levels are significantly higher in invasive and poorly 
differentiated breast cancers as compared to well-differentiated cancers [233, 319, 320]. 
Specifically, increased levels of HIF-1α mRNA and the core hypoxic transcriptional 
response are associated with hormone receptor negative breast cancers [92, 320]. 
?
Clinically, breast tumors are categorized based on immunohistochemistry for 
estrogen receptor (ER), progesterone receptor (PR) and HER2 and have also been 
categorized into molecular subtypes based on gene expression profiling [321]. The least 
aggressive luminal subtype tumors are either ER+/PR+ (luminal A) or ER+/PRlow/null  
(luminal B), while tumors lacking ER, PR and HER2, termed triple negative breast 
cancers (TNBC), are typically more aggressive. TNBCs largely fall into the basal and 
claudin-low molecular subtypes and have a worse prognosis relative to luminal breast 
cancers (reviewed in [322]) in part, because these patients are not candidates for targeted 
therapies that block ER and HER2. TNBC patients are treated with systemic 
chemotherapies that include cytoskeletal- or DNA-damaging agents, which can be 
effective, but fail to specifically target the unknown and presumably diverse molecular 
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drivers of cancer metastasis. Therefore, new molecular targets for TNBC patients are 
desperately needed. As Brk is aberrantly expressed in both luminal and TNBC subtypes, 
but is not found in the normal mammary tissue, it is an attractive candidate for specific 
targeting of invasive breast cancer cells. 
 
Herein, we sought to examine the mechanism of Brk induction in breast cancer, 
with a specific focus on TNBC/basal-type breast cancers, which abundantly express both 
Met and HIF target genes.  We hypothesized that Brk, a known mediator of Met signaling 
and stress activated kinase pathways, is directly upregulated in response to cellular 
hypoxia, thereby promoting cancer cell survival, cell motility, and metastasis. 
 
 
Materials and Methods 
 
 
Generation of Modified MDA-MB-231 Cells and Cell Culture  
 
MDA-MB-231 cell lines were cultured in Dulbecco’s modified Eagle’s medium 
(HyClone Thermo Scientific) without pyruvate supplemented with 10% FBS (Gibco, 
Invitrogen) and 1% pen/strep. Stable knockdown of HIF1A, HIF2A or both genes in 
MDA-MB-231 cells was generated by transduction with pLKO.1-based shRNA-
expressing lentiviruses as previously described for MCF-7 cells (see Supplemental 
Methods) [233]. MDA-MB-231 shControl, shHIF1A, and shHIF2A cells were 
maintained in growth medium supplemented with 4µg/mL puromycin, and MDA-MB-
231 shHIF1A/2A cells maintained in growth medium supplemented with 8µg/mL 
puromycin, and 2mg/mL hygromycin. MDA-MB-231 cells were authenticated 4/11/13 
by SoftGenetics LLC or DDC Medical and results compared to the ATCC STR database. 
Cells were maintained in 5% CO2 at 21% O2 (normoxia, ambient air) or at 1-2% O2 
(hypoxia).  
 
 
Cell Proliferation Assay 
 
Cell proliferation was measured via the MTT (3-[4,5-dimethylthiazol-2-yl]- 2,5-
diphenyltetrazolium bromide) assay as previously described [323]. MDA-MB-231 cells 
were plated at 2.5 x 103 cells per well in 24-well plates and cultured in hypoxia (1% O2) 
for the indicated amounts of time.  
 
 
Protein Extraction 
 
Flash frozen, patient-derived xenograft tissue fragments maintained by the HCI 
breast tumor bank resource [132] were obtained directly from Dr. Alana L. Welm. A 
summary of the features of the HCI tumors used in this study is included in 
Supplementary Table 1. High-salt enriched whole cell lysates (HS-WCE) were prepared 
from HCI tumors or MDA-MB-231 tumors as previously described [127]. Whole cell 
lysates from cultured cells were isolated as described in [324]. Additional human tumor 
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specimens were obtained from the University of Minnesota Tissue Procurement Facility’s 
Biological Materials Procurement Network (BioNet) and histologically subtyped and 
processed for protein expression as previously reported [323].  
 
 
Immunoblotting 
 
Proteins were resolved on 7.5% SDS-PAGE or 3-8% Tris-Acetate gels and 
transferred to PVDF membrane. Membranes were probed with primary antibodies: HIF-
1α (Novus Biologicals, NB100-134 or NB-100-479), HIF-2α (Novus Biologicals, 
NB100-122), p38 (Cell Signaling, 9212), Vinculin (Sigma, V9131), Actin (Sigma, 
A4700), Brk (Santa Cruz, sc-1188), Sik (Santa Cruz, sc-916) or β-Tubulin (AbCam, 
6046). Secondary horseradish peroxidase-conjugated antibodies (Bio-Rad or Santa Cruz) 
were visualized with SuperSignal West Pico or Millipore ECL substrate. Representative 
images of triplicate experiments are shown in each figure. Densitometry was performed 
via ImageJ analysis and normalized to the loading control. 
 
 
qPCR  
 
qPCR assays were performed as previously described [324]. Briefly, cells were 
plated at 2.5 x 105 cells/well in 6 well plates and cultured at normoxia for 32hrs, then 
were transferred to hypoxia (1% O2) for 24 hrs or left at normoxia. Target gene 
expression was normalized to the expression of internal control, TATA-binding protein 
(TBP).  
 
 
ChIP Assays 
 
Chromatin Immunoprecipitation (ChIP) assays were performed as previously 
described [324]. Briefly, MDA-MB-231 cells were plated at a density of 12 x 106 cells 
per 15cm cell culture dish and cultured at normoxia for 32 hrs, then were left at normoxia 
or transferred to 1% O2 for 24 hrs. Lysates were immunoprecipitated (IP) overnight (18 
hrs) with 2 µg of HIF-1α antibody (Novus Biologicals, NB100-134), HIF-2α (Novus 
Biologicals, NB100-122), and RNA polymerase II (Covance, 8WG16) or an equal 
amount of rabbit IgG.  
 
 
Transgenic Mice and Generation of Tumors in NOD/scid/gamma Recipients 
 
MMTV-PyMT+ HIF-1 wild type (WT) and knockout (KO) mammary tumors 
were generated as described in [127]. WAP-Brk transgenic mice [307] and Met mutant 
knock-in mice were generated as described [325]. Mice were monitored daily for tumor 
development and euthanized when tumor volume approached 1 cm3. Cultured MDA-MB-
231 cells were dissociated into single cells, counted and diluted into 1:1 (vol:vol) with 
growth-factor reduced Matrigel-Hank’s balanced salt solution (HBSS) at a density of 
250,000 cells per 10 µl. Cells were kept on ice until injection into the right inguinal 
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mammary fat pad of 3-6-week old female NOD/scid/ILR2γ (NSG) recipients using a 26-
gauge PT2 needle mounted on a Hamilton syringe. Recipients were palpated up to two 
times per week, and tumor volumes were calculated by caliper measurement as described 
previously [126]. At experimental endpoint, tumor wet weight was also measured. 
 
 
Immunostaining 
 
Immunohistochemistry of HIF-1 WT and KO mammary formalin-fixed paraffin-
embedded tumor sections was performed as previously described [307]. Briefly, tissues 
were incubated for 1 hour at room temperature with serum-free protein block (Dako 
X0909).  Blocked sections were incubated overnight at 4oC with primary anti-Sik 
antibody diluted 1:1000 in Dako Antibody Diluent (S0809) and developed by DAB 
peroxidase staining. For immunofluorescence staining, FFPE sections (5-7 um) were 
antigen retrieved using 1x citrate buffer, stained with Sik primary antibody (sc - 916) at 
1:50 dilution overnight at room temperature, followed by Alexa Flour-594 (Invitrogen) 
secondary and mounted with VECTASHIELD (Vector Laboratories, Inc. Burlingame, 
CA). 
 
 
Kaplan-Meier Curves 
 
Survival analysis was done using the van’t Veer microarray dataset [236]. 
Normalized Brk expression values were divided into four quartiles: 75 tumors with high 
Brk expression (>0.074) and 76 tumors with lowest Brk (<-0.036) expression. The y-axis 
(probability) is defined as the frequency of survival. Data were analyzed using the 
survival package within WinSTAT® for Excel.  
 
 
Statistical Analysis 
 
Unless noted elsewhere, results are presented as means +/- SEM. Statistical 
significance for qPCR assays was determined using unpaired Student’s t-tests.  Tumor 
xenograft growth significance over time was determined via two-way ANOVA with 
Bonferroni correction. Tumor latency was analyzed using Kaplan-Meier methodology 
and curves compared using the Mantel-Cox Log-rank test. Brk mRNA levels were 
assessed using the Cancer Genome Atlas (TCGA) data.  
 
 
Results 
 
 
Brk Is Upregulated in Response to Hypoxia and Cellular Stress 
 
Numerous studies have demonstrated Brk overexpression in breast and other 
cancers relative to a limited set of normal control tissues [308]. Data from the Cancer 
Genome Atlas (TCGA) were analyzed via Oncomine to compare the levels of Brk mRNA 
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expression in a large number of high quality samples representing both invasive ductal 
and invasive lobular breast cancer versus normal breast tissues. Interestingly, independent 
of tumor subtype, Brk expression was significantly increased in both invasive ductal 
carcinoma (p=1.50E-35) and invasive lobular carcinoma (p=3.35E-10), relative to normal  
breast tissue samples (Figure A-1A). To investigate Brk expression levels specifically in 
basal/TNBCs, we collected a panel of TNBC cell lines and tumors. Human tumor 
samples were histologically scored and processed as previously described [323]. We 
observed a range of Brk expression by Western blot in all TNBC cell lines and tumor 
samples (Figure A-1B). Additionally, Brk expression was assayed in a subset of 
previously described [132] xenografted tumors maintained in the Huntsman Cancer 
Institute (HCI) breast tumor tissue bank. All HCI TNBC and luminal B (HER2+) subtype 
xenografts exhibited high levels of Brk protein expression relative to luminal B (Her2-) 
tumors (Figure A-1C). In addition, both HIF-1α and HIF-2α proteins were highly 
enriched in the TNBC samples relative to HER2 or steroid hormone receptor positive 
tumors. These data confirm that Brk, HIF-1α and HIF-2α are co-expressed in human 
breast carcinomas, particularly in TNBCs. 
 
Multiple mechanisms of Brk upregulation exist, including gene amplification 
[313] and Brk-induced phosphorylation and degradation of c-Cbl [326], an E3-ubiquitin 
ligase responsible for downregulation of numerous oncoproteins, including ErbB family 
members [327]. We hypothesized that Brk expression may also be induced upon cellular 
stress. To address this question, we exposed TNBC cells to various stresses, including 
hypoxia, and examined Brk protein and mRNA expression. MDA-MB-231 breast cancer 
cells were subjected to mild hypoxic conditions (2% O2), for increasing periods of time 
and harvested for Western blot analysis. HIF-1α protein was upregulated following 
exposure of MDA-MB-231 cells to low oxygen for 4-30 hours relative to cells incubated 
in normoxic conditions (Figure A-2A). HIF-1α protein levels peaked at approximately 6 
hours of hypoxia, followed by decreased but sustained expression out to 30 hours. 
Interestingly, Brk levels increased at 6 hours of hypoxia compared to normoxic controls, 
coinciding with the peak of HIF-1α protein expression. Elevated Brk protein levels were 
maintained out to 30 hours. The same experiment was performed in non-tumorigenic 
immortalized MCF10A cells, previously reported to be Brk-null [328] (Figure A-2B), as 
well as ER+/PR+ MCF7 and T47D breast cancer cells (data not shown). Following 24 
hours of hypoxia exposure, Brk levels were consistently increased in all cell lines. These 
data demonstrate that hypoxic conditions induce Brk expression in a variety of breast cell 
lines, and that HIF-1α protein levels peak slightly before the rise in Brk protein levels.  
 
To assess the transcriptional regulation of Brk during hypoxia, we cultured 
Hs578T and MDA-MB-231 cells for 24 hours in 1% O2 and examined Brk mRNA levels 
by quantitative real-time PCR (qPCR). Brk transcript levels increased significantly at 
hypoxia compared to normoxia, in both TNBC cell lines (Figure A-2C). Levels of 
VEGF, a known HIF-1 target gene, also significantly increased in both cells lines. 
Interestingly, transcript levels of ERBB2 and Met receptor (MET), growth factor 
receptors known to activate Brk signaling, were also increased significantly by hypoxia 
in MDA-MB-231 cells. Similar results were observed in MCF7 breast cancer cells. These 
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Figure ?-1. Brk is upregulated in breast cancers and in human TNBC cell lines. 
A. Brk mRNA levels were compared using the Cancer Genome Atlas (TCGA) dataset via 
Oncomine, comparing normal breast tissue to invasive ductal carcinomas (IDC), and to 
invasive lobular carcinomas (ILC). B. Western blot analysis of Brk protein levels in 
TNBC cell lines the (MDA-MB-231, MDA-MB-435, DKAT, HCC1937, and HS587T) 
and in triple negative human tumor specimens obtained from the University of Minnesota 
BioNet with antibodies to Brk and p38 (loading control). C. Human breast cancer 
xenograft fragments derived from the HCI resource were obtained at generation 3-5. HS-
WCE (10 mg/lane) were subjected to Western blot analysis for Brk, HIF-1α, HIF-2α, and 
ß-tubulin (loading control). 
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Figure ?-2. Hypoxia and other cellular stresses induce Brk expression.  
A. MDA-MB-231 cells were cultured in normoxia or 2% O2 (hypoxia) for the indicated 
times and subjected to Western blot analysis for Brk or p38 (loading control). B. 
MCF10A cells were cultured in normoxia or 2% O2 (hypoxia) for 4 or 24 hours. Whole-
cell lysates were resolved on SDS-PAGE gels and probed with antibodies to Brk or 
vinculin (loading control).  C. Hs578T and MDA-MB-231 cells were cultured at 
normoxia or hypoxia for 24 hours and then mRNA levels were analyzed by qPCR after 
normalization to TBP expression. Asterisks (*) indicate statistical significance (p <0.05; 
an unpaired Student’s t test). D. MDA-MB-231 cells were treated with 0, 1, 10, 50 or 100 
μM H2O2. Lysates were resolved on SDS-PAGE gels and probed for antibodies specific 
for Brk, HIF-1α, and p38 (loading control). E. MDA-MB-231 cells were cultured in 
media with either 4.5g/L (DMEM-Hi) or 1.0 g/L (DMEM-Lo) glucose. Duplicate 
samples (independent lysates) were resolved by SDS-PAGE and probed with antibodies 
to Brk, HIF-1α and p38 (loading control). 
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data indicate that expression of Brk, a downstream effector of the Met and ERBB2 
signaling pathways, is upregulated by hypoxia. The above results suggest that Brk 
induction may be characteristic of more universal responses to cellular stresses that also 
input to HIF-1α [329]. We therefore assessed the levels of Brk expression in response to 
increasing concentrations of reactive oxygen species (ROS) by treatment with hydrogen 
peroxide (H2O2) and to glucose deprivation. When MDA-MB-231 cells were exposed to 
increasing levels of H2O2 (0-100 μM), Brk and HIF-1α protein levels were induced or 
stabilized, respectively, in a dose dependent manner (Figure A-2D). A similar response 
occurred when cells were exposed to media containing lowered glucose (1g/L) as 
compared to base DMEM-Hi media (4.5g/L) (Figure A-2E). These data indicate that cell 
stresses such as hypoxia, H2O2 exposure, and nutrient starvation are capable of stabilizing 
HIF-1α and inducing Brk mRNA and protein over similar time courses. Brk induction by 
multiple cell stress pathways suggests a mechanism for coordinate regulation of 
downstream signaling in response to HIF activation. 
 
 
Brk Is a Novel, Direct HIF Transcriptional Target Gene 
 
We hypothesized that hypoxia/HIF signaling is directly responsible for the 
upregulation of Brk mRNA and protein in response to hypoxic conditions. Upon 
examination of the Brk promoter, we identified multiple potential hypoxia response 
elements (HREs) within 20 kb of the transcriptional start site (TSS) (Figure A-3A). To 
examine HIF-α recruitment to the Brk promoter, we performed chromatin-
immunoprecipitation (ChIP) assays with MDA-MB-231 cells cultured at normoxia or 
hypoxia for 24 hours. We observed that HIF-1α and HIF-2α were robustly recruited to 
HRE 1 located 1.5 kb upstream of the Brk TSS at hypoxia compared to normoxia  
(Figure A-3B). As a functional correlate of transcriptional activity associated with this 
HRE, we assessed the recruitment of RNA polymerase II to this region (HRE 1) and 
observed robust recruitment of this enzyme following exposure to hypoxia  
(Figure A-3B). These data suggest that HIF-containing transcriptional complexes present 
at HRE 1 in hypoxia are active. Essentially identical results (i.e. hypoxia-regulated 
recruitment of HIF-1α, HIF-2α, and Pol II) were obtained for HREs 2-5. HIF-1α 
recruitment to the VEGF promoter (Figure A-3C) was included as a positive control 
[330]. The first intron in the globally methylated and transcriptionally inactive 
hemoglobin B (HBB) gene [331] served as a negative control (Figure A-3D). These data, 
strongly implicate HIFs in upregulation of Brk mRNA under conditions of cellular stress 
in MDA-MB-231 cells.  
 
We next sought to determine if HIF−1α was required for the induction of Brk in 
aggressive, metastatic mammary tumors. To this end, we first examined the expression of 
Sik, the mouse homologue of Brk, in end-stage HIF-1 wildtype (WT) or knockout (KO) 
mouse mammary tumors initiated by expression of the mouse mammary virus-driven 
polyoma middle T oncoprotein (MMTV-PyMT) transgene, as previously described [127]. 
Colorimetric immunohistochemistry staining for Sik revealed a substantial loss of Sik 
protein expression in HIF-1 KO mammary tumors relative to WT tumors (Figure A-4A). 
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Figure ?-3. Brk is a direct HIF target gene.  
A. Schematic representation of HREs in the proximal Brk promoter that were assessed 
for HIF-1α/2α recruitment. B. MDA-MB-231 cells were cultured at normoxia or hypoxia 
(1% O2) for 24 hours. Formaldehyde fixed lysates were subjected to ChIP with HIF-1α, 
HIF-2α or RNA pol II antibodies and qPCR was performed on the isolated DNA to 
determine HIF and pol II recruitment to HRE 1. As controls, ChIP for HIF-1 was 
performed for the VEGF promoter (C), or the negative control HBB intron (D). 
Representative examples from triplicate experiments are shown. 
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Figure ?-4. Sik protein in PyMT+ murine mammary tumors is dependent upon 
HIF-1α  expression.  
A. Immunohistochemistry of paraffin embedded sections from WT or HIF KO tumors 
stained for Sik or secondary antibody only (No 1-Ab) and developed with conventional 
DAB staining also revealed a dramatic decrease in Sik expression in HIF KO tumors.  B. 
Immunofluorescence images of HIF-1 WT or KO tumors derived from the MMTV-
PyMT transgenic model. Paraffin embedded tissue sections were probed for Sik (detected 
with AlexaFluor-594, red) and stained with DAPI (blue). A no primary antibody control 
was run and showed no detectable staining (data not shown). C. Protein lysate from four 
HIF WT or HIF KO tumors were resolved by SDS-PAGE and probed with antibodies for 
HIF-1α, Sik, and vinculin as a loading control. A light and dark exposure of the HIF-
1α blot are shown. Relative expression, via densitometry, is listed beneath. 
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These results were confirmed by immunofluorescence staining for Sik (red) and DAPI-
nuclear staining (blue) (Figure A-4B). Expression of Sik was localized in the tumor  
epithelium and stroma. A no primary-antibody control was included to demonstrate that 
all immunoreactivity was due to the primary Sik antibody (Figure A-4A); the specificity 
of Sik antisera was shown previously [332]. Additionally, four HIF-1 WT and four HIF-1 
KO PyMT tumors were assessed for Sik protein levels by Western blotting. We observed 
a marked reduction in Sik protein in HIF-1 KO tumors relative to HIF-1 WT tumors 
(Figure A-4C). Therefore, HIF-1α is required for robust expression of Sik in PyMT-
mouse mammary tumors. Despite dramatic reduction in HIF-1 KO PyMT-tumors, Sik 
protein was still weakly detected (Figure A-4). Notably, HIF-1α and HIF-2α have 
overlapping transcriptional targets [233, 333-335], although the specific role of HIF-2α 
in breast tumors has been less well investigated, particularly in TNBCs [233]. Therefore, 
we tested the dependence of Brk expression on HIFα molecules in human breast cancer 
cells cultured under hypoxic conditions. MDA-MB-231 cells expressing empty vector 
(shControl), HIF1A shRNA, HIF2A shRNA, or both HIF1A and HIF2A shRNAs (DKD) 
were cultured at normoxia or 1% O2 for 6 or 24 hours. As expected, HIF-1α protein was 
increased at 6 and 24 hours in shControl cells cultured at hypoxia. HIF-1α expression 
was reduced by more than 90% in hypoxic shHIF1A cells and undetectable in DKD cells 
(Figure A-5A). Similarly, HIF-2α protein increased in hypoxia in shControl cells, but 
was diminished in cells expressing shRNAs targeting either HIF2A alone or both HIF 
factors (DKD). Notably, we observed a substantial hypoxia-induced increase in HIF-2α 
protein expression in cells expressing shHIF1A relative to shControls. The up-regulation 
of HIF-2α in response to efficient HIF1A knockdown was previously shown in MCF-7 
cells [233]. Importantly, only double-knock down (DKD) cells simultaneously expressing 
both HIF1A and HIF2A shRNAs completely lacked both HIF molecules (Figure A-5A). 
Brk mRNA was significantly decreased in MDA-MB-231 cells expressing either 
shHIF1A or shHIF2A relative to shControl cells, but significantly induced by hypoxia 
relative to normoxia (Figure A-5B). However, when both HIF1Α and HIF2Α were 
simultaneously knocked down, we observed an almost complete ablation of Brk 
transcript expression. Likewise, Brk protein levels were also decreased substantially 
following knockdown of both HIF1Α and HIF2Α (Figure A-5B inset). Similar results 
were observed in MCF7 cells. These data suggest that when expression of either HIF-1α 
or HIF-2α is lost, the other HIFα subunit may compensate to induce Brk expression, 
consistent with the regulation of numerous other HIF-target genes, as previously shown 
in MCF-7 cells [233].  
 
 
Ectopic Brk Expression Enhances Growth of HIF1A/HIF2A Knockout Tumors in 
vivo 
 
Overexpression and enhanced activity of HIFα subunits is common in a variety of 
cancer types and has been shown to be a key mediator of tumor formation and 
progression [85, 95, 320]. Previous studies showed that tumors derived from MDA-MB-
231 cells that lack HIF-1α and HIF-2α displayed significantly decreased growth relative 
to wildtype controls [71, 292, 293]. When overexpressed in the normal mammary gland,  
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Figure ?-5. Brk mRNA and protein expression are ablated upon loss of both HIF-
1α  and HIF-2α .  
A. MDA-MB-231 cells expressing shControl, shHIF1Α, shHIF2Α, or DKD were cultured 
at normoxia or hypoxia (1% O2) for 6 or 24 hours. Lysates were analyzed by Western 
blotting with antibodies to HIF-1α or HIF-2α, or β-Tubulin (loading control). The 
asterisk indicates a cross-reactive band just above HIF-2α and the arrow indicates HIF-
2α.   B. MDA-MB-231 cells expressing shControl, shHIF1A, shHIF2A, or DKD were 
cultured at normoxia or hypoxia (1% O2) for 24 hours. Protein and mRNA were isolated 
and mRNA was analyzed by qPCR after normalization to TBP. Inset: Western blotting 
analysis for Brk and ERK1/2 (loading control). 
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Brk mediates delayed involution via activation of pro-survival signaling pathways and 
acts as a latent breast oncogene [307]. As Brk knockdown in breast cancer cells has been 
shown to inhibit proliferation and block cell migration in vitro [308] as well as 
decreasexenograft tumor size in vivo [336], we sought to determine if Brk overexpression 
could rescue decreased tumor growth caused by loss of HIF-1 and HIF-2 activity (i.e. a 
model where endogenous Brk is not HIF-induced). Thus, MDA-MB-231 cells expressing 
both shHIF1A and shHIF2A (DKD) cells were retrovirally infected with a pFB-neo-WT-
Brk overexpression construct. Western blot analysis confirmed that knockdown of 
HIF1Α  and HIF2Α was maintained in DKD cells, and the cells were thus unable to 
induce endogenous Brk. In contrast, DKD cells engineered to over-express wildtype 
BRK exhibited constitutive Brk expression, as expected. Consistent with previously 
published in vivo results [71, 292, 293], DKD cells grew significantly less than shControl 
cells via in vitro MTT assays. This growth defect was recovered (days 1-3) and then 
surpassed (day 5) upon re-expression of WT-Brk (Figure A-6A). These cells (shControl, 
DKD and DKD + Brk) were then used to establish orthotopic mammary tumors in NOD 
scid gamma female recipients (n=9 mice/cohort).  Xenografts were palpated and tumor 
growth was measured with digital calipers as previously described [126]. In agreement 
with previous reports, which utilized independent shRNA targeting sequences to HIF1A 
or HIF2A [71, 292, 293], knockdown of both HIF1A and HIF2A significantly decreased 
breast cancer cell growth in vivo relative to shControl cells at day 38; 780.6 ± 98.4 mm3 
vs. 558.0 ± 36.0 mm3, respectively (Figure A-6B-C). Surprisingly, DKD cells 
constitutively expressing exogenous Brk (DKD + Brk) exhibited robust in vivo xenograft 
growth that not only reversed the HIF DKD growth phenotype (p <0.05 at day 35 and 
p<0.001 at day 38; day 38 mean tumor volume 921.9 ± 88.5 mm3 vs. 558.0 ± 36.0 mm3, 
respectively), but the mean tumor volume of DKD + Brk xenografts exceeded that of 
shControl tumors at day 38 post-transplant (Figure A-6B, 921.9 ± 88.5 mm3 vs. 780.6 ± 
98.4 mm3, respectively; p<0.05). These data indicate that constitutive Brk expression is 
sufficient to recover the diminished growth phenotype of HIF DKD cells. In addition, 
comparison of mean ex vivo tumor mass confirmed that the shControl xenograft tumors 
were significantly larger than DKD tumors (Figure A-6C, p = 0.05). Similarly, 
comparison of tumor wet weight revealed that DKD + Brk xenograft tumors were 
significantly larger than DKD tumors (p<0.01). End-stage tumors were harvested and 
analyzed by Western blot, which confirmed the maintenance of HIF knockdown over the 
experimental time course (data not shown).  
 
These results were independently repeated in a second experiment, in which we 
also necropsied the axillary region to detect the presence of lymph node lesions. We 
observed that 40% of the mice transplanted with DKD + BRK xenograft tumors harbored 
lymph node macrometastases (2/5 mice), with node masses greater than 2 mm in 
diameter (Figure A-6D), while no mice bearing DKD or shControl xenograft tumors 
exhibited overt node involvement by necropsy or H&E analysis (0/5 mice per genotype). 
The presence of human breast cancer cells in these lymph nodes was confirmed by 
staining for human-specific anti-cytokeratin, CAM5.2, as in [132] (Figure A-6D). These 
data suggest that in vivo, Brk is a major driver of breast cancer phenotypes that are 
typically associated with HIF-1α/2α mediated tumor progression and metastasis. 
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Figure ?-6. Brk promotes growth in HIF DKD cells in vitro and in vivo.  
A. MTT cellular proliferation assays were performed with MDA-MB-231 cells cultured 
at 1% O2 for the indicated amounts of time. B. Mammary fat pad xenografts were 
established with either shControl, DKD or DKD + Brk MDA-MB-231 cells (n=9 mice 
/cohort). Mean tumor volume per cohort was plotted over time; asterisks indicate 
significant differences via two-way ANOVA between DKD and DKD+ Brk tumors at 
both day 35 and day 38 post-transplant (p <0.05, p<0.001). Mean tumor volumes at day 
38 for DKD and DKD + Brk cohorts are listed. C. Mean ex vivo tumor wet weight. 
Significance was calculated via ANOVA (* p< 0.05, ** p<0.01). D. Representative 
histological images depicting CAM5.2 positive axillary lymph nodes (LN) from mice 
with DKD+Brk xenograft tumors. An image from a no primary antibody control is also 
shown (No 1°-Ab control). 
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Brk Increases the Appearance of Basal-like Mammary Tumors in METmut Mice 
 
Numerous in vitro studies have implicated Brk in oncogenic signal transduction 
pathways that contribute to aggressive phenotypes in breast cancer cells, including 
migration, anchorage independent growth, and resistance to targeted therapies [311, 313-
315]. WAP-Brk transgenic mice exhibited increased p38 MAPK signaling associated 
with delayed forced involution. In addition, aged multiparous mice developed more 
mammary tumors relative to mice lacking mammary gland-specific Brk expression [307]. 
Our recent work demonstrated that Brk signals downstream of Met receptors to increase 
HGF-driven malignant processes in vitro [311]. Tissue microarray-based analyses of 
human breast cancers demonstrated that high Met receptor levels are strongly correlated 
with TNBC and basal-like breast cancers [325]. Therefore, we sought to determine the 
effects of Brk-dependent signaling on mammary tumor development in a well-
characterized mouse model of human breast cancer. To generate mammary tumors, 
WAP-Brk (FVB) transgenic mice were crossed with METMut knock-in (FVB) mice, 
which express a constitutively active Met receptor and mimic the pathological features of 
human basal-like breast cancer [307, 325]. As the Met receptor is known to be an 
upstream activator of Brk, mammary epithelial cells derived from WAP-Brk x METMut 
mice are predicted to have constitutive activation of Brk [310, 311].  
 
Following continuous pregnancies (n=3) to activate mammary gland specific 
WAP-driven Brk transgene expression, groups of age-matched, multiparous female mice 
(n=17 mice per cohort; Wildtype, Brk alone, METmut alone, or Brk x METMut) were 
monitored for tumor formation weekly and sacrificed once tumors grew to a volume of 
approximately 1 cm3. Mice in the wildtype and WAP-Brk (i.e. non-activated Brk) cohorts 
failed to develop mammary tumors over the experimental time course (Figure A-7A). As 
predicted [325], nearly 100% of METmut mice developed mammary tumors (by day 700). 
However, increased tumor formation and decreased overall tumor-free survival were 
observed in WAP-Brk x METMut mice relative to METMut mice (log-rank p=0.03,  
Figure A-7A). The median survival of WAP-Brk x METMut mice was 228 days, whereas 
median survival of METMut was 368 days. We collected tissues (lung, liver, brain, 
ovaries) from mice upon necropsy for analysis of potential (latent) metastatic events 
(Table A-1). Importantly, Brk x METMut mice developed more (20%) metastases relative 
to METMut mice (12%) (Figure A-7B, Table A-1). Notably, metastases were observed in 
mice that survived (i.e. were not euthanized due to primary tumor size) at least 275 days; 
of these, 3/6 (50%) Brk x METMut mice developed distant metastases, while 2/15 (13%) 
METMut mice developed distant metastases. Taken together, these data suggest that Brk 
activation in the mammary epithelium, whether driven by hypoxia or constitutive MET 
expression, is a driver of rapid tumor progression in vivo.  
 
Most solid tumors are hypoxic. Our in vitro studies related to hypoxia regulation 
of Brk expression (Figures A2-A3) suggested that endogenous Sik expression may be 
induced during the course of tumor progression in METmut mice. Therefore, all tumors 
extracted from mice were screened for Sik mRNA expression via qPCR. Notably, when 
data was stratified by Sik expression alone, regardless of Brk transgene genotype, there 
was a strong association between Sik positivity and decreased tumor-free survival (log- 
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Figure ?-7. Growth of basal-like mammary tumors that originate in METmut mice 
is accelerated by expression of the Brk transgene or endogenous Sik.  
A. Percent tumor-free survival of METMut mice compared to Brk x METMut transgenic 
mice by Kaplan-Meier analysis and significance determined by Mantel-Cox Log-rank test 
(hazard ratio, 2.39; 95% CI = 1.082 to 5.276). B. Representative hemotoxylin and eosin 
(H&E) stained section from a Brk x METMut mouse lung harboring metastases is 
depicted. C. Percent tumor-free survival, stratified by endogenous Sik expression status. 
Significance was determined with Mantel-Cox Log-rank test (hazard ratio, 5.47; 95% CI 
= 2.060 to 14.50). D. Tumors were harvested from end-stage METMut or WAP-Brk x 
METMut mice, and mean expression of Sik mRNA was analyzed by qPCR after 
normalization to TBP. Early tumors were classified as those that developed by 300 days 
and latent tumors were classified as those that developed after 300 days (* p<0.05). E & 
F. Kaplan-Meier curves were derived from data analyzed from 117 primary human breast 
tumor specimens [337] for overall survival (E.) and metastasis-free survival (F.), 
stratified by high (top quartile, >75%) and low (lower quartile, <25%) Brk expression. 
Significance was determined by Mantel-Cox Log-rank test.  
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Table ?-1. Enhanced metastasis in Brk x METMut mice relative to METMut and 
WAP-Brk mice. 
 
 Number of Mets/Genotype/Site   
Genotype Lung Ovary Total # of Mice with Mets 
Total # of 
Mice with 
Mets after 
Day 275 
WT 0 0 0/15 (0%) 0/15 (0%) 
Brk 0 0 0/17 (0%) 0/17 (0%) 
METMut 2 0 2/17 (12%) 2/15 (13%) 
Brk x METMut 3 1 3/15 (10%)a,b 3/6 (50%)c 
 
aOne mouse had multiple organs with distant metastases. 
bp = 0.26 (χ2 test). 
cp = 0.02 (χ2 test). 
 
 
rank p=0.0006) (Figure A-7C). Mice with Sik-positive tumors had a median survival of 
221 days, whereas mice with Sik-negative tumors had a median survival of 397.5 days. 
Overall, the decreased latency correlated with significantly higher levels of Sik in tumors 
(Figure A-7C-D), suggesting that Sik expression accelerates tumor development and 
progression.  
 
Collectively, our studies suggest that Brk is an important driver of breast tumor 
progression. Brk expression in human breast cancers may signify the need for more 
aggressive cancer therapies. To further support these findings as relevant to human 
tumors, we stratified 117 primary human breast tumor samples according to Brk mRNA 
expression [337]. High Brk expression correlated significantly with both decreased 
overall survival (Figure A-7E) and decreased metastasis-free survival (Figure A-7F). 
These data suggest that the WAP-Brk x METMut mice model human disease with high 
Brk expression. These mice may provide a useful model system for pre-clinical testing of 
novel therapies that may include Brk inhibitors. 
 
 
Discussion 
 
Although an improved understanding of Brk signaling in breast cancer is rapidly 
emerging [308, 310-312], the mechanisms by which Brk is aberrantly expressed in the 
majority of breast cancers remains undefined. We have identified cellular 
microenvironmental stressors, including hypoxia, to be major cues that result in increased 
Brk expression in both normal and neoplastic mammary epithelial cells. We have 
additionally shown through ChIP assays and gene expression analysis that this 
mechanism of Brk transcriptional regulation is HIF-dependent. This finding is 
particularly relevant to breast cancer subtypes that exhibit high constitutive expression of 
HIFα subunits, specifically, TNBCs (Figure A-1) and inflammatory breast cancers [92, 
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320]. Importantly, forced expression of Brk in cells lacking both HIF-1α and HIF-2α 
increased xenograft growth in vivo and promoted lymph node metastasis, suggesting that 
Brk is a key mediator of the hypoxia-induced metastasis program. Furthermore, using a 
mouse model of Brk overexpression (WAP-Brk x METMut knock-in), we demonstrated 
that activated Brk signaling drives mammary tumor initiation and rapid tumor growth in 
vivo. Tumor growth is further accelerated in the presence of activated endogenous Sik 
(the mouse homologue of Brk, which is not expressed in the normal mammary gland). 
Sik expression is tightly linked to rapid tumor onset and shortened survival, regardless of 
Brk transgene genotype. The impact of activated Brk signaling on metastatic progression 
is of particular interest, as 20% of the Brk x METMut mice developed distant metastases, 
compared to only 12% of the METMut mice. This difference trended toward significance 
(Figure A-7, Table A-1), despite that our experimental design was powered for the 
detection of differences in primary tumor formation and growth rate rather than the 
detection of distant metastases (i.e. all mice are euthanized when tumors reach 1mm3, 
which limits the ability to detect metastatic events derived from rapidly growing primary 
lesions). Clearly, high Brk expression in primary human breast tumors is significantly 
correlated with decreased overall survival as well as decreased metastasis-free survival 
(Figure A-7E-F). Further studies, designed specifically to assess differences in 
metastases (i.e. following removal of primary tumors and/or using larger cohorts [338]), 
are needed to better define the details of how Brk signaling contributes to the stepwise 
process of metastasis. 
 
Our ChIP data suggest that HIF-1α/2α directly regulate Brk expression via 
contact with one or more distinct HREs located throughout the Brk promoter. We 
detected abundant recruitment of HIF-1α/2α and Pol II to at least five HREs the Brk 
promoter in response to hypoxia. Brk mRNA and protein were subsequently increased 
(Figures A-3 and A-4). In support of this finding, Sik expression was significantly 
diminished in mammary tumors that arose in MMTV-PyMT HIF-1 KO mice relative to 
WT controls. However in human MDA-MB-231 (and MCF-7) breast cancer cells, upon 
loss of HIF-1α, although the response was dampened, we still observed a net increase in 
hypoxia-induced Brk mRNA and protein expression. As previously shown for MCF7 
cells [233], HIF-2α is likely able to compensate for the loss of HIF-1 transcriptional 
activity in cells expressing shHIF1A, thereby maintaining Brk expression in hypoxia. Our 
data support the hypothesis that Brk can be up-regulated during hypoxia by either HIF-1 
or HIF-2, particularly since HIF-2α protein levels were indeed increased when HIF1A 
was knocked-down in MDA-MB-231 cells (Figure A-5A). Moreover, when both HIF-1 
and HIF-2 activity is depleted using shRNAs, we observed an almost complete loss of 
both basal and inducible Brk mRNA and protein expression in MDA-MB-231 cells 
(Figure A-5) as well as MCF-7 cells. Numerous studies have determined that HIF-1α 
and HIF-2α regulate several of the same genes [233, 333, 334], as expected since the 
core binding sequence (RCGTG) is recognized by both HIF-1 and HIF-2 [335, 339]. 
Indeed, significant levels of both HIF-1α and HIF-2α have been observed to bind to 
almost all of the HIF binding sites identified by ChIP genome wide. However, functional 
analysis of the role of individual HREs in the regulation of Brk expression by HIFs is 
outside the scope of this study. Genome-wide studies have also shown that, despite 
sharing the same response element, each HIFα subunit also differentially regulates a 
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unique core of distinct genes [335]. These studies highlight the complexity of HIF gene 
regulation and the possibility that HIF-1α and HIF-2α may be involved in both 
cooperative and compensatory gene regulation that is highly context-dependent [233], 
and underscore the need for further study. Additionally, molecular compensation (i.e. of 
one HIF for another) is an important consideration for targeting HIF-specific actions in 
the clinic. 
 
Solid tumors experience widespread cell stress that acts as a form of selection 
pressure. Our previous studies have elucidated downstream mediators of Brk signaling 
that include stress-activated protein kinases (p38 MAPK and ERK5) as well as their 
substrates MEF2 and Sam68 [310-312]. Breast cancer cells maintain high soluble and 
growth factor receptor tyrosine kinase activities relative to untransformed cells [340]; 
these pathways may act as inputs to increased Brk and ERK5 activities [308, 314]. 
Intriguingly, Schweppe and co-workers have shown that HIF-1 transcriptional activity 
was enhanced by ERK5, and that numerous hypoxia-regulated and HIF-1α target genes 
were also specifically regulated by ERK5 [341]. These results suggest that HGF, Met, 
Brk, ERK5, and HIF-1α may function together as a “feed-forward” autocrine signaling 
loop in response to hypoxia, ultimately resulting in high levels of Brk expression and 
adaptation to cell stress that enables cancer cells to migrate away from hypoxic regions to 
more hospitable microenvironments at distant sites. Related to this process is the 
epithelial to mesenchymal transition (EMT), a quintessential step that precedes 
carcinoma cell metastasis [342]. HIF-1 is known to mediate EMT in breast tumors [127] 
and knock-down of Brk in MCF7 breast cancer cells partially reverses EMT, as measured 
by a decrease in mesenchymal markers (fibronectin and N-cadherin) and an increase in 
epithelial associated markers (E-cadherin and β-catenin) [343]. Taken together, these 
studies support the hypothesis that increased Brk expression allows breast cancer cells to 
successfully migrate, in part via modulation of EMT-associated molecules. Importantly, 
Brk appears to act as a convergence point downstream of diverse growth factor receptors 
that are frequently overexpressed in breast cancer. This biology, in conjunction with our 
findings that Brk is a major effector of in vivo HIF-mediated tumorigenesis and 
metastasis, suggests that targeting Brk (in addition to MET and/or HIF-dependent 
signaling) as part of combination breast cancer treatment strategies may more effectively 
subvert HIF-driven processes that contribute to aggressive tumor progression. 
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